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Abstract 
Fluorescent flow cytometry (FFC) is an accessible, high-throughput and 
sensitive technique that is well suited to analysis of cells suspended in 
complex heterogeneous media. Using a wide variety of live, fixed, 
extracellular, intracellular, dye/antibody/peptide based FFC assays, multiple 
and novel aspects of platelet biology including; activation, inflammation and 
mitochondrial function were examined. 
Through the examination of platelet activation with multiparameter and 
multidimensional analysis three platelet subsets in PAR1/GPVI activated 
whole blood samples were described. This same assay in the presence of 
PGI2 suggested a dichotomy in inhibition when comparing fibrinogen binding, 
phosphatidylserine (PS) exposure and CD62P. Using novel phosphoflow 
protocols the inhibition resistant expression of CD62P was shown to be 
independent of robust cAMP signalling. This CD62P expression was then 
shown to mediate platelet monocyte interactions – in the presence of 
inhibition. 
Caspase-1 cleavage as a marker of NLRP3 inflammasome activity was 
measured using fluorescent peptide dyes. Activation was induced by 
canonical activators of the complex, but it was observed that this was 
significantly potentiated by oxidised LDL (oxLDL). ROS and calcium were also 
shown to have a vital role in activation of platelet NLRP3 and scavenging or 
chelation of either induced a loss of signal. Furthermore, active caspase-1 
signal also correlated with PS exposure. 
Finally, mitochondrial function in response to oxLDL in vitro and in the context 
of murine hyperlipidaemia ex vivo was measured using live cell dyes. In vitro 
stimulation with oxLDL drove an increase in both mitochondrial superoxide 
production and mitochondrial membrane potential. However, this was 
demonstrated to be important in vivo, as transgenic models of hyperlipidaemia 
showed a significant increase in basal mitochondrial superoxide compared to 
wild type control. This was recapitulated diet-induced obesity murine models 
and a trend towards increased mitochondrial superoxide and membrane 
potential was described. 
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Chapter 1 
Introduction 
1.1 PLATELETS 
1.1.1 Platelet production and death 
Platelets are anucleate cells that have been shown to have roles in haemostasis, 
thrombosis, innate immunity, wound healing and angiogenesis (Gibbins, 2004, 
Koupenova et al., 2018, Golebiewska and Poole, 2015, Blair and Flaumenhaft, 
2009). They circulate in the body at a clinical reference range of 150-400 x 109 cells/L 
of blood (Bonaccio et al., 2016) and have a lifespan in circulation of approximately 
ten days. They are removed via Ashwell-Morrell receptors, in the hepatic vasculature, 
which recognise the desialyted surface proteins aged platelets display (Hoffmeister 
and Falet, 2016). As part of the apoptotic pathway in platelets, several key events 
occur which include; mitochondrial depolarisation, cytochrome C release, activation 
of apoptotic caspases culminating in caspase-3,  exposure of phosphatidylserine and 
finally cellular blebbing and fragmentation (Gyulkhandanyan et al., 2012). Ageing of 
platelets is controlled by the major anti-apoptotic protein BCL-XL (Vogler et al., 2011) 
and this is suggested to be further regulated by cAMP-PKA activity (Zhao et al., 
2017). The majority of platelets are produced within the bone marrow by the platelet 
pre-cursor cell, megakaryocytes (Parise, 2016), however, there is also evidence of a 
megakaryocyte population within the pulmonary system (Lefrancais et al., 2017). 
Megakaryocytes are large diffuse cells which exhibit polyploidy with many copies of 
nuclear DNA, often 64 copies at maturity (Italiano and Battinelli, 2009). 
Megakaryocytes trail filopodia into the circulation which shed pro-platelets. Pro-
platelets undergo maturation in the vasculature and further break apart in their final 
discoid mature platelet morphology (Italiano and Battinelli, 2009). Megakaryocytic 
platelet production is mostly driven by the hormone thrombopoietin and a steady 
- 2 - 
platelet count is maintained within the body, although certain conditions may 
predispose individuals towards changes in the number of platelets produced such as 
in acute coronary syndrome (Martin et al., 2012), while pathogenic disease such as 
sepsis can result in consumption of platelets (Guclu et al., 2013).  
 
 1.1.2 Platelet structure 
Platelets are small discoid cells with a diameter between 2-4 µm and despite their 
size they are complex cells with over 4,191 proteins listed on a recent proteomic 
study (Burkhart et al., 2012). These proteins may be membrane bound, cytosolic or 
within secretory α- or δ-granules (Figure 1). Platelets have evolved for rapid 
haemostatic function and are able to respond rapidly to stop haemorrhage at vascular 
sites of both arterial and venous shear, including; tethering against shear forces, 
degranulation, spreading over a damaged site and binding to and recruiting other 
platelets and facilitating the coagulation cascade.  
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Figure 1. Platelet structure and typical contents. (Upper) Equatorial section of a 
resting human platelet taken by transmission electron microscopy (x36,000). 
(Lower) Ultrastructural features of resting human platelets. Abbreviations in 
each area of the cell include peripheral zone; Exterior coat (EC), trilaminar unit 
membrane (CM), submembrane (SMF) and open canalicular system (OCS). 
Sol-gel zone; microtubules (MT) and glycogen (Gly). Organelle zone; 
mitochondria (M), alpha granules (G), dense bodies (DB) and dense tubular 
system (DTS). Adapted from (White, 2004). 
 
  1.1.2.1 Membrane 
The platelet membrane is a typical cellular phospholipid bilayer, presenting 
phosphatidylcholine on the exterior and phosphatidylserine on the interior, which is 
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regulated by flippase and scramblase enzymes (Lhermusier et al., 2011). However 
when platelets are activated, some platelets present phosphatidylserine (PS) on the 
surface of the cell (Agbani and Poole, 2017), with these negatively charged 
phospholipids facilitating coagulation (Hoffman and Monroe, 2001). Outside of the 
platelet lipid bilayer is the polysaccharide rich glycocalyx, in which the glycoprotein 
surface receptors sit (Bennett, 1963). Platelets also demonstrate a phenomenon of 
folding of the membrane, suggested to be important for quickly increasing the platelet 
surface area on activation and spreading, this is termed the open canalicular system 
(OCS) (Escolar and White, 1991). More recently, changes of the OCS in disease has 
been suggested to play a role in platelet activation (Selvadurai and Hamilton, 2018). 
The platelet lipid membrane is a dynamic environment which has been shown to 
undergo extensive remodelling, allowing receptor recycling and localisation, this is 
facilitated by cholesterol rich lipid rafts (Lopez et al., 2005). Lipid rafts are suggested 
to form islands of lipids within the phospholipid bilayer, presenting a fluid mosaic 
structure which can readily move and rearrange to facilitate membrane bound protein 
reorganisation. The islands are cholesterol sphingolipid rich domains and can, 
therefore, remain distinct from phospholipid lipid rich regions, which allows them to 
move independently of the total membrane (Lopez et al., 2005). These rafts, carrying 
receptors, are thought to play an important role in allowing receptors to cluster, which 
is a central requirement for signalling in the case of Immunoreceptor Tyrosine-based 
Activation Motifs (ITAMs), notably platelet GPVI clustering and signalling (Locke et 
al., 2002). Lipid rafts have also been linked to roles in compartmentalisation of 
inhibitory cAMP signalling, which may control spatial inhibition (Raslan and Naseem, 
2015). 
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  1.1.2.2 Cytoskeleton 
The platelet cytoskeleton is vital to the ability of platelets to rapidly change 
morphology on activation and their role in driving clot retraction. The cytoskeleton in 
resting platelets is apparent as a cell spanning coil of microtubules (Figure 1), which 
support the resting discoid cell shape of platelets (Behnke, 1965). Upon activation 
the coil of microtubules are contracted and the platelets lose their discoid shape 
(Menche et al., 1980). Platelets also contain an active actin cytoskeleton controlled 
by a wide variety of kinases which is also mobilised on activation driving formation of 
filopodia, lamellipodia and finally stress fibres (Atkinson et al., 2018, Yusuf et al., 
2017). Together these two processes result in the collapse of the platelet discoid 
shape and the ability to rapidly spread over a large surface area. 
 
1.1.2.3 Cytosol and granules 
Like other cells, the platelet cytosol contains many of the typical eukaryotic 
organelles, although it also contains platelet specific granules (Figure 1). In similarity 
to all other cells (excluding red blood cells), in the cytosol platelets carry mitochondria 
for the efficient production of ATP (Zharikov and Shiva, 2013). A platelet specific 
organelle termed the dense tubular system (DTS) is also present, and this stores 
intracellular Ca2+ (Ebbeling et al., 1992). Platelets contain three types of granules, of 
which the α-granule is the most numerous, this is followed by δ-granules and 
lysosomal granules. There are ~65 α-granules per platelets and they are roughly 0.2 
– 0.5 µm in diameter (Blair and Flaumenhaft, 2009). The contents of each granule 
type vary. In general, α-granules contain adhesion proteins, chemokines, coagulation 
factors, fibrinolytic enzymes and growth factors. The function of α-granules, 
therefore, spans haemostasis, thrombosis, repair/growth and immunity (Golebiewska 
and Poole, 2015). The role of α-granules is diverse. They not only release 
haemostatic modulators such as; thrombospondin-1 (TSP-1), fibrinogen, von 
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Willebrand factor (vWF), but also contain growth factors such as; vascular 
endothelium, platelet-derived, fibroblast, epidermal, hepatocyte and insulin-like 
growth factors (Blair and Flaumenhaft, 2009). Further to this α-granules also play a 
role in immunity through the release of soluble chemokine factors; CXCL4, CXCL7, 
CXCL12, CCL2 and CCL3 and the surface presentation of CD62P and CD154 from 
within the granules (Blair and Flaumenhaft, 2009). This led to discussion over the 
wide-ranging roles of platelet α-granules and whether they may be distinctly sorted 
into subsets of granules, such as “haemostatic” or “inflammatory” granules (Italiano 
and Battinelli, 2009). Classically, the role of secreted chemokines and growth factors 
has been suggested to facilitate thrombus resolution and subsequent wound healing, 
however, the platelet: immune cell interactions facilitated by α-granules proteins has 
also been reported to be important to atherosclerotic plaque development 
(Golebiewska and Poole, 2015). 
In contrast, δ-granules contain primarily small molecules such as polyphosphates, 
ADP, ATP, Ca2+ and serotonin, all of which support coagulation or directly promote 
further platelet activation through the P2X1, P2Y1/12 and 5-HT2A g-coupled 
receptors respectively (Stalker et al., 2012). 
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1.2 HAEMOSTATIC FUNCTION 
 1.2.1 Platelet activation at the site of injury 
The initiation of haemostasis is a major function of platelets in the vasculature. 
Platelets circulate the body in a state of tonic inhibitory quiescence, which is 
maintained by endothelial derived nitric oxide and prostacyclin. This inhibitory state 
is rapidly overcome at sites of injury, which is vital to fast cessation of bleeding. 
Platelet activation and subsequent thrombus formation consists of several distinct 
stages; rolling, tethering, spreading, recruitment and finally resolution (Figure 2). 
Blood flow forces platelets to the periphery of vessels due to their relatively small 
size, which places them near walls of the vessels, allowing them to rapidly detect 
vascular injury. When the vasculature is damaged the sub-endothelial matrix is 
exposed and the fibrillar protein collagen is exposed. von Willebrand factor (vWF), 
which circulates in the blood in a conformation unable to bind collagen, binds to 
collagen when shear induces a conformational change in the protein. This vWF can 
then ligate GP1b/V/IX receptor complex on the platelet surface. Ligation of the 
receptor acts to slow circulating platelets, allowing them to roll and come into further 
contact with the exposed surface. This initiates a major haemostatic activation of 
blood platelets, where the receptor GPVI can interact with collagen.  
The platelet receptors facilitating adhesion to collagen are α2β1 integrins and GPVI. 
When bound to GPVI, collagen stimulates signalling events that lead to platelet 
activation. Collagen cross-links GPVI resulting in tyrosine phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) on Fc receptor γ-chains 
(FcRγ) which is co-expressed and physically associated with GPVI at the platelet 
membrane. These phosphorylation events are mediated by Src-family kinases, Lyn 
and Fyn, and lead to the recruitment of the tyrosine-kinase Syk to phosphorylated 
FcRγ ITAMs where it becomes activated by autophosphorylation. This leads to the 
activation of phospholipase γ 2 (PLCγ2) and phosphatidylinositol 3-kinase (PI 3-K). 
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PLCγ2 hydrolyses membrane phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) into 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). DAG activates the serine-
threonine kinase protein kinase C (PKC). This leads to the mobilisation of intracellular 
calcium through IP3 binding to its receptors on the DTS. This rapid activation cascade 
drives conformational changes in platelet integrins. The integrin α2β1 binds firmly to 
collagen and allows firm tethering on the endothelial matrix. The integrin αIIbβ3 also 
undergoes a conformational change through its controlling proteins, including talin. 
The conformational change exposes the site of the integrin which binds to the RGD 
domain on the bivalent ligand fibrinogen. As a single platelet expresses over 50,000 
copies of this integrin, and can, therefore, bind to many fibrinogen monomers, this 
bridges many platelets into a platelet rich aggregate. The platelets then spread 
across this three-dimensional matrix and recruit further platelets from the blood by 
secretion of additional mediators. The binding of fibrinogen to integrin αIIbβ3 not only 
provides a mechanical attachment, but also causes outside-in signalling when ligated 
and this drives further activation. Simultaneously, the localised release of both α- and 
dense granules and the synthesis of eicosanoids (thromboxane A2 (TxA2)) acts to 
further drive platelet activation. Platelet α-granules contain many inflammatory and 
haemostatic mediators, and those which support haemostasis include fibrinogen, 
factor XIII and vWF. The release of ADP from dense granules activates platelets 
through binding to the P2Y1 and P2Y12 receptors, which drive further activation and 
inhibit adenylyl cyclases. The synthesis of thromboxane A2 (TxA2) through cyclo-
oxygenase 1 (COX1) drives further secondary activation through the thromboxane 
receptor (TP). A subset of these robustly activated platelets express 
phosphatidylserine on their surface through enzymatic activation of flippases. The 
expression of phosphatidylserine supports coagulation through the recruitment of 
factor X. The factor Xa complex drives the activation of pro-thrombin (factor II) to 
thrombin (factor IIa). Thrombin cleaves fibrinogen into fibrin monomers, which can 
polymerise into vast interlinked webs of protein that form the major protein net-like 
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structure of a clot. Thrombin also further potentiates platelet activation through the 
protease activated receptors 1 and 4 (PAR1/4). Platelets are also able to begin the 
resolution of thrombus formation. Firstly, platelets induce clot and thrombus retraction 
by pulling on the fibrinogen network (Tucker et al., 2012). Secondly, within the α-
granules are many chemokines; PF4, CXCL7 and SDF-1, cytokines; TGF-β and MIP-
1α and growth factors; PDGF and VEGF (Golebiewska and Poole, 2015). These 
factors all play an important role in the recruitment of neutrophils to remove cellular 
debris and in the development of an healing response. 
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Figure 2. Schematic of platelet activation induced by exposure of a vascular 
wound. Tethering occurs through GPIb-IX-V binding to vWF which in turn 
interacts with exposed collagen. Robust activation can occur when GPVI is able 
to cluster on collagen inducing ITAM signalling motifs. This leads to activation 
of the integrin αIIbβ3 which facilitates platelet: platelet interactions through the 
bivalent ligand fibrinogen. Further platelet recruitment is mediated by ADP 
release, thromboxane synthesis and granule secretion. Finally, full thrombus 
formation occurs, procoagulant platelets are formed and thrombin (FIIa) is 
produced leading to fibrin mesh production. (Left to right, upper then lower). 
 
 1.2.2 Procoagulant activity 
Alongside typical platelet-platelet homotypic interactions driven by integrin αIIbβ3 
binding the bivalent ligand fibrinogen, vital for clot retraction and platelet-rich 
thrombus formation (Tucker et al., 2012), an alternative mode of platelet function is 
supported through their procoagulant function (Heemskerk et al., 2013). 
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Procoagulant platelets externalise PS on their outer leaflet membrane, a 
phospholipid whose expression is normally conserved to the inner leaflet of the cell 
membrane. Exposure of PS plays a vital role in the support of the coagulation 
cascade and thrombin generation (Hoffman and Monroe, 2001). The procoagulant 
platelet phenotype has been described for many years under a variety of 
pseudonyms (COATED, collagen and thrombin activated-activated; FIB-CAP, 
fibrinogen-capped platelets; SCIP, sustained calcium-induced platelet morphology; 
and BNS, balloon non-spread), however, many of these suggested subpopulations 
have now been unified as all falling within the procoagulant super-family (Agbani and 
Poole, 2017). Studies have identified key roles for the externalised PS on the surface 
of procoagulant platelets in the recruitment of coagulation factors (Podoplelova et al., 
2016). It is also widely accepted that for the procoagulant platelets to form, a robust 
stimulus of dual PAR1 and GPVI ligation is key (Agbani and Poole, 2017) and that 
these platelets likely form at the core of a thrombus where both thrombin and collagen 
(respective to the above receptors) will be present (Stalker et al., 2013). 
Procoagulant platelets have been described by many methods including fluorescent 
flow cytometry using primarily annexin V and lactadherin conjugates (Sodergren and 
Ramstrom, 2018), fluorescent imaging cytometry (Reddy et al., 2018) and ex vivo 
flow models (Kuijpers et al., 2005). However, procoagulant activity can also be 
measured through thrombin generation assays both directly in PRP and in PPP which 
contain platelets and platelet microparticles respectively, although for direct 
measurement fluorescent flow cytometry remains the gold standard. This thorough 
phenotyping has helped describe some of the pathways vital to procoagulant platelet 
activation and formation. Primarily a sustained calcium flux has been shown to be 
vital (Choo et al., 2012), which is driven by the simultaneous activation of both PAR1 
and GPVI. In addition, mitochondrial depolarisation has been shown as a key event 
prior to PS exposure (Choo et al., 2017). While a consensus on the overall description 
of procoagulant platelets in the literature has now been reached (Agbani and Poole, 
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2017), there are still several open questions regarding roles they may play in vivo, 
how number of procoagulant platelets may change in disease and further 
understanding of the regulation and activation of procoagulant platelets. A key 
argument for the important role of procoagulant platelets in in vivo haemostasis is 
illustrated in Scott syndrome patients whom demonstrate no scramblase activity, and 
cannot expose PS and as a result show a strong bleeding phenotype (Lhermusier et 
al., 2011). In disease, initial observations suggest that PS exposing platelets are 
formed in individuals who have Wiskott-Aldrich syndrome, at a greatly increased rate 
(Obydennyi et al., 2019) and it has also been shown that in individuals who have 
suffered an ischaemic stroke, PS positive platelets can be detected in the blood 
(Pretorius et al., 2012). The first definitive description of procoagulant platelets were 
described in trauma patient undergoing haemorrhage by imaging cytometry, further 
validated by transmission electron microscopy (Vulliamy et al., 2019). These 
procoagulant platelets were stimulated by histone H4 and shown to release PS 
positive microparticles that interacted with leukocytes (Vulliamy et al., 2019). These 
studies propose that PS platelets may well play a role in platelet-pathogenesis in 
disease or act as sensitive biomarkers of disease. 
 
 1.2.3 Platelet heterogeneity 
Platelet heterogeneity has been a widely discussed topic for several years, with 
several suggested sources of heterogeneity within the platelet population. A widely 
accepted source of heterogeneity within the total platelet population is the 
procoagulant subset (Agbani and Poole, 2017), however it must be noted that this 
heterogeneity only emerges on activation. To date there have been no pre-activation 
features identified to recognise which platelets may assume a procoagulant 
phenotype on stimulation, if discovered this may prove to be a valuable biomarker of 
the future of propensity to form the procoagulant subset. Beyond the previously 
described 1/3 of platelets becoming procoagulant, in recent years the procoagulant 
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subset has been described to contain further heterogeneity. Initially procoagulant 
platelet subsets were suggested to be distinguished by calcium signalling and 
modulation of the integrin αIIbβ3 (Topalov et al., 2012), however this was later refuted 
as a result of erroneous flow cytometry gating (Choo et al., 2017), the study described 
herein goes further to describe heterogeneity within the procoagulant platelet subset. 
Platelet size has also been shown as another feature of platelet heterogeneity 
associated with procoagulant exposure. It was described that platelet size correlated 
very closely with procoagulant activity, where it was small cells that primarily 
expressed PS (Sodergren and Ramstrom, 2018). 
In addition to the platelet heterogeneity characterised by procoagulant formation, 
which only emerges on activation, platelet age can also be used to describe 
heterogeneity within the platelet population, vitally in resting platelets. Young 
platelets which have been recently released from the megakaryocytes and carry 
more vestigial mRNA are described as reticulated platelets (Harrison et al., 1997) 
and are typically enumerated by their thiazole orange staining intensity (Bonan et al., 
1993). Many studies have since pursued these immature cells and they have been 
characterised in vitro which has shown they exhibit a phenotype of hyperactivity in 
comparison with aged platelets (Lador et al., 2017), furthermore reticulated platelets 
have also been shown to be clinically relevant in vivo and potentially prognostic of 
cardiovascular disease (Lev, 2016).  
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1.3 REGULATION OF PLATELET FUNCTION 
Platelet activation is a rapid process which if uncontrolled can lead to pathological 
thrombosis. Therefore, it is vital that platelets are maintained in a sensitive but 
quiescent state of inhibition in circulation. Endothelial derived PGI2 and NO  are the 
two major endogenous inhibitors of platelet function (Mitchell et al., 2008). These 
inhibitors are both synthesised by the vascular endothelium in response to the 
pulsatile flow of blood which ensures that circulating platelets are maintained in an 
inhibitory state throughout circulation. These inhibitors regulate platelets through 
cyclase mediated production of cyclic nucleotides, and activation of downstream 
inhibitory protein kinases. 
 
 1.3.1 Nitric oxide 
NO is a potent vasodilator that relaxes vascular smooth muscle and diffuses across 
platelet membranes to activate intracellular soluble guanylyl cyclase (sGC) to 
produce cyclic guanosine monophosphate (cGMP) which activates a dependent 
serine/threonine kinase, protein kinase G (PKG), which in turn mediates various 
inhibitory phosphorylation events (Mitchell et al., 2008, Stalker et al., 2012) (Figure 
3). Notable among these are inhibition of Rap1b, TxA2 receptors, RhoA and IP3 
receptors on the DTS, which result in inhibition of the integrin αIIbβ3, secondary 
activation, actin remodelling and calcium mobilisation respectively. Moreover, PKG 
activates sarcoendoplasmic reticulum calcium ATPase (SERCA) which pumps 
cytoplasmic calcium back into the DTS, returning its concentration to basal levels. 
 
 1.3.2 Prostacyclin 
PGI2 is a prostanoid which is derived from arachidonic acid freed by phospholipase 
A (PLA). PGI2 is secreted by the endothelium and has a short half-life in the blood 
(Cho and Allen, 1978). It binds to the prostacyclin Gαs-linked IP receptors on 
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platelets. Gαs activates adenylyl cyclase, which converts adenosine triphosphate 
(ATP) to cyclic adenosine monophosphate (cAMP). High intracellular levels of cAMP 
signal within the cell driving activation of protein kinase A (PKA), which drives the 
inhibitory effects within the cell (Figure 3). 
Similar to cGMP via PKG, cAMP targets several key pathways in the cell to mediate 
inhibition via PKA. In terms of receptors and their immediate signalling, PKA controls 
several routes of activation. PKA modulates GPIb-V-IX by phosphorylation of GPIbβ 
which reduces vWF binding (Bodnar et al., 2002). PKA is able to further target GPVI 
dimerization (Loyau et al., 2012), which is vital to GPVI signal transduction (Locke et 
al., 2002), thereby reducing collagen mediated signalling. It also modules Gα13 
thereby blocking signal transduction from both TP receptors and PAR (Manganello 
et al., 1999, Manganello et al., 2003). The major integrin αIIbβ3 is also blocked from 
activation by phosphorylation of Ca2+ dependent Rap1b (Lapetina et al., 1989). In 
combination, these demonstrate that PKA can modulate the major activatory platelet 
receptors via a combination of direct or indirect phosphorylation of related 
components. Calcium mobilisation is, as described, a major outcome of platelet 
activation and is vital to almost all aspects of activity (Varga-Szabo et al., 2009). 
cAMP-PKA inhibitory signalling also modulates calcium signalling via targeting IP3 
receptors which would, in turn, prevent the release of internal stores of calcium 
downstream of PLCγ2 (Quinton et al., 1996). More recently, however, aspects of 
calcium signalling via P2X1 calcium entry have been shown to remain independent 
of cAMP-PKA activity, which suggests that cAMP does not result in the complete 
shutdown of platelet activity (Fung et al., 2012). An additional key aspect of platelet 
activity is shape-change and spreading, primarily mobilised by the highly active actin 
cytoskeleton. PKA phosphorylates several actin binding proteins including LASP 
(LIM and SH3 protein), HSP27 (heat-shock protein 27) and vasodilator-stimulated 
protein (VASP) (Butt et al., 1994, Butt et al., 2001, Butt et al., 2003). VASP is heavily 
phosphorylated on two serine residues, 157 and 239 (Benz et al., 2009), and provides 
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a valuable readout of cAMP-PKA activity by immunoblot and phosphoflow (Spurgeon 
et al., 2014). 
 
 1.3.3 Regulation of inhibitory signalling 
Given the potent inhibitory effects of cAMP signalling, levels must be maintained 
within the cell to ensure that activation of platelets can take place when required. 
Phosphodiesterases (PDEs) can terminate PGI2- and NO-stimulated signalling 
events and are thus important regulators of platelet function and many other cells. 
PDEs form a large group of enzymes that hydrolyze the 3’ cyclic phosphate bond of 
either cAMP or cGMP, yielding their inactive 5’ metabolites. Although cyclic 
nucleotides can be transported across the platelet membrane, the catalytic action of 
PDEs represents the only known mechanism for rapidly lowering platelet cyclic 
nucleotide contents and thereby controlling signalling events. Platelets contain at 
least three different PDE isozymes including cGMP-stimulated PDE2, cGMP-
inhibited PDE3A and the cGMP-specific PDE5. Binding of cGMP to an allosteric 
binding site leads to the PDE2-catalysed degradation of both cAMP and cGMP. 
Binding of cGMP to PDE3A, on the other hand, inhibits the preferential hydrolysis of 
cAMP. The second messenger, cGMP, can, therefore, attenuate or enhance the level 
of intraplatelet cAMP. Indeed, significant cross-talk exists between the cAMP and 
cGMP signalling cascades. PDE3A is phosphorylated and activated by cAMP-
dependent protein kinase in a negative feedback loop that eventually restores basal 
levels of cAMP. There is also evidence that the transporter ABCC4 (Cheepala et al., 
2015), can drive efflux of cAMP out of a platelet to rapidly diminish the inhibitory 
burden, although phosphodiesterases are currently considered the major regulator 
of cAMP levels. 
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Figure 3. Overview of platelet inhibitory signalling mediated by prostacyclin 
and nitric oxide. Prostacyclin (PGI2) and nitric oxide (NO) are synthesised in 
endothelial cells by phospholipase A (PLA) and nitric oxide synthetase (NOS) 
respectively. They are then subsequently released in the cytoplasm. PGI2 binds 
to the platelet prostacyclin receptor (IP) which in turn activates adenylyl 
cyclases (AC) which produce cAMP in an ATP dependent manner. Intracellular 
pools of cAMP are regulated by phosphodiesterase 3A (PDE3A), but when 
production exceeds breakdown cAMP activates protein kinase A (PKA), which 
acts as the key effector of PGI2-mediated inhibition and phosphorylates multiple 
targets within the platelet. NO does not require a receptor and diffuses across 
the phospholipid membrane where it activates soluble guanylyl cyclase (sGC) 
which produces cGMP. Phosphodiesterase 5a regulates intracellular levels of 
cGMP, but when levels are raised over breakdown rate protein kinase G (PKG) 
is activated. PKG acts as the effector of the NO pathway and phosphorylates 
multiple targets in the platelet. 
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1.4 PLATELET METABOLISM 
 1.4.1 Mitochondria and metabolism 
Metabolism is a series of chemical processes which occur to support life, primarily to 
provide energy substrates for cellular processes. Eukaryotic cells carry mitochondria, 
which are organelles with a complex internal structure and defined external 
membrane. Mitochondria are vital to cellular homeostasis as they allow the more 
efficient aerobic respiration to occur rather than anaerobic glycolysis. Mitochondria 
are 0.5 – 1 µm in length and are mobile organelles, continually undergoing fission 
and fusion. Structurally mitochondria have four regions (Figure 4); the internal matrix, 
which contains enzymes required for the citric acid cycle along with mitochondrial 
DNA (mtDNA), then surrounding this is the inner membrane which is folded into 
cristae that increase the intracellular membrane surface area in order to increase the 
number of proteins to drive oxidation in the electron transport chain (ETC). It is this 
membrane which the electrochemical gradient is maintained over. The 
intermembrane space is sandwiched between the inner and outer membranes and 
finally the outer membrane carries mitochondrial receptors and vitally the porin 
voltage-dependent anion channel (VDAC) which makes this membrane permeable 
to molecules <5 kDa (Alberts et al., 2008). 
The core process of energy production relies on the harnessing of chemiosmotic 
coupling, namely chemical bond-forming reactions facilitated by changes in osmotic 
pressure and electric charge. In brief, electrons derived from oxidation are 
transported along the ETC embedded in the mitochondrial membrane in a process 
which liberates energy allowing H+ to be pumped across the membrane, driving 
formation of an electrochemical gradient. This gradient is a form of energy, which 
when flowing back into the mitochondria via ATP synthase produces adenosine 
triphosphate (ATP) from adenosine diphosphate (ADP) and inorganic phosphate (Pi) 
(Alberts et al., 2008). ATP then acts as fuel within the cell for many processes.  
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Figure 4. Mitochondrial structure. The complex internal structure of mitochondria 
is apparent in this three-dimensional model, with folded inner membrane 
forming cristae (o, c and b), the central free channel (fc) demonstrating 
increased surface area within the smaller confines of the outer membrane (a1, 
a2, a3 demonstrate sites of section removal), adapted from (Palade, 1953). 
 
 1.4.2 Platelet metabolism and disease 
Platelets are among the most numerous cells in the blood and are known to be very 
metabolically active. In recent years, studies have begun to assess how platelet 
mitochondrial dysfunction may be linked to changes in platelet function. A major part 
of this push, is the understanding that mitochondria are not only important for energy 
production (Alberts et al., 2008), but play a vital role in cellular signalling, 
predominantly through production of ROS (Tait and Green, 2012, Schulz et al., 2014). 
The important role of ROS in platelet biology, is easily summarised in the canonical 
spike in ROS (typically cytosolic not mitochondrial) when GPVI is activated (Walsh et 
al., 2014). Indeed, mitochondrial superoxide is readily produced from platelet 
mitochondria and it is converted to hydrogen peroxide where it may leave and act as 
a cellular messenger (Anand et al., 2013). 
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Platelets have a high energy consumption, and in circulation resting platelets derive 
35% of their energy from oxidation phosphorylation and the majority (65%) from 
glycolysis (Zharikov and Shiva, 2013). When platelets are activated, they do not 
differentiate between the two sources of energy and the rate of both oxidative 
phosphorylation and glycolysis can be elevated relative to substrate availability 
(Aibibula et al., 2018). Studies have identified a role for mitochondrial function in 
several aspects of platelet biology. The formation of the mitochondrial permeability 
transition pore (MPTP) has been linked to platelet activation, notably the MPTP is 
formed on a subset of platelets on treatment with both thrombin and convulxin which 
leads to phosphatidylserine exposure, it was further suggested that mitochondrial 
cyclophilin D was regulating this (Jobe et al., 2008). Follow up studies later identified 
that it is specifically mitochondrial calcium and mitochondrial ROS which facilitated 
PS exposure (Choo et al., 2012). Highlighting an important role for mitochondria in 
regulating procoagulant platelet activity. 
However, what is emerging, is that mitochondrial dysfunction likely plays an important 
role in modulating many aspects of platelet function (Wang et al., 2017a). To highlight 
several studies, in ageing mice mitochondrial membrane potential was suggested to 
be raised, hypothesising that this may lead to age associated degeneration of 
response (Xu et al., 2007). In the well-known disorder Wiskott-Aldrich Syndrome 
(WAS), the platelet thrombocytopaenia was recently shown to be dependent on 
mitochondrial dependent necrosis (Obydennyi et al., 2019). In several diseases there 
have also been observations of mitochondrial dysfunction noted specifically within 
platelets; in cardiovascular disease (CVD) there have been reports of increased 
mtDNA methylation (Baccarelli and Byun, 2015), in polycystic ovary syndrome 
(PCOS) AMPK and respiration rate are both decreased but rescued by metformin 
treatment (Randriamboavonjy et al., 2015), in sickle cell disease (SCD) complex V 
activity is reduced (Cardenes et al., 2014), in sepsis mitochondrial depolarisation 
correlates with disease severity (Grundler et al., 2014) and finally in diabetes mellitus 
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aldose reductase activity is reduced (Tang et al., 2014). Importantly all these 
conditions are also associated with platelet dysfunction; CVD increased thrombotic 
events and platelet transcriptional remodelling (Ramos-Arellano et al., 2014, Heffron 
et al., 2018), PCOS increased platelet hyperactivity (Aye et al., 2014), SCD increased 
platelet NLRP3 inflammasome activity (Vogel et al., 2018a), sepsis increased platelet 
activity and IL-1β production (Brown et al., 2013, Damien et al., 2015) and diabetes 
increased platelet activity and loss of inhibitory IP receptors (Angiolillo et al., 2005, 
Knebel et al., 2015). This suggests there may well be a link between mitochondrial 
dysfunction and platelet dysfunction in these conditions. Understanding what is 
driving these changes in platelet mitochondrial dysfunction will be key to 
development of pharmacological protection from these changes. 
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1.5 PLATELETS AND INFLAMMATION 
The role of platelets in inflammation and immune response is a relatively new field of 
research, but there is now also evidence of platelet involvement in these responses 
(Vogel and Thein, 2018, Koupenova et al., 2018). There are indications of a 
concurrent role to thrombosis, of platelets as a blood-borne sentinel cell, and as such 
they are now thought to be involved in the development and progression of vascular 
inflammation, both sterile and unsterile (Koupenova et al., 2018). A growing body of 
evidence suggest that platelets are capable of mediating multiple immune responses 
(Morrell et al., 2014, Gaertner et al., 2017, Clark et al., 2007, Koupenova et al., 2018). 
This has been illustrated through showing their ability to respond to danger and 
pathogen-associated molecular patterns (D/PAMPs), which can be characterised into 
endogenous danger ligands such as oxidised LDL (oxLDL) and exogenous 
pathogenic ligands such a lipopolysaccharide (LPS) (Podrez et al., 2007, Damien et 
al., 2015). Platelet inflammatory responses can be manifested through many routes 
but key pathways include; direct synthesis of the cytokines IL-1β (Brown et al., 2013), 
and IL-18 (Allam et al., 2017), P-selectin mediated leukocyte recruitment, CD40L 
release or neutrophil extracellular trap (NET) activation (Morrell et al., 2014, 
Koupenova et al., 2018, Clark et al., 2007), and deposition and release of 
chemokines such as PF4 and RANTES (Golebiewska and Poole, 2015). These 
inflammatory mediators suggest platelets have the capacity to modulate all major 
immune cell classes within the vasculature, monocytes, lymphocytes and 
granulocytes. 
 
 1.5.1 Platelet-leukocyte interactions 
A well described pathway which platelets modulate systemic inflammation through is 
heterotypic interactions with leukocytes. Platelets are demonstrated to have potent 
activatory checkpoint roles in the recruitment and activation of many white cell 
subsets including neutrophils, monocytes and lymphocytes. Numerous examples of 
- 23 - 
platelet leukocyte interactions have been described by both in vitro and in vivo with 
multiple partner cell types (Koupenova et al., 2018, Vogel and Thein, 2018, Morrell 
et al., 2014, Golebiewska and Poole, 2015, Li et al., 2017). Below, examples of how 
platelets interact with each major immune cell class are presented. Via CD62P-PGL1 
interaction platelets activate neutrophils and receive eicosanoid precursors in return 
to drive thromboxane synthesis and stimulate inflammatory neutrophil extravasation 
(Rossaint et al., 2016). Platelets can also recruit monocytes via CCN1 and facilitate 
inflammatory monocyte patrolling in an animal model of inflammation (Imhof et al., 
2016). Lymphocyte activation via platelet expressed CD40 ligand (CD154) has also 
been demonstrated (Stokes et al., 2009). However, beyond these studies the 
association between platelets and leukocytes primarily occurs through interaction of 
P-selectin and P-selectin glycoprotein ligand-1 (PSGL1). 
 
 1.5.2 CD62P-PSGL1 
CD62P (P-selectin, granule membrane protein 140 or platelet activation-dependent 
granule to external membrane protein) is a platelet protein which is contained within 
α-granules, and as such is expressed on the surface of platelets when granule 
secretion is stimulated (Harrison and Cramer, 1993). The secretion of α-granules, as 
previously mentioned, will induce the release of many other chemokines and other 
recruitment mediators such as CD154 (CD40L) alongside CD62P. However, the 
interaction of CD62P with PSGL1 is among the most well described mediators of 
platelet: leukocyte interaction. CD62P is expressed in both platelet α-granules and 
also endothelial Weibal-Palade bodies and is also present as a soluble (cleaved) 
form in the blood as sCD62P, which can be cleaved from platelets (Andre, 2004). 
CD62P interacts with PSGL-1 (P-selectin glycoprotein ligand-1 or CD162) which 
facilitates both interactions between cells in suspension and rolling in vasculature as 
well as transducing activating signal, the partner for CD62P, PSGL1 is expressed on 
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monocytes, neutrophils and platelets themselves (Moore, 1998). Early descriptions 
of the CD62P-PSGL1 interaction were carried out in vitro and concentrated on the 
mediation of rolling, this study demonstrated that at a range of a shear rates 
neutrophils would roll on Chinese hamster ovary (CHO) cells which expressed 
CD62P (Moore et al., 1995). Further studies followed on and examined the affinity of 
the CD62P-PSGL1 interaction, the binding was highly specific and interestingly they 
demonstrated that sCD62P also binds with a high affinity, suggesting sCD62P may 
act as a regulator of the interaction or to drive signalling itself (Mehta et al., 1998). A 
reciprocal approach was later used, where PSGL1 was significantly increased on the 
platelet surface on activation, but treatment with an anti-PSGL1 antibody abrogated 
platelet-endothelial rolling when measured by in vivo intravital microscopy (Frenette 
et al., 2000). Although there had been a clear indication that the CD62P-PSGL1 axis 
may be important in disease, a consensus was reached that P-selectin played a vital 
role in the recruitment of leukocytes to the endothelial and that increased levels of 
sCD62P in CVD indicated it may play a role in the pathophysiology of atherogenesis 
(Blann et al., 2006). Alongside the indication of CD62P-PSGL1 playing a role in the 
modulation of vascular inflammation, there was also evidence emerging that it played 
a role in thrombosis as a stabilising agent between platelet-platelet interactions and 
the recruitment of leukocytes, which in turn facilitates a role in coagulation for CD62P-
PSGL1, where it induces tissue factor expression on the monocyte surface (Andre, 
2004). Clinical studies have also highlighted correlations between sCD62P and 
cardiovascular disease/events, which are vitally rescued in CD62P/PSGL1 knockout 
models (Wang et al., 2007, Ye et al., 2019). While the CD62P-PSGL1 interactions 
between platelets and monocytes and themselves vitally, important, they can lead to 
further interactions between the two cells. The major receptor on monocytes which 
is upregulated in response to CD62P/PSGL1 interactions is Mac-1 (integrin αMβ2 or 
CD11b/CD18) (Meerschaert and Furie, 1995). Mac-1 interacts with GP1bα on the 
platelet surface, which is a constitutive component of the GP1b-V-IX complex, and 
- 25 - 
this has been suggested to drive thrombosis (Wang et al., 2017b). In addition to this 
Mac-1 also binds to fibrinogen thereby driving heterotypic platelet-monocyte 
interactions via the integrin αIIbβ3 (Wright et al., 1988). These studies have continued 
to progress and the CD62P-PSGL1 axis is now understood to regulate many vascular 
events and drive the progression of atherogenesis, vascular inflammation, 
thrombosis and more recently described cancer (Kappelmayer and Nagy, 2017). 
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1.6 OXIDISED LOW-DENSITY LIPOPROTEINS AND PLATELETS 
1.6.1 Low-density lipoprotein and atherosclerosis 
Elevated plasma lipids, particularly cholesterol in the form of low-density lipoproteins 
(LDL), are correlated with increased CVD risk. However, the precise mechanisms of 
hyperlipidaemia mediated thrombosis are unclear. Lipoproteins are spherical rich 
particles, comprised of an ‘outer shell’, hydrophobic ‘lipid core’ and protein 
component that serve to transport lipids to the tissues. The outer shell is composed 
predominantly of a phospholipid monolayer, with traces of cholesterol and contains 
specialised apolipoproteins which act to direct the transport of lipoproteins. These 
proteins facilitate recognition of particles by cell surface receptors or enzymes. The 
lipid core contains triglycerides and cholesterol esters, but predominantly cholesterol 
esters in LDL, which are transferred to tissues during the lipoprotein’s lifetime. There 
are several lipoprotein subtypes including; chylomicrons, vLDL, LDL and LP(a) 
which are atherogenic, and HDL which is anti-atherogenic, but it is LDL that is most 
strongly implicated in CVD (Feingold et al., 2000).  
LDL are an intermediate size particle when compared with HDL, LDL, vLDL and 
chylomicrons, ranging from 18-25 nm in diameter with a molecular weight of ~2,300 
kDa and density of 1.019 – 1.063 g/mL. In addition to their lipid content, the outer 
shell also contains a single apolipoprotein (Apo B-100). Apo B-100 is one of the 
largest proteins in the human genome and is comprised of 4,536 amino acid residues. 
Functionally, Apo B-100 is essential for the delivery of cholesterol by acting as a 
ligand for cells bearing the LDL-receptor (LDL-R) (Feingold et al., 2000). In patients 
with familial hypercholesterolemia, the amount of LDL increases due to mutations in 
the LDL-R, significantly increasing the risk of CVD (Defesche et al., 2017), clearly 
implicating excess plasma LDL with CVD. At sites of endothelial dysfunction, LDL 
can transverse the endothelial cell layer and accumulate in the intima layer of the 
blood vessel by binding to proteoglycans. Once retained in the intima, LDL undergoes 
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chemical modification resulting in oxidised LDL (oxLDL), a lipoprotein with distinct 
biological function and central in the pathogenesis of atherosclerosis. The degree of 
oxidation of LDL particles yields multiple species with different biological functions. 
The presence of oxLDL in the intima alters the local environment, causing changes 
to the secreted chemokine profile from activated EC and inflammatory cells, leading 
to the recruitment of monocytes to the area of inflammation, where they differentiate 
into macrophages and encounter oxLDL. Recognition of LDL, both native and 
modified, by LDL-R and scavenger receptors, causes unregulated lipid uptake into 
the macrophages and causes their phenotype to change, becoming ‘foam cells’ 
(Stocker and Keaney, 2004). In addition, internalised LDL can also be modified 
further due to the acidic conditions within the macrophage lysosome. Increased 
numbers of foam cells in the vessel wall manifests as a fatty streak, the earliest 
hallmark of pathological lesion formation in atherosclerosis (Wadhera et al., 2016). 
More recently oxLDL has been shown to be increased in the circulation of subjects 
with atherosclerosis, early cardiovascular disease (obesity) and stroke (Kato et al., 
2009, Ramos-Arellano et al., 2014, Wadhera et al., 2016). Circulating oxLDL 
functions as a vascular DAMP and is able to induce activation of both immune cells 
and platelets, which in turn drives vascular inflammation, endothelial dysfunction, and 
atherogenesis (Golia et al., 2014, Steinberg, 2009). Indeed, oxLDL has been shown 
to drive macrophage foam cell formation, specifically via the receptor CD36 (Podrez 
et al., 2002a), which further confirms that oxLDL plays a key role in the development 
of atherosclerotic plaque. 
 
 1.6.2 Oxidation of LDL 
When oxidised, the LDL particle becomes highly atherogenic. Oxidation of LDL is a 
multi-step process which results in change to both surface phospholipids (oxPL) and 
protein modification (Apo B-100). This allows oxidised LDL to be recognised by 
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certain scavenger receptors (Levitan et al., 2010) which can drive monocyte 
polarisation, cytokine expression, expression of endothelial adhesion molecules and 
platelet hyperactivity among several characterised effects (Feingold et al., 2000). 
Several cells in the atherosclerotic plaque/vessel wall have been shown to be able to 
oxidise LDL, notably endothelial cells, smooth muscle cells, macrophages (including 
foam cells) and lymphocytes (Wilkins and Leake, 1994a). Oxidation of LDL in vivo 
has been suggested to be predominantly via the production and release of reactive 
oxygen species into the locale, notably superoxide anion and hydrogen peroxide, 
which can interact with LDL in the extracellular matrix. Indeed, it has been 
demonstrated that superoxide dismutase regulates early stages of LDL oxidation, 
suggesting it is primarily the superoxide anion which controls the oxidation of LDL 
(Cathcart et al., 1988). Additionally, transition metal ions have been suggested to 
drive oxidation of LDL, while the zinc ion (ZnSO4) was shown to protect LDL from 
oxidation – whereas copper ion and ferrous ions were not (Wilkins and Leake, 
1994b). Myeloperoxidase (MPO) a ROS producing enzyme expressed in leukocytes 
produces hypochlorous acid (HOCl), which dissociates into the OCl- hypochlorite 
anion and can oxidise LDL, however, other enzymes including lipoxygenase and 
nitric oxide synthase can also oxidise LDL in vitro (Carr et al., 2000). 
To use oxLDL experimentally, it must be isolated directly from blood which contains 
modified LDL or produced by in vitro oxidation of native LDL (nLDL). Modified LDL 
has been successfully isolated from patients in the context of chronic kidney disease. 
isolating carbamylated LDL (cyanic acid adduct) (Holy et al., 2016) and from ST-
segment elevation myocardial infarction (STEMI) patients isolated electronegative 
LDL (L5-LDL) (Yang et al., 2017b). However, typically LDL is modified in vitro to 
prevent multiple heterogenous modifications which may occur in vivo and to produce 
specifically oxidation, carbamylation, glycation or acetylation products which drive the 
phenotype. Of these varied species of modified LDL, oxLDL is the most researched 
modified LDL. Typically oxLDL is modified in vitro using well characterised oxidation 
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protocols, where oxidation is catalysed by the addition of copper ions (CuSO4), 
although it is possible for other transition metal ions to replace copper in this model 
(Gerry et al., 2008). The output of this copper catalysed oxidation can be modified by 
the researcher through changes in temperature at which the oxidation is carried out, 
however, in all models oxidised LDL particles present a very heterogeneous particle 
with a variety of oxidation products, both phospholipids and modified Apo B-100 
(Lenz et al., 1990). By oxidising LDL in the presence of copper ions at either 4◦C or 
37◦C, the reactive species produced on the LDL can be manipulated. Through 
oxidation at 4◦C, LDL rich in hydroperoxides can be produced, at 4◦C the breakdown 
of these hydroperoxides is protected. Conversely if oxidised at 37◦C, an oxLDL of 
predominantly oxysterols is produced, as the hydroperoxides are fully broken down 
(Gerry et al., 2008). As the outer, and therefore accessible, surface of lipoproteins is 
formed of mainly phospholipids, therefore it is these which are most vulnerable to 
oxidative modification. In the presence of hydroxyl radicals (OH-), lipid radicals are 
formed which react with molecular oxygen to form lipid peroxides (LOO-). These LOO- 
further propagate the hydrogen abstraction from surrounding moieties or react with 
themselves to become oxidised phospholipids (Equation 1) (Feingold et al., 2000), 
such as KOdiA-PC, which is commonly used as an oxLDL mimetic (Biswas et al., 
2017, Kar et al., 2008, Podrez et al., 2002a, Podrez et al., 2002b). Alongside 
production of oxPL, lipid aldehydes are also formed which modify surrounding 
proteins, notably Apo B-100 in the case of LDL (Feingold et al., 2000). 
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Equation 1. Copper mediated lipid peroxidation. Reaction 1 and 2, copper ions 
are involved in redox reactions with endogenous lipid hydroperoxides. Reaction 
3 and 4, peroxyl and alkoxyl lipid radicals oxidised the parent polyunsaturated 
fatty acid by hydrogen abstraction. Reaction 5, oxygenation of lipids propagates 
reactions 3 and 4. Abbreviations; LOOH, lipid hydroperoxide, LOO◦ lipid 
peroxyl, LO◦ lipid alkoxyl, LH polyunsaturated fatty acid. Adapted from (Burkitt, 
2001). 
 
1 𝐶𝑢2+ +  𝐿𝑂𝑂𝐻 → 𝐶𝑢+ + 𝐿𝑂𝑂 ∙ + 𝐻+ 
2 𝐶𝑢+ +  𝐿𝑂𝑂𝐻 → 𝐶𝑢2+ + 𝐿𝑂 ∙ + 𝑂𝐻− 
3 𝐿𝑂𝑂 ∙  + 𝐿𝐻 → 𝐿𝑂𝑂𝐻 + 𝐿 ∙ 
4 𝐿𝑂 ∙  + 𝐿𝐻 → 𝐿𝑂𝐻 + 𝐿 ∙ 
5 𝐿 ∙  + 𝑂2 → 𝐿𝑂𝑂 ∙ 
 
The understanding of specific oxPL which are produced on the surface of LDL on 
oxidation has allowed deeper characterisation of where precisely these adducts may 
bind to various receptors, including LOX-1 (Chen et al., 2001), SRB1 (Levitan et al., 
2010) and CD36 (Podrez et al., 2002b, Kar et al., 2008). 
 
 1.6.3 Effects of oxLDL on platelets 
Early evidence exists to show that human platelets are able to both bind and 
sequester labelled nLDL-Au (Zhao et al., 1994). Further studies then suggested that 
platelets recognise exclusively oxLDL, but not acetylated LDL, and that this was not 
via the typically described scavenger receptors A, but by CD36 (Volf et al., 1999). To 
provide further functional outcome of the platelet: oxLDL interaction, it was also 
shown that oxLDL induced platelet activation (Naseem et al., 1997). In studies similar 
to the initial LDL-Au study, oxLDL labelled with a fluorescent label was again shown 
to both bind and be internalised in platelets and these oxLDL positive platelets were 
shown to modulate endothelial inflammation in vitro (Daub et al., 2010). This study 
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was supported by a later ex vivo observation in patients with acute coronary 
syndrome (ACS), of increased oxLDL retention on circulating platelets paired with 
increased binding of platelets to the endothelium (Stellos et al., 2012). These initial 
studies have been followed by a comprehensive series of studies examining both the 
in vitro signalling biology of platelet: oxLDL and the translational aspects of this 
interaction in vivo. 
oxLDL has been shown to drive many aspects of platelet function, indeed almost all 
facets of platelet function have been shown to be upregulated in some form by 
oxLDL. These include shape change in suspension and also static adhesion and 
spreading on immobilised oxLDL (Wraith et al., 2013), which in the context of 
immobilised oxLDL was shown to be accompanied by calcium flux, integrin activity 
and expression of CD62P (Nergiz-Unal et al., 2011). Other studies in response to 
modified electronegative LDL, which shares many hallmarks with oxLDL have shown 
platelet α-granule secretion, integrin activity, potentiation of aggregation and 
increased platelet-endothelium interactions, likely a result of increased platelet 
CD62P expression and endothelial activation (Chan et al., 2013). Alongside the 
described shape change, adhesion, calcium flux, α-granule secretion and integrin 
activity; δ-granule secretion has also been demonstrated as measured by ATP 
release (Nergiz-Unal et al., 2011), which suggests a model where oxLDL induces 
both cytoskeletal rearrangement and granule secretion, where dense granule 
secretion then releases ADP which provides an activatory feedback loop leading to 
complete platelet activation (Stalker et al., 2012), vitally all downstream of oxLDL 
(Nergiz-Unal et al., 2011). 
Further studies began to interrogate the precise signalling events which led to oxLDL 
mediated platelet activation or hyperactivity, with a view to link these events to 
translational in vivo observations. A critical study in 2007 demonstrated that oxLDL 
could drive an in vivo prothrombotic phenotype via platelet CD36, demonstrated with 
murine models (Podrez et al., 2007). Many key studies emerged following this, which 
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began to elucidate the pathways by which oxLDL may drive platelet hyperactivity. 
Early work suggested that oxLDL, via CD36, signalled through a tyrosine kinase 
dependent pathway via Src family kinases Fyn and Lyn (Chen et al., 2008), a 
pathway common to several platelet signalling cascades, notably that of GPVI 
(Stalker et al., 2012). CD36: oxLDL induced signalling was further shown to drive 
cytoskeletal Rho-kinase, via tyrosine kinases, leading to platelet shape change and 
activation (Wraith et al., 2013). Further important roles for oxLDL in vivo were then 
described, where oxLDL was not only driving direct platelet activity but reducing tonic 
inhibition (disinhibition). Firstly, oxLDL, via CD36 and NOX2 was shown to reduce 
PKG activity – the key mediator of NO inhibitory signalling (Magwenzi et al., 2015). 
Following this, oxLDL were shown to activate PDE3a which regulates cAMP levels 
downstream of PGI2, driving disinhibition of cAMP-PKA signalling in a CD36 
dependent mechanism. Further to the involvement of CD36 and NOX2, a subsequent 
signalling study confirmed that this converged on the activatory kinase, ERK5, which 
was shown to regulate aspects of the oxLDL mediated platelet hyperactivity (Yang et 
al., 2017a). Finally, a new aspect of the CD36: oxLDL signalosome was suggested, 
which included toll-like receptors. Using a combination of murine models, it was 
demonstrated that TLR2 and TLR6 form a signalling complex with CD36 which then 
signals via the canonically described TLR-MyD88-IRAK pathway (Biswas et al., 
2017). 
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1.7 INFLAMMASOMES 
The inflammasomes are a broad group of large multimeric protein complexes with 
enzymatic activity. The complexes are related in their ability to drive an inflammatory 
response mediated by subsequent cytokine or interferon synthesis (Schroder and 
Tschopp, 2010). Inflammasomes respond to both DAMPs and PAMPs, although are 
often highly specific to a single ligand. 
 
 1.7.1 NLRP3 inflammasome 
While NLRP3 is part of the larger family of inflammasomes, it remains distinct since 
it appears to play a role in many diseases, notably in multiple sterile inflammatory 
diseases including gout (Martinon et al., 2006), systemic lupus erythematosus (SLE) 
(Kahlenberg et al., 2013), cardiovascular disease (Yang et al., 2017b) and 
rheumatoid arthritis (Mathews et al., 2014). However, there is also evidence that the 
NLRP3 inflammasome is involved in systemic viral infections (Hottz et al., 2013) or 
bacterial sepsis (Dolunay et al., 2017). The multiple diseases NLRP3 is associated 
with, is likely due to the number of ligands it can be activated by. This is atypical of 
other inflammasomes, as the majority have a single specific agonist. This agonist 
specificity is vital to the tight regulation of inflammasomes, which when dysregulated 
drive severe inflammatory disease (Rowczenio et al., 2017). The NLRP3 
inflammasome has been shown to respond to multiple ligands including the bacterial 
toxin nigericin, bacterial membrane component LPS, cellular stress signal ATP, gout 
monosodium urate crystals, atherosclerotic plaque cholesterol crystals, oxLDL and 
amyloid-β protein (Sheedy et al., 2013, Agostini et al., 2004). Conversely, the AIM2 
inflammasome is only stimulated by viral double stranded DNA (dsDNA) presented 
when cells are infected by dsDNA viruses (Sagulenko et al., 2013), and the IPAF 
inflammasome is only stimulated by type III or IV secretion systems, commonly 
employed by gram negative bacteria to deliver toxins (Schroder and Tschopp, 2010). 
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The NLRP3 inflammasome is thought to respond to many ligands as they are 
assumed to converge on a common signalling pathway, where although they initiate 
from divergent points, there is a subsequent convergence on a shared node that has 
been suggested to be mitochondrial dysfunction paired with reactive oxygen species 
(ROS) production (Zhou et al., 2011, Ye et al., 2017, Murakami et al., 2012). This 
suggests that all the canonical agonists of the NLRP3 inflammasome are not yet 
known, but where mitochondrial ROS dysfunction is a result of the given ligand, 
NLRP3 inflammasome activation could be conjectured to occur. 
The NLRP3 inflammasome has been comprehensively described in leukocytic 
models since the first report of the complex in 2004 (Agostini et al., 2004), and this 
has provided a robust understanding of the structure of the complex and each subunit 
of the multimer. The NLRP3 inflammasome when activated is comprised of the nacht-
leucine rich repeat pyrin domain containing protein 3 (NLRP3) subunit, which binds 
to apoptosis-associated speck-like protein containing a CARD (ASC) via its pyrin 
domain. ASC subsequently recruits the thiol protease caspase-1 via its caspase 
recruitment domain (CARD). Once recruited, caspase-1 undergoes auto-cleavage 
and activation. The active caspase-1 tetramer is then able to cleave both gasdermin 
D and pro-interleukin-1β (IL-1β), which facilitate secretory pore formation and 
synthesis of IL-1β respectively (Figure 5). 
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Figure 5. Molecular structure of the NLRP3 inflammasome. Upon activation, the 
NLRP3 inflammasome is recruited and oligomerises. This results in the 
recruitment and activation of caspase-1 which in turn cleaves pro-IL-1β and 
gasdermin D. Abbreviations; LRR – leucine-rich repeat, NACHT – nucleotide-
binding and oligomerisation domain, PYD – pyrin domain, CARD – caspase 
recruitment domain, p20/p10 – active caspase-1 domains, p17 – mature IL-1β, 
PFD – pore forming domain, RD – repressor domain. 
 
1.7.2 Activation and regulation of the NLRP3 inflammasome 
For activation, the NLRP3 inflammasome must first undergo a priming event 
(Schroder and Tschopp, 2010). This is an intrinsic requirement of the complex, where 
it needs two distinct signals to permit activation. This two-step activation is a common 
feature of immune cell activation as it reduces aberrant activation which can drive 
severe inflammatory diseases. A classic example of this two-signal process is the 
memory B-cell class switch (Litinskiy et al., 2002), where a lack of dual signals, in 
this case, drives hypogammaglobinaemia (Salzer et al., 2005). In the context of the 
NLRP3 inflammasome, this requirement ensures careful regulation of the highly 
inflammatory IL-1β or IL-18 cytokines. The two-step activation is characterised firstly 
as a priming event which prepares the complex for recruitment and increases 
expression of constituent proteins, followed by a second signal that recruits the 
complex and drives activation (Schroder and Tschopp, 2010). It is now understood 
that priming is a combination of two concurrent events and can be further sub-divided 
into transcriptional and non-transcriptional priming. Transcriptional priming is 
transcription of inflammasome genes and translation of mRNA into inflammasome 
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component proteins – which of the five components, pro-IL-1β is required in particular 
abundance (Estruch et al., 2015). Non-transcriptional priming, is conversely 
regulatory events not driven by transcription, and has been shown to have several 
mediators including ubiquitination (Py et al., 2013, Rodgers et al., 2014, Song et al., 
2016) and phosphorylation of multiple components including ASC (Lin et al., 2015) 
and NLRP3 (Song et al., 2017). This two-step model of NLRP3 inflammasome 
activation means that for a classical laboratory stimulation assay/experiment a two-
step process of adding LPS followed by ATP or nigericin is required, to provide a 
priming and then an activating signal (Shi et al., 2016). 
 
 1.7.3 Platelets and the NLRP3 inflammasome 
While several publications have demonstrated a role for the NLRP3 inflammasome 
in platelets, it is still an emerging field with many aspects of expression, regulation 
and function not yet understood. The NLRP3 inflammasome in platelets was first 
reported in 2013 and the authors described a role for platelets in the pathogenicity of 
viral haemorrhagic fever caused by dengue virus infection (Hottz et al., 2013). With 
the application of flow cytometry, this study demonstrated dengue virus driven 
shedding of IL-1β rich platelet microparticles which correlated with caspase-1 
activation. Using pharmacological inhibitors against caspase-1, mitochondrial ROS 
and RIP1 kinase, these mediators were shown to be vital in the activation of NLRP3 
(Hottz et al., 2013). Later it was reported that Brutons tyrosine kinase (BTK) caused 
the activation of the NLRP3 inflammasome downstream of the classical platelet 
agonists collagen and thrombin and it was proposed that NLRP3 had an important 
role in platelet haemostatic activation (Murthy et al., 2017). In 2018, NLRP3 
inflammasome mediated regulation of platelet function was further explored and was 
shown to be key to the regulation of integrin outside-in signalling, and when tested in 
a NLRP3 knockout model (of note this was not a PF4/GP1b-cre model), platelet 
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thrombus formation was significantly reduced and bleeding times increased (Qiao et 
al., 2018). Although these two studies agreed on the importance of the NLRP3 
inflammasome in platelet activation, they disagreed with respect to the existence of 
phenotypes associated with α-granule secretion. Murthy et al., (2017) found no 
phenotype associated with α-granule secretion, whilst Qiao et al., (2018) found an α-
granule phenotype. Indeed, the role of the cytokine IL-1β itself on platelets and the 
effects it may have regarding function remains largely un-investigated. 
The platelet NLRP3 inflammasome model has also been applied to a sickle cell 
disease (SCD) cohort and murine model (Vogel et al., 2018a). A series of 
experiments were performed concentrating on fluorescence measurements of 
caspase-1 cleavage with the fluorochrome labelled inhibitors of caspase (FLICA) 
(Bedner et al., 2000). Their data suggested that the platelet derived TLR4 ligand, 
high-mobility group box 1 (HMGB1) through BTK drives NLRP3 inflammasome 
activation. Furthermore, this ligand is present in the plasma of SCD patients, 
correlates with basal caspase activation and diseased plasma can also stimulate 
naïve platelets from healthy donors (Vogel et al., 2018a). This is consistent with work 
from the same group which showed that increased NLRP3 inflammasome activity 
drove platelet aggregation and thereby supports their previous findings (Murthy et al., 
2017). A further short study again from the same group was published which 
reinforced their previously suggested aggregatory role of the platelet NLRP3 
inflammasome in a murine model of hind limb ischemia downstream of platelet TLR4 
ligation and caspase-1 cleavage (Vogel et al., 2018b). The same group then followed 
this up with a similar murine study which identifies that the platelet NLRP3 
inflammasome plays a role in the development of pancreatic cancer in a murine 
model (Boone et al., 2019). While not directly referencing NLRP3, and as such not 
considered part of these core publications, in 2017 a group described a role for 
platelet secreted IL-1β in the stimulation of endothelial cells in the context of SLE 
(Nhek et al., 2017). 
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In summary of the NLRP3 inflammasome in platelets, these papers agree on the core 
hypothesis determined from the literature identified above, that the NLRP3 
inflammasome plays an important role in platelet biology. However, they do not agree 
on the specific roles which the NLRP3 inflammasome may play, ranging from a 
systemic effect of secreted IL-1β driving vascular inflammation in dengue infection or 
SLE (Hottz et al., 2013, Nhek et al., 2017), to an autocrine effect which is vital for 
platelet activation (Brown et al., 2013, Qiao et al., 2018) or control of platelet 
activation (Murthy et al., 2017, Vogel et al., 2018a, Vogel et al., 2018b). 
 
1.7.4 Expression of NLRP3 components in platelets 
The current platelet NLRP3 inflammasome studies all provide convincing functional 
evidence of NLRP3 in platelets (Hottz et al., 2013, Murthy et al., 2017, Qiao et al., 
2018, Vogel et al., 2018a, Vogel et al., 2018b), and in addition to this there is prior 
evidence that platelets can produce IL-1β (Brown et al., 2013, Nhek et al., 2017) and 
IL-18 (Allam et al., 2017) that is indicative of NLRP3 activity. 
An additional valuable and comprehensive resource available to platelet researchers 
are transcriptomic or proteomic studies. In a brief overview of human and murine 
platelet proteomes and transcriptomes, the human proteome reports only ASC and 
gasdermin D, with copy numbers of both proteins predicted to be no more than 1500 
per cell (Burkhart et al., 2012). In contrast, the transcriptome of both human and 
murine platelet RNA reports the presence of all components; NLRP3, ASC, caspase-
1, IL-1β and gasdermin D, yet none are ranked within the 3000 most common 
transcripts (Rowley et al., 2011). The murine platelet proteome is identical to that for 
humans and suggests that only ASC and gasdermin D are present (Table 1) (Zeiler 
et al., 2014). These reports suggest that the presence of the complete NLRP3 
inflammasome in healthy individuals is unlikely, as expression of NLRP3 was not 
detected within the healthy donors which the proteomic and transcriptomic studies 
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where performed, yet as previously described there is a functional role for platelet 
NLRP3 in the literature. This could be attributed to either low copy numbers of these 
proteins or transcripts below current detection thresholds. In support of this, the 
human proteome does not detect the presence of Toll-like receptors (TLR), but their 
expression has been evidenced by traditional biochemistry in multiple studies 
(Biswas et al., 2017, Fung et al., 2012, Rex et al., 2009, Damien et al., 2015, Vogel 
et al., 2018a, Vogel et al., 2018b). Alternatively, and discussed at greater length in 
the following section, within healthy naïve donors the complexes are not present until 
after an initial inflammatory insult. 
Table 1. Relative expression or copy number of NLRP3 inflammasome 
components in human and murine platelets respectively (Rowley et al., 2011, 
Burkhart et al., 2012, Zeiler et al., 2014). Rowley et al., rank transcripts on assumed 
count from highest to lowest. Burkhart et al., and Zeiler et al., use an estimated copy 
number of each protein. 
 Protein or 
transcript 
Rowley, 
human rank 
Burkhart, 
human copy 
number 
Rowley, 
murine rank 
Zeiler, murine 
copy number 
C
o
m
p
o
n
e
n
ts
 
NLRP3 5913 - 10955 - 
ASC 3005 1000 4178 3743 
Caspase-1 3365 - 6354 - 
Interleukin1-β 4972 - 5773 - 
Gasdermin D 4114 1500 9645 308 
U
p
s
tr
e
a
m
 
TLR2 5465 - 10865 - 
TLR4 7930 - 11414 - 
TLR6 11362 - 12714 - 
MyD88 3858 940 1906 1044 
C
o
n
tr
o
ls
 
GPIX 48 32400 16 63503 
CD36 615 16700 6093 - 
GPVI 367 9600 155 7822 
BTK 599 11100 1590 12146 
Fyn 548 6800 490 4145 
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 1.7.5 Priming of the NLRP3 inflammasome in platelets 
The two-step model of NLRP3 activation of priming then activation is understood to 
be vital for robust synthesis of IL-1β via the NLRP3 inflammasome. However, no 
platelet NLRP3 inflammasome studies to date have explored this signalling 
dichotomy nor suggested it as necessary for NLRP3 activity. To date, the published 
work in this area agrees that platelets are able to demonstrate activation with only a 
single signal, but disagrees on whether this is inflammatory (Vogel et al., 2018a), 
pathogenic (Hottz et al., 2013), or thrombotic (Qiao et al., 2018). While this disagrees 
with current literature in nucleated cells, where the use of thrombotic ligands has 
been described, this is not surprising since platelets are unique cells and lack the 
capacity to undergo extensive transcriptional priming. They are instead more likely 
released from a megakaryocyte with the inflammasome component proteins; NLRP3, 
ASC, caspase-1, IL-1β and gasdermin D present in an inactive state. Therefore, it is 
possible to hypothesise that pre-programming is occurring, and it is the 
megakaryocyte which receives the transcriptional priming signal and the platelet the 
non-transcriptional priming and second activatory signal. This suggests there may be 
a complex cross-cellular process in place regulating this potent inflammatory event 
controlling a platelet population which is pre-programmed by megakaryocytes whom 
have adapted to the systemic environment and produced platelets tailored to 
requirement, not dissimilar to the model proposed by Davizon-Castillo et al., who 
propose that in ageing megakaryocytes produce inflammatory and metabolically 
defective platelets (Davizon-Castillo et al., 2019). 
In support of platelet pre-programming by the megakaryocyte, the concept of disease 
altering the platelet proteome has already been demonstrated in severe obesity 
(Heffron et al., 2018). This would further suggest that the lack of inflammasome 
components in the Burkhart (Burkhart et al., 2012), Rowley (Rowley et al., 2011), and 
Zeiler (Zeiler et al., 2014) studies may be due to the use of naïve donors for analysis. 
It is tempting to suggest the pulmonary megakaryocyte subset (Lefrancais et al., 
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2017), which it can be assumed are constantly bombarded with various airborne 
DAMPs, exhaust emissions or smoke, and PAMPs may be a source of early 
inflammatory platelets. Early work on this megakaryocyte subset suggested that the 
blood concentration of platelets was changing in response to respiratory insult 
(Sharma and Talbot, 1986), and it could be hypothesised that this increase in cell 
count was paired with a change in proteome. However this has not been further 
pursued to date. 
Conversely or alongside this theory of platelet pre-programming, there is some 
evidence platelets have synthetic capacity and they are packaged with mRNA for 
pro-IL-1β (Brown et al., 2013), and pro-IL-18 (Allam et al., 2017), which has been 
shown to be spliced upon activation. This suggests there is flexibility within the 
platelets to splice selected mRNAs and upregulate proteins (Denis et al., 2005), 
therefore platelets may also inherently have the capacity for transcriptional priming 
and undergo post-megakaryocyte proteomic changes. 
What remains clear is that where there are 150-400,000 platelets per microlitre of 
human blood, or ~75-200 x1010 platelets per individual, any inflammatory event they 
can initiate must be tightly controlled and aberrant activation avoided. It is the 
relationship between megakaryocytes and platelets in an inflammatory environment 
which undoubtedly remains vital to the pro-inflammatory platelet phenotype which 
the NLRP3 inflammasome evidences. This strongly suggests that understanding the 
changes which megakaryocytes undergo in inflammation will be just as vital as those 
which the platelets themselves demonstrate.  
 
1.7.6 NLRP3 inflammasome and atherosclerosis 
While the role of the NLRP3 inflammasome in platelets is not yet fully understood, it 
is possible to hypothesise a role for platelets in other systemic inflammatory diseases 
beyond the example of an acute dengue virus infection (Hottz et al., 2013), or the 
- 42 - 
more recently established role for platelets in chronic sickle-cell disease (Vogel et al., 
2018a). While many chronic inflammatory roles for other cells via the NLRP3 
inflammasome have been demonstrated, the blood borne inflammation that drives 
atherogenesis is an area which platelets could be proposed to play a key role 
(Sheedy et al., 2013). Particular clinical emphasis has recently been placed on the 
role of NLRP3 inflammasome produced IL-1β in the progression of atherosclerosis 
(Grebe et al., 2018, Baldrighi et al., 2017). The link between IL-1β and atherosclerosis 
has been proposed for several years and has been demonstrated in animal models 
by different research groups. Heijden et al. used the ApoE-/- murine model, which 
rapidly develops atherosclerosis, to demonstrate that pharmacological NLRP3 
inhibition leads to reduced plaque size (van der Heijden et al., 2017). Similarly, van 
Hout et al. used a wild type porcine model and observed that with NLRP3 inhibition, 
and therefore reduced IL-1β synthesis, the severity of myocardial infarction was 
reduced (van Hout et al., 2017). Finally, the ApoE-/-/ IL-1β-/- double knockout murine 
model has been shown to present with reduced atherosclerotic plaque size compared 
to ApoE-/-/IL-1β+/+ (Kirii et al., 2003). These all identify a key role for IL-1β in 
atherosclerotic development and progression of cardiovascular disease. 
Further to these observations, clinical studies have begun to explore the relationship 
between the NLRP3 inflammasome and atherosclerosis. A recent human study has 
associated genetic polymorphisms in the genes which code for NLRP3 and caspase-
1 with increased risk of developing acute coronary syndrome (Gonzalez-Pacheco et 
al., 2017). These studies and others have prompted the clinical trial into the 
effectiveness of canakinumab, a monoclonal antibody targeting IL-1β, as a therapy 
to target atherosclerotic disease (Ridker et al., 2011). Early results have indicated 
that anti-IL-1β therapy leads to a significantly reduced rate of cardiovascular events 
against the control group (Ridker et al., 2017a). A further studies outcomes of note 
included that canakinumab also appeared to exert protective effects in lung cancer 
incidence, considering the pulmonary megakaryocyte/platelet pool this could be 
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considered as another proposed role for platelet inflammatory function (Ridker et al., 
2017b). Importantly for platelet researchers, these studies are global knockouts or 
systemic non-targeted treatment, leaving the question as to which cells contribute to 
these overt atherosclerotic phenotypes open. 
OxLDL has been shown to modulate cellular function in many ways (Levitan et al., 
2010), however, an implication in driving vascular inflammation and atherogenesis 
suggests it is a potential clinical target. OxLDL has been implicated in driving 
atherogenesis through activation of the NLRP3 inflammasome in macrophages and 
monocytes (Sheedy et al., 2013, Estruch et al., 2015, Yang et al., 2017b), which is 
likely via CD36 in a heteromeric signalling platform with TLRs 2/4/6 (Chavez-Sanchez 
et al., 2014, Stewart et al., 2010). OxLDL has also been shown to modulate 
endothelial cell biology, mostly by driving production of ROS which in turn impacts 
cell viability and lifespan (Touyz, 2014, Vindis et al., 2005, Zmijewski et al., 2005). 
The majority of the ROS produced in endothelial cells downstream of oxLDL have 
been functionally linked to mitochondrial dysfunction (Giovannini et al., 2002). This is 
likely via the LOX1 receptor (Christ and Latz, 2014, Touyz, 2014, Yang et al., 2017b), 
although CD36 also mediates cellular dysfunction (Sheedy et al., 2013) and can also 
be found directly on the mitochondrial surface (Smith et al., 2011). Taking all of these 
points in other cell types together and the functional expression of the NLRP3 
inflammasome in platelets, it is possible to hypothesise a role for oxLDL and platelet 
NLRP3 in atherogenesis and vascular inflammation (Figure 6). 
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Figure 6. Proposed model of NLRP3 activity in platelets. DAMPs or PAMPs ligate 
their appropriate receptor which drives (post-)transcriptional priming of the 
NLRP3 inflammasome, followed by a second signal which drives recruitment, 
speck formation and cleavage of gasdermin D and IL-1β 
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1.8 AIMS OF STUDY 
-Understand how platelet regulation may determine novel platelet subpopulations 
-Explore the function of the NLRP3 inflammasome in platelets downstream of oxLDL 
-Determine the role of oxLDL in driving platelet mitochondrial dysfunction 
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Chapter 2 
Materials & Methods 
2.1 REAGENTS 
2.1.1 Chemicals & reagents 
Sodium Citrate (367691), ACD-A (8304451), Sodium Heparin BD Vacutainer Tubes 
(8516324), BD DC Protein Assay Kit (5000112) and BD Phosflow Lyse/Fix Buffer 5X 
(558049) were from BD Biosciences. TMRE-Mitochondrial Membrane Potential 
Assay Kit (113852) was from Abcam. SFLLRN (Thrombin Receptor Activating 
Peptide) (58927) was from Anaspec. Collagen-related peptide (CRP-XL) was from 
Collagen Toolkits. Prostaglandin I2 (sodium salt) (61849-14-7) was from Cayman 
Chemical. VersaComp Antibody Capture Bead Kit (B22804) was from Beckman 
Coulter Life Sciences. 4% Paraformaldehyde Aqueous Solution (157-4) was from 
Electron Microscopy Sciences. All other reagents were from Sigma-Aldrich. 
 
2.1.2 Antibodies 
Annexin V APC Ready Flow Conjugate (R37176), CD63 Monoclonal Antibody 
(H5C6) eFluor 660 (50-0639-42), CD154 Monoclonal Antibody (24-31) FITC (11-
1548-42), Mouse IgG1 kappa Isotype Control (P3.6.2.8.1) eFluor 660 (50-4714-82), 
Mouse IgG1 kappa Isotype Control (P3.6.2.8.1) FITC (11-4714-81), and Goat anti-
Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody Alexa Fluor 488 (A-
11034) were from ThermoFisher Scientific. BB700 Mouse Anti-Human CD42b 
(742219), APC Mouse Anti-Human CD42b (551061), FITC Mouse Anti-Human PAC-
1 (340507), PE Mouse Anti-Human CD62P (555524), PE Mouse IgG1 κ Isotype 
Control (556650), FITC Mouse Anti-Human CD14 (347493) and PerCP Mouse Anti-
Human CD42a (340537) were from BD Biosciences. Anti-Human Fibrinogen/FITC 
(F0111) was from Agilent Technologies. Phospho-VASP (Ser157) Antibody (3111) 
was from Cell Signalling Technology. 
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2.2 METHODS FOR THE ISOLATION OF BLOOD CELLS 
2.2.1 Isolation of human platelets 
Platelets were isolated from whole blood obtained from healthy volunteers in 
accordance with the declaration of Helsinki. All donors were consenting and healthy 
on presentation and also confirmed they had taken no anti-coagulants or anti-platelet 
drugs. Careful isolation procedures were required since platelets are very sensitive 
to artefactual activation during handling. The first approach was to use prostaglandin 
I2 (PGI2) to inhibit activation during isolation (Vargas et al., 1982). However, when 
cAMP signalling was being studied, a second approach where the pH was lowered 
using citric acid, which also inhibits platelets, was used. The average yield from 16 
mL of healthy human donor blood was 2.4 mL of cell suspension at 5 x 108 
platelets/mL (Figure 7). 
 
 
Figure 7. Average yield of washed platelets from 16 mL of whole blood. Platelets 
washed from 16 mL of whole blood drawn into ACD-A and resuspended to a 
final count of 5 x 108 platelets/mL and total volume measured. (Mean±SD, 
n=22) 
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2.2.2 Isolation methods 
Blood was obtained from palpable veins located in the ante-cubital fossa through 
venepuncture with a 21g butterfly needle by trained phlebotomists. Blood was drawn 
into acid citrate dextrose (ACD, 2.9 mM citric acid, 29.9 mM sodium citrate, 72.6 mM 
NaCl, 113.8 mM glucose, pH 6.4) syringes at a 1:5 ratio with anticoagulant or into 
commercial ACD-A (BD) vacutainers at 1:5 ratio with anticoagulant (85 mM sodium 
citrate, 136 mM dextrose, 42 mM citric acid, 1 mM potassium sorbate), then 
transferred to a 50 mL falcon tube at a fill rate of 20 mL per tube, and centrifuged at 
100 g for 20 minutes (no brake) to isolate platelet-rich plasma (PRP). PRP was 
removed using a 1.5 mL Pasteur pipette and equally distributed between two 15 mL 
falcon tubes. 
In some cases, PRP was treated for 2 minutes with PGI2 (200 nM) then centrifuged 
at 1000 g for 10 minutes (with brake) to pellet the cells. Supernatant plasma was 
removed, and the pellet was re-suspended in 5 mL of modified Tyrode’s buffer (0.5 
mM MgCl2, 0.55 mM NaH2PO4, 2.7 mM KCl, 5 mM HEPES, 5.6 mM glucose, 7 mM 
NaHCO3, 150 mM NaCl, pH 7.4), 0.5 mL of ACD and 200 nM PGI2 and incubated for 
2 minutes. This was then centrifuged at 1000 g for 10 minutes (with brake) to pellet 
washed cells. Supernatant wash buffer was removed, and the pellet was re-
suspended in 1 mL of modified Tyrode’s buffer, counted and rested at 37◦C for 20 
minutes prior to assay initiation to allow for recovery from PGI2 treatment. 
As an alternative approach, a citric acid-based wash buffer, which both reduces pH 
and contains EDTA to chelate calcium ions, was used to inhibit platelet activation in 
the absence of PGI2. Here PRP was treated for 2 minutes with citric acid (0.3 M) at a 
ratio of 20 µL/1 mL PRP. This was then centrifuged at 1000 g for 10 minutes (with 
brake) to pellet the cells. Supernatant plasma was removed, and the pellet was re-
suspended in 5 mL of wash buffer (5 mM glucose, 5 mM KCl, 9 mM NaCl, 10 mM 
EDTA, 36 mM citric acid, pH 6.4) and centrifuged at 1000 g for 10 minutes (with 
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brake) to pellet washed cells. Supernatant wash buffer was removed, and the pellet 
was re-suspended in 1 mL of modified Tyrode’s buffer, counted and rested at 37◦C 
for 20 minutes prior to assay initiation to allow for recovery from isolation. 
 
2.2.3 Isolation of murine platelets 
Murine blood was drawn from the exposed vena cava of isoflurane anaesthetised 
mice with a 25g needle into a 1 mL syringe pre-filled and coated with 200 µL of ACD. 
This was transferred to a 15 mL falcon tube and 200 µL of modified Tyrode’s buffer 
was added prior to centrifugation at 100 g for 5 minutes (no brake) to isolate PRP. 
PRP was removed to a 15 mL falcon tube and the remaining blood cell pellet was 
remixed with an addition of 200 µL of modified Tyrode’s buffer prior to a second 
centrifugation at 100 g for 5 minutes (no brake). The resulting PRP was combined 
with the previously isolated PRP. The PRP volume was then adjusted to 2 mL with 
modified Tyrode’s buffer and PGI2 (200nM). The PRP was centrifuged at 1000 g for 
6 minutes (with brake), then the supernatant removed, and the isolated platelets 
resuspended in 500 µL of modified Tyrode’s buffer, before counting and resting at 
37◦C for 20 minutes prior to assay initiation to allow for recovery of cAMP levels. 
 
2.2.4 Counting isolated platelets 
Platelet counting was performed on a Beckman Coulter Z1 particle counter. The 
platelet suspension was diluted 1/2000 (5 µL in 10 mL) of isotonic count buffer 
(Beckman Coulter) and analysed for particles between 2 – 7 µm in diameter using a 
50 µm aperture. This count was multiplied by 2000, to account for the dilution factor, 
giving a concentration per resuspended millilitre of cells. The count was adjusted to 
the desired concentrations for each assay using Equation 2. For example, 
concentrations of 2.5 x 108/mL, 5 x 108/mL and 10 x 108/mL were used for 
aggregation, flow cytometry and immunoblotting respectively. 
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(
𝑎𝑐𝑡𝑢𝑎𝑙 𝑐𝑜𝑢𝑛𝑡
𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑜𝑢𝑛𝑡
) − 𝑎𝑐𝑡𝑢𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 = 𝑎𝑑𝑗𝑢𝑠𝑡𝑚𝑒𝑛𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 
Equation 2. Used to calculate volume of buffer to add to adjust platelet count. Where 
adjustment volume is the volume of buffer to add to reach the desired 
concentration. 
2.3 METHODS FOR STUDYING PLATELET FUNCTION 
 2.3.1 Fluorescent flow cytometry 
Flow cytometry, as the name suggests is the measurement of cells under flow in 
suspension. This simple description hides the true power, which is the 
multiparameter analysis of single cells in complex media at a rate of >1000 
cells/second. This allows not only descriptive characterisation of single cells, but 
vitally their comparisons within their given population, and subsequent division into 
phenotypically distinct subpopulations. However, given the current relative ease of 
accessibility, appropriate application of technical aspects and biological controls is 
key to the correct interpretation of data (Cossarizza et al., 2017). 
Flow cytometry relies on several key principles, each of which feed into one another; 
(i) cells are in suspension at a suitably low concentration, (ii) the fluidic forces of 
sheath can push the sample into a sample core of single cells, (iii) lasers are able to 
excite each individual cell as it passes through and detectors collect the emitted and 
scattered light (Cossarizza et al., 2017). 
The essential principle of a flow cytometer is the ability of a sheath of fluid under 
pressure to force a suspension of particles into a linear core, and this was first 
described and used for counting particles in suspension (Crosland-Taylor, 1953). 
This hydrodynamic focusing forces Brownian suspensions of particles into streams 
of single particles (Figure 8). Yet on some occasions events can pass through the 
flow cell simultaneously (swarming) or aggregates/agglomerates of cells/particles 
can form resulting in erroneous data as these are counted as single particles or 
events. Therefore, it is key that both, concentration of particles does not allow 
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swarming and the milieu in which the particles are suspended does not encourage 
precipitate or doublet formation, or commonly in the case of platelets, homotypic 
aggregate formation. Here we used a Beckman Coulter CytoFLEX, which uses a 
peristaltic pump as oppose to the more traditional syringe drive to maintain a 
consistent flow of sample through the flow cell (Beckman Coulter). 
Typically, the digital information presented on an interface attached to a flow 
cytometer has gone through several transformations. Cells and fluorophores which 
are passed through the flow cell are excited by lasers and emitted light intensity is 
measured. This collected light, or photons, are routed to detectors after pre-
processing in optical filters, which is a key step as the detectors are insensitive to the 
wavelength of light. In the CytoFLEX, avalanche photodiodes (APDs) are used rather 
than the more commonly used photomultiplier tubes (PMT), APDs have been shown 
to give a greater detection of near-infrared signals than PMTs (Lawrence et al., 2008), 
allowing greater flexibility in panel design. The detectors convert photons into 
photoelectrons which are then processed and amplified accordingly and then 
converted to a digital signal via an analogue digital converter (ADC) (Cossarizza et 
al., 2017). The optimal set up of the cytometer and performance of each component 
should lead to a low signal: noise ratio, which is the key determining factor of the 
sensitivity of a flow cytometer. 
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Figure 8. Fluidic system of a fluorescent flow cytometer. Sample is drawn into 
the flow cell and focussed into a beam of single cells by hydrodynamic focusing. 
These then pass through excitation lasers which drive emission of tagged 
fluorophores and allow physical light scattering to be collected. Adapted from 
(Cossarizza et al., 2017) 
 
2.3.1.1 Applications of FFC to platelet biology 
Flow cytometry has been used for the analysis of platelets for many years. It is a 
technique which is well suited for platelet research, since platelets typically exist 
within suspensions of complex media (blood or plasma) and express unique markers 
on activation which can be easily detected. Several major milestones of platelet flow 
cytometry have been reached. Firstly, the use of the peptide Glycine-Proline-
Arginine-Proline (GPRP) was shown to allow activation analysis in thrombin 
stimulated whole blood to be carried out (Michelson, 1994). Secondly, the 
widespread use of the PAC1 antibody, which detects the conformational change in 
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the integrin αIIbβ3, was presented as an alternative marker to fibrinogen binding 
(Frelinger, 2018). Thirdly the use of phosphoflow to detect intracellular changes to 
phosphorylation state in platelets (Spurgeon et al., 2014) Fourthly, the first six-
parameter platelet panel was reported on in 2018 (Sodergren and Ramstrom, 2018), 
and finally the application of cytometry by time of flight (CyTOF) was applied to 
platelet biology (Blair et al., 2018). These milestones have all pushed the frontiers of 
platelet analysis by flow cytometry, and vitally have opened an important discussion 
on standardisation of technique and how these assays may be translated to clinics 
(Welch et al., 2018, Linden et al., 2004, Harrison, 2009, Harrison et al., 2011, 
Ramstrom et al., 2016, Spurgeon and Naseem, 2019). Based on the current 
progression of the cellular immunology field, platelet biology assessed by fluorescent 
flow cytometry is likely to continue to grow with an increased uptake of 
multiparameter assays with multidimensional analysis which will, in turn, drive the 
potential for discovery of rare cell subpopulations. Furthermore, the phosphoflow 
protocol has not yet been fully realised in the study of platelet biology, where the 
simultaneous measurement of multiple phosphorylation events paired with changes 
in surface marker expression (Leelatian et al., 2015), will provide a hugely powerful 
platform for the interpretation of platelet signalling in the future. 
 
2.3.1.2 Multiparameter flow cytometry 
As multiparameter flow cytometry becomes more routine, there is a requisite increase 
in demand for multidimensional analyses, which avoid the biased and time-
consuming manual gating strategy in lieu of algorithm based deconvolution and 
clustering. There are several such variants now available for the researcher to use 
on an open access basis. The three most common variants currently in use are 
SPADE (Spanning-tree progression analysis of density-normalized events), 
flowSOM (Flow self-organising map) and tSNE (T-stochastic neighbourhood 
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embedding) and they can be applied from open-source GitHub resources or through 
packages such as FlowJo or Cytobank. A brief overview of the three main 
multidimensional analyses are as follows. 
SPADE (2011), is a computational approach to analysis of flow cytometry data which 
is used to uncover cellular heterogeneity from multiparameter flow cytometry data 
sets. SPADE provides the researcher with a “tree” of clusters of cells which are 
grouped into major groups of related cells (branches), i.e., granulocytes, and then 
within that will be individual clusters (leaves), i.e., belonging to neutrophil, basophil 
and eosinophils – providing that the marker panel chosen distinguishes these cells.  
FlowSOM (2015), analysis was developed as an alternative means of clustering and 
dimensionality reduction. FlowSOM produces a tree of related cells similar to SPADE, 
but has been shown to be roughly 100x faster in analysis as it does not require 
subsampling (Van Gassen et al., 2015). However, it is generally not compatible with 
less than 7-parameter cytometry as it loses power of resolution. 
t-SNE (2008), is a visualisation tool which reduces the dimensionality of 
multiparameter data onto a 2-dimensional plot of arbitrary t-SNE axes (van der 
Maaten and Hinton, 2008). Unlike SPADE, which plots only clusters representative 
of cells as relatively size globes on a tree, t-SNE plots all cells/events analysed. Using 
a random seed and a series of exaggeration phases it pulls together related events 
and pushes apart non-related events giving rise to islands. t-SNE is used for both 
genomic data as well as flow cytometry data, although initially the algorithm struggled 
with very large (>1 x 106 events) datasets, several iterations have since been 
proposed to address these initial pitfalls. Further improvements include the 
development of optimal parameter t-SNE, opt-SNE (Belkina et al., 2018), which 
provided automated tools as part of the analysis package which deploy prior to tSNE 
analysis to determine optimal pre-t-SNE conditions. This demonstrated a significant 
improvement in the size of datasets which could be processed, allowing up to 20 x 
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106 events to be processed and populations resolved. In this study, we use fast 
Fourier transform-accelerated interpolation-based t-SNE, Fit-SNE (2019). This re-
iteration of the original algorithm sped analysis time, reduced computational load and 
enhanced scaling to larger data sets through application of Fourier transform and 
using an ANNOY library lookup to calculate nearest neighbours as oppose to using 
vantage-point trees (Linderman et al., 2019). None of these methods of analysis have 
yet been applied to fluorescent flow cytometry data of platelets, while two papers 
using CyTOF analysis of platelets have used t-SNE (Blair et al., 2018) or both t-SNE 
and flowSOM (Blair and Frelinger, 2019) and have used these to describe differences 
in marker expression across the entire platelet population, although have not 
definitely identified subpopulations based on specific marker expression yet. 
The following protocols focus primarily on human platelet analysis, although the 
assays are interchangeable with murine platelets providing an antibody that targets 
the murine platelets protein is available. 
 
2.3.1.3 Platelet identification 
Platelets can be identified on a flow cytometer based on their distinct physical 
characteristics of forward scatter (FSC) and side scatter (SSC), as they are 
considerably smaller than both red-blood cells and leukocytes. However, where 
possible and compatible with the assay, positive gating was used to confirm the gated 
population of cells are platelets. This uses the expression of platelet specific surface 
markers and excludes debris which may fall into the physical gate (Figure 9). In 
platelet activation assays, a further physical gate was analysed to ensure cellular 
doublets were not analysed. 
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Figure 9. Platelet gating on a fluorescent flow cytometer. Platelets can be gated 
for using physical characteristics on FSC and SSC (left) or using CD42b 
positive events (right), where a small amount of debris (left shift) which positive 
gating omits can be seen, as can the platelet doublet events which are twice as 
bright for the platelet marker (right shift). Here a CD42b-BB700 was used to 
provide a platelet positive gate. 
 
 
2.3.1.4 Platelet activation 
Flow cytometric measurement of platelet activation utilises a variety of different 
antibodies or protein conjugates, which bind to either constitutive or inducible protein 
markers on the platelet surface. Typically, we used antibodies or conjugates raised 
against CD62P (P-selectin), fibrinogen, the active integrin αIIbβ3 or annexin V which 
binds to PS in a calcium dependent manner. 
Regardless of the antibody mixture used, platelet activation assays on the flow 
cytometer were performed under the following conditions. All reagents bar blood was 
added, and the tube was mixed thoroughly on whole blood addition, incubated for 20 
minutes and then fixed in 10x volume of 1% paraformaldehyde/PBS. Table 2 provides 
an overview of the reagents required for a mock experiment comparing basal with 
stimulated and an isotype control tube. Where many conditions were being 
performed a 1.1 mL 96-well round bottomed plate was used to allow for high 
throughput processing of samples. 
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Table 2. A generic design of a platelet activation flow cytometry assay. Working 
with a total volume of 50 µL, whole blood, titrated antibodies and 10x agonists 
are added to an appropriate amount of modified Tyrode’s buffer. There is 
flexibility in the additions as the volume of modified Tyrode’s buffer can be 
adjusted to account for additional inhibitors or larger volumes of antibodies and 
agonists. 
Condition M. 
Tyrode’s 
Whole 
blood 
Antibodies Agonists Control 
Antibodies 
Basal 40 5 5 0 0 
Stimulated 35 5 5 5 0 
Control 35 5 0 5 5 
 
Platelet activation can then be measured as median/mean fluorescence intensity 
(MFI), fold over basal or percent positive cells over control (Figure 10). MFI is a total 
reading of signal from the population of events and as such is quantitative for volume 
of antibody bound and therefore antigen exposed. Fold over basal also uses MFI, but 
all data is normalised to a basal signal, this eliminates a requirement for an IgG or 
fluorescence minus one (FMO) control. However, this approach prevents the 
researcher making any comment on basal activity. Percent positive cells is a 
qualitative readout, by setting a background fluorescence baseline of 2% on an IgG 
or FMO control, any fluorescence which exceeds this is determined to be positive 
signal, and the event is therefore considered positive for the marker. This measure 
is insensitive to quantity of antibody bound but can be very sensitive to subtle 
changes. Preferably, both quantitative MFI and qualitative percent positive are used 
when expressing data, as they present more fully the depth of data available and 
may provide insight into nuances which one data set alone would not illustrate. 
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Figure 10. Two-parameter platelet activation. Fibrinogen-FITC (Y-axis) and 
CD62P-PE (X-axis) were measured in platelets at basal (left) and stimulated 
(right) with SFLLRN (5 µM). Gates were determined using EDTA and IgG-PE 
control which allows for percentage positive cells to be calculated. 
 
In this study many antibodies were used to measure activation. They were often 
combined into panels (Table 3) to study activation and therefore compare markers 
and provide data for advanced analysis. 
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Table 3. Multicolour panels used to examine platelet activation. In combination 
these panels allow 7 markers to be compared for changes in expression upon 
activation. The breadth of markers was designed to allow several phases of 
platelet activation to be monitored including; aggregatory activation, 
degranulation of alpha and dense granules and procoagulant activity. 
 Filter (band pass) 
Panel 525/40 585/42 660/10 712/25 
1 Fibrinogen 
-FITC 
CD62P 
-PE (AK-4) 
CD42b 
-APC (HIP1) 
- 
2 Fibrinogen 
-FITC 
CD62P 
-PE (AK-4) 
Annexin V 
-APC 
CD42b 
-BB700 
(HIP1) 
3 PAC1 
-FITC 
CD62P 
-PE (AK-4) 
CD42b 
-APC (HIP1) 
- 
4 PAC1 
-FITC 
CD62P 
-PE (AK-4) 
Annexin V 
-APC 
CD42b 
-BB700 
(HIP1) 
5 CD154 
-FITC (24-31) 
CD62P 
-PE (AK-4) 
CD63 
-eF660 
(H5C6) 
CD42b 
-BB700 
(HIP1) 
 
2.3.1.5 Platelet counting in whole blood 
In brief, by diluting 5 µL of blood within 45 µL of staining cocktail, that contained an 
antibody which targets a platelet marker such as CD41, CD42b or CD61, and then 
adding 450 µL of PBS a dilution factor of 1/100 was maintained. By running samples 
at a low acquisition rate (10 µL/minute) for 2.5 minutes, the events/µL and therefore 
cell count can be compared between donors, or transgenic murine strains. 
 
2.3.1.6 Platelet leukocyte aggregates 
Platelet-leukocyte aggregates are measured on a flow cytometer using a multi-
fluorescence approach and through a gating strategy that uses cell specific surface 
markers to identify the leukocyte of interest (Figure 11). For example, in enriched 
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PBMC suspension monocytes are distinguished using gates set as SSC-A/CD14-
FITC (CD45 positive) and lymphocytes with SSC-A/CD45-PE (CD14 negative). 
 
 
Figure 11. Monocyte and lymphocyte gating strategy in enriched PBMC 
suspension. Enriched PBMC suspension was probed with CD14-FITC and 
CD45-PE to allow for identification of monocytes (CD14-FITC, mid) and 
lymphocytes (CD45-PE, right) respectively.  
 
Gating of the leukocyte of interest then allowed for platelet fluorescence to be 
measured from this gate, where signal for platelet specific markers indicated that 
platelets are bound to the leukocyte. For example, platelet monocyte interactions 
were measured using a CD14-FITC monocyte gate and then these cells were 
examined for CD42b-BB700 fluorescence. The basal sample exhibited little platelet 
monocyte aggregates and the stimulated sample (SFLLRN 10 µM, 20 minutes) 
demonstrated the majority of monocytes are bound to platelets (Figure 12). 
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Figure 12. Platelet monocyte interactions. Whole blood is left at basal (left) or 
stimulated (right, SFLLRN 10 µM, 20 minutes) and probed with CD14-FITC and 
CD42b-BB700 (detected with the APC-A700 filter) to identify monocytes and 
platelets respectively. 
 
In this study several antibodies were used to distinguish platelets, monocytes, 
lymphocytes and neutrophils. They include CD42b-APC, CD42b-BB700, CD42a-
PerCP, CD14-FITC, CD16-APC, CD45-PE. 
 
2.3.1.7 Technical development of assays 
The use of multiple fluorophores allows the simultaneous acquisition of numerous 
markers on the cell surface. However, spectral overlap of fluorophores is considered 
the major issue with multi-colour fluorescent flow cytometry. With the Beckman 
Coulter CytoFLEX allowing up to 13 channels to be measured in a spectral range 
which covers only 330 nm, this means that panel design, fluorophore selection and 
compensation must all be used to eliminate the inclusion of false data. 
 
2.3.1.8 Panel design 
For the panel design used in this study, the targets were ranked by expression level 
and then by those markers which are used qualitatively for gating or those used 
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quantitatively for accurate measurement of expression. By arranging targets like this 
it was possible to assign appropriate fluorophores based on brightness, stability and 
the amount of spectral compensation each channel will require. For example, a target 
of interest which has low expression but is suspected to change only a small amount 
on activation is a good candidate for a bright fluorophore such as PE. However, if the 
target was simply a cell marker used for gating which is highly expressed and 
changes are not expected to occur, a less sensitive fluorophore could be used, such 
as far-red BB700. 
 
 2.3.1.9 Compensation 
Compensation is the calculation of spectral overlap between fluorophores into 
adjacent channel bandpass filters, allowing the subsequent subtraction of 
fluorescence which is deemed to be from outside of the target fluorophores emission. 
It is performed with either antibody binding beads or cells. Several tubes of cells or 
beads are produced with each one stained with a single fluorophore and compared 
to an unstained tube. By analysing each tube individually, it is then possible to 
calculate the degree to which each fluorophore bleeds into each adjacent channel. 
Using software such as CytExpert or FlowJo, a compensation matrix can then be 
produced, an example of which is given (Table 4). A compensation matrix is specific 
to the fluorophores, gains and spectral characteristics for the specific cytometer on 
which it was acquired. Applied properly, a compensation matrix will subtract spectral 
overlap and allow multicolour fluorescent flow cytometry to be performed. 
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Table 4. An example compensation matrix. This matrix was produced using beads 
bound to antibodies with the appropriate fluorophore. It allows compensated 
four-colour measurement of Fibrinogen-FITC, CD62P-PE, Annexin V-APC and 
CD42b-BB700. 
Channel -FITC% -PE% -APC% -APC-A700% 
FITC  0.64 0.00 14.11 
PE 27.62  0.00 42.67 
APC 0.00 0.00  10.24 
APC-A700 0.00 0.00 37.66  
 
In practice, compensation can be demonstrated using a population of three differently 
stained beads. Beckman Coulter VersaComp beads stained with FITC, PE and APC 
were run separately to produce a compensation matrix which was automatically 
calculated by the CytExpert compensation calculator, before running individually and 
the data was then compared for spectral overlap in both uncompensated and 
compensated data sets. FITC and PE were shown to overlap heavily as they are of 
similar emission and both excited by the 488 nm laser, while APC which is excited 
by the 638nm laser was not affected by either of these fluorophores. The matrix 
compensated the spill-over between FITC and PE, but it also induced an increase in 
spreading of the data around the median point (Figure 13). Which is the major caveat 
of compensation, which will result in a increase in data spread and therefore a small 
loss of a sensitivity, although often this caveat is outweighed by the increased power 
that multiple parameters bring to a cytometry assay. 
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Figure 13. Three colour compensation in practice. Staining with FITC, PE and 
APC conjugated antibodies demonstrate the principles of spectral bleed from 
each channel in the uncompensated column (left), but when a compensation 
matrix is applied the spectral overlap is eliminated with some increased 
spreading of compensated parameters (right). 
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2.3.1.10 Phosphoflow 
Phosphoflow is a novel method for analysing the phospho-proteome by fluorescent 
flow cytometry (Oberprieler and Tasken, 2011). Typically, phosphorylation events are 
measured through a combination of immunoblot and immunoprecipitation and this 
provides a bulk phosphorylation measurement for the entire population of cells. By 
flow cytometry each cell is analysed as an individual event, this allows 
phosphorylation of cellular subpopulations to be examined. Furthermore, flow 
cytometry is also high throughput and needs only small samples, whereas traditional 
immunoblot techniques take upwards of a day and require large sample volumes. 
The method is based on permeabilisation of cells to allow the entry of phospho-
specific antibodies (Spurgeon and Naseem, 2018).  
Whole blood (20 µL) was incubated with PGI2 (1 – 1000 nM) for 2 minutes within the 
wells of 96-well plate. Each sample then had 10x volume of 1x BD fix/lyse at room 
temperature to fix and lyse RBC. This was centrifuged at 1000 g for 10 minutes with 
low brake to pellet cells and supernatant removed. The subsequent pellet was 
resuspended in 300 µL of ice-cold PBS/Triton-X100 0.1%, mixed by pipetting 20x 
avoiding aeration, incubated for 10 minutes and was followed by the addition 300 µL 
of ice-cold PBS then centrifuged at 1000 g for 10 minutes with low brake to pellet 
cells and supernatant removed. The pellet was then resuspended in 100 µL of ice-
cold PBS/anti-phospho VASP s157 (1 µg/mL), and incubated for 30 minutes at 4◦C. 
This was followed by the addition 300 µL of ice-cold PBS followed by centrifugation 
at 1000 g for 10 minutes with low brake to pellet cells and supernatant removed. The 
pellet was then resuspended in 100 µL of ice-cold PBS/anti-rabbit-PE (1 µg/mL). At 
30 minutes, 300 µL of ice-cold PBS was added and this was centrifuged at 1000 g 
for 10 minutes with low brake to pellet cells. The supernatant was removed, and the 
pellet was then resuspended in 150 µL of ice-cold PBS and analysed by fluorescent 
flow cytometry recording 10,000 platelet positive events. It is important that buffer 
post-fix is kept cold to prevent residual phosphatase activity reducing the 
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phosphorylation state of target proteins. Typically, IgG controls are not used in 
phosphoflow experiments and the increases in phosphorylation are expressed as fold 
over basal, however this does exclude the assays from commenting on changes in 
basal phosphorylation. 
The basic protocol can be adapted to suit other phospho-site or protein specific 
antibodies which have been validated and optimised. 
 
2.3.1.11 Surface staining and phosphoflow 
A recent adaptation of phosphoflow developed here in platelets for the first time 
allows both intracellular phosphorylation and extracellular markers to be measured 
simultaneously. Here a novel protocol was developed to allow an intracellular 
signalling event to be compared directly to a change in expression of an activation 
marker. This protocol followed a simultaneous stimulate/probe (surface), fix, 
permeabilise, probe (intracellular), analyse approach, which allowed for 
simultaneous measurement of surface CD62P-PE and CD42b-APC with intracellular 
phospho VASP s157. The use of a probe, fix, permeabilise, probe was applied here 
as excessive fixation and permeabilisation would prevent the surface targeted 
antibodies from binding correctly due to loss of epitope. Permeabilisation also 
meaning that all CD62P would be measured, not just that expressed on the surface 
on activation, which would render the assay insensitive to changes if probed for 
CD62P post-permeabilisation. 
For this assay whole blood was stimulated for 2 minutes with PGI2 (10 – 1000 nM) 
followed by 20 minutes with SFLLRN (20 µM) in the presence of the surface staining 
antibodies. This is then fixed with 10x volume of 1x BD fix/lyse and then a standard 
phosphoflow protocol was used. 
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2.3.1.12 Application of novel dyes in platelet biology 
The flow cytometry protocols described so far have relied primarily on the use of 
conjugated antibodies, aside from the annexin V-APC conjugate, as markers of 
changes to the platelet surface or signalling machinery. However, there are many 
other methods of staining markers which have no direct sites of recognition for 
antibodies to target. In this work three such dyes were applied. 
 
2.3.1.13 Fluorochrome-labelled inhibitors of caspases 
Fluorochrome-labelled inhibitors of caspases, or FLICA dyes are designed around 
an inhibitory motif specific to caspase enzymes (Bedner et al., 2000). Each caspase 
enzyme has a high affinity for four amino acid motifs, which can be used to target 
them with a relatively high specificity (Garcia-Calvo et al., 1998). Here FLICA was 
used to target caspase-1, and the motif applied was YVAD. The YVAD motif is 
sandwiched between FAM-YVAD-FMK where FAM is a carboxyfluorescein and FMK 
is a fluoromethylketone. An additional YVAD-FMK was used conjugated to a far-red 
fluorophore to validate findings with the FAM conjugate. When caspase-1 binds to 
the YVAD motif in attempt to cleave the moiety, it is covalently bound to the enzyme 
by the FMK group, this means that the fluorescent tag is directly bound to active 
caspase-1 (Figure 14).  
 
Figure 14. Overview of method by which FLICA detects activated caspase-1. 
The fluorescently tagged peptide motif YVAD binds to the active site of 
caspase-1 and forms a covalent bond with the FMK moiety. This fluorescently 
tags active caspase-1 enzymes. 
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A protocol was developed to detect caspase-1 activity in platelets. Washed platelets 
(2 x 106) were suspended in a total volume of 50 µL of calcified modified Tyrode’s 
buffer (2 mM) and the inflammasome activated by the bacterial potassium pore 
forming toxin nigericin (1-10 µM). If other agonists or inhibitors were used, they were 
added prior to nigericin to allow them to take effect. This activated suspension is 
mixed and incubated for 20 minutes and then 5.5 µL of 1x FLICA dye is added to this 
and mixed thoroughly. This is then incubated for a further 40 minutes to allow the dye 
to enter the cells and bind to active caspases. The samples are then fixed in 10x 
volume of 1% paraformaldehyde/PBS for 10 minutes prior to two washes in PBS at 
1000 g for 10 minutes to remove unbound dye. The samples are then run and 
analysed for carboxyfluorescein fluorescence in the 525/40 bandpass filter or the far-
red FLICA in the 660/10 bandpass filter. As there is no FMO, IgG or competitive 
control in this instance, MFI or fold over basal was used to present the data. 
 
2.3.1.14 MitoSOX 
MitoSOX is a mitochondrial superoxide dye, which is not fluorescent until it is oxidised 
by superoxide, for which it has a high specificity. The dye rapidly collects specifically 
within mitochondria, and when superoxide anions leak from the electron transport 
chain within the mitochondria, mitoSOX within the organelle will be rapidly oxidised 
and become fluorescent. 
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Figure 15. MitoSOX specificity for mitochondrial superoxide. Washed platelets 
(2 x 106) were suspended in a total volume of 50 µL and incubated with 
mitoSOX at basal and treated with antimycin A (100 µM). Fluorescent signal 
increases over basal (blue histogram) when treated and is measured in the 
585/42 BP channel (pink histogram). 
 
In this assay platelets (2 x 106) in a total volume of 50 µL of reaction mixture, 
containing modified Tyrode’s buffer, mitoSOX (5 µM), agonists and inhibitors. 
Platelets in buffer are pre-incubated with MitoSOX for 10 minutes, to allow it to enter 
the mitochondria, and the reaction was started by the addition of agonists. However, 
where mitochondrial radical scavengers such as mitoTEMPO were used, these were 
pre-incubated for 20 minutes prior to mitoSOX. Agonists were then added and 
incubated at 37◦C for up to 180 minutes. At the endpoint, 10x volume of PBS was 
added and samples were then immediately analysed. As this was a live cell dye, it 
was important that cells were run immediately as the levels of reactive oxygen 
species may continue to change. Antimycin A was used throughout as a positive 
control to ensure cell viability and dye function (Figure 15). Although there was a 
negative control in the form of the mitochondrial superoxide scavenger it was most 
appropriate to express the data as total MFI or fold over basal. 
 
2.3.1.15 TMRE 
Tetramethyl rhodamine ethyl ester (TMRE) is a stain which collects specifically within 
the mitochondria of live cells, in the presence of polarised mitochondria which have 
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membrane potential. When mitochondria exhibit a loss of membrane potential, they 
also lose their capacity to be stained with TMRE. Furthermore, if mitochondria gain 
potential, they will accumulate more TMRE and therefore stain more brightly. 
 
 
Figure 16. TMRE specificity for mitochondrial membrane potential. Resting 
platelets have active mitochondria and collect TMRE and therefore 
fluorescence in the 585/42 BP channel (red histogram). However, upon 
treatment with the negative control FCCP, fluorescence is lost (green 
histogram). 
 
An assay to examine TMRE accumulation was established. Washed platelets (2.5 x 
106) were suspended in 50 µL of 50 nM TMRE in modified Tyrode’s buffer, mixed 
and left to stain for 20 minutes. The negative control, FCCP (20 µM), was added for 
10 minutes prior to TMRE addition to fully depolarise the mitochondria (Figure 16). 
At 20 minutes, 10x excess of PBS was added and samples were immediately 
analysed. This assay was not fixative compatible, as this killed the cells and the 
mitochondria lost any mitochondrial membrane potential, as a result, alike to 
mitoSOX, there is no halt step so samples must be run as soon as possible. 
 
2.3.2 Aggregometry 
Light transmission aggregometry (LTA) was developed by Gustav Born in 1962 to 
examine platelet function (Born, 1962). The turbidimetric assay is based on changes 
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in light scattering through a platelet suspension which is detected by a photocell. It is 
assumed that when using small volumes with stirring that resting platelets are 
uniformly distributed in suspension and presented with shear stress. This forms an 
optically dense medium which is refractory to the passage of light. However, following 
their activation, platelets aggregate into clumps generating an increasingly 
transparent suspension that allow light to pass through (Figure 17). The extent of 
light transmission is proportional to the level of platelet aggregation which is in turn 
dependent on the degree of platelet activation.  
 
Figure 17. Principles of platelet light transmission aggregometry. Resting 
platelets in suspension show a turbid solution, however when stimulated, 
aggregation occurs then transmission of light increases and this correlates with 
level of aggregation and activation. 
 
Aggregometry was performed on a Chrono-log aggregometer using washed platelets 
at 2.5 x 108/mL, stirred at 1000 RPM at 37◦C. Activation was stimulated with collagen 
(1 - 10 µg/mL) or thrombin (0.01 - 0.1 U/mL) and recorded for 3 minutes. Aggregation 
traces were exported, and amplitude measured. 
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2.4 ISOLATION AND OXIDATION OF HUMAN LOW-DENSITY LIPOPROTEIN 
LDL can be isolated from humans and oxidised, to produce oxLDL. In the laboratory 
LDL and oxLDL are stored at 4◦C, however shelf life is often limited to <12 weeks 
before native LDL becomes passively oxidised by environmental oxygen. Therefore, 
regular isolation and oxidation is a necessity. 
 
2.4.1 Isolation 
LDL has a density ranging between 1.019 and 1.063 g/mL and can therefore be 
isolated from other plasma lipoproteins based on density (Feingold et al., 2000). Here 
continuous density gradient isolation was used, although sequential density gradient 
ultracentrifugation is also appropriate (Wilkins and Leake, 1994a). Blood (40 mL) was 
drawn from the ante-cubital fossa through venepuncture with a 21g butterfly needle 
directly into EDTA (5 mM) and then centrifuged at 1500g for 20 minutes to allow for 
separation of acellular plasma. Plasma was placed into a 50 mL falcon tube in wet 
ice to preserve LDL and prevent any unwanted oxidation. 
 
 2.4.2 Density buffers 
This protocol relies on the use of buffers of known densities. High (Table 5) and low-
density (Table 6) buffers are first made and then buffers in the range between these 
can be made by mixing the 1.316 and 1.006 g/mL buffers at calculated ratios. 
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Table 5. Reagents for 1 L of high-density buffer (1.316 g/mL). 1 L of buffer is made, 
and pH is set at 7.4. 
Reagent Molarity (M) g/L 
KBr 2.97 354 
NaCl 2.62 153 
EDTA.Na22H2O 0.297 mM 0.1105 
 
 
Table 6. Reagents for 5 L of low-density buffer (1.006 g/mL). 5 L of buffer is made, 
and pH is set at 7.4. 
Reagent Molarity (mM) g/5L 
NaCl 150 43.83 
EDTA.Na22H2O 0.297 0.5645 
 
A 2 L solution of 1.109 g/mL density was made by adding a 1.316 g/mL solution to a 
1.006 g/mL solution using the following equation. 
(
0.013 ∗ 2000
1.316 − 1.019
) = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 1.316 𝑡𝑜 𝑎𝑑𝑑 
The density of the resulting solution was then checked using a 100 mL volumetric 
flask weighed on a fine balance.  
(
𝑤𝑒𝑖𝑔ℎ𝑡 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑙𝑎𝑠𝑘
100
) = 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 1 𝑚𝐿 𝑜𝑓 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 
If required, the density was then adjusted using appropriate volumes of either the 
1.006 g/mL or 1.316 g/mL buffer calculated from the equation below if the density 
was too high, then the 1.006 g/mL solution was added, and conversely if is the density 
was too low then the 1.316 g/mL solution was added. 
(𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑣𝑜𝑙𝑢𝑚𝑒 × 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑑𝑒𝑛𝑠𝑖𝑡𝑦) + (𝑥 × 𝑎𝑑𝑗𝑢𝑠𝑡𝑖𝑛𝑔 𝑏𝑢𝑓𝑓𝑒𝑟)
= (𝑣𝑜𝑙𝑢𝑚𝑒 + 𝑥) × 𝑡𝑎𝑟𝑔𝑒𝑡 
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2.4.3 Continuous gradient ultracentrifugation 
Continuous gradient ultracentrifugation has advantages over discontinuous gradient 
ultracentrifugation as it is far more time efficient and also requires a smaller starting 
volume of blood (Naseem et al., 1997). To carry out the procedure plasma density 
was adjusted through the addition of solid KBr, at a ratio of 0.44285 g/1 mL which 
was dissolved with gentle stirring. Beckman Coulter QuickSeal 13.5 mL tubes were 
pre-filled with 1.006 g/mL density solution (150 mM NaCl, 297 µM EDTA.Na22H2O, 
pH 7.4) and underlaid with 5 mL of density adjusted plasma. Tubes were then 
balanced to +/- 10 mg on a fine balance and ultra-centrifuged at 200,000 g at 4◦C for 
4.5 hours in a Beckman Coulter 70.1Ti rotor. This yielded a distinct band of LDL which 
could be removed by piercing the tube with a 21g butterfly needle and syringe, with 
an additional needle to release the vacuum (Figure 18). 
 
Figure 18. Adjusted plasma after the first stage of continuous gradient 
ultracentrifugation. A distinct LDL fraction rests in the middle of the tube and 
is distinct from other regions by clear zones of buffer, it can be isolated for 
further purification. 
 
LDL fraction 
Transition zone 
HDL fraction 
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This preliminary LDL was then overlaid over 1.151 g/mL density solution into 
QuickSeal tubes before being itself overlaid with 1.063 g/mL density solution. This 
was then balanced to +/- 10 mg on a fine balance and ultra-centrifuged at 200,000 g 
at 4◦C for 16 hours in a Beckman Coulter 70.1Ti rotor. This yielded a clear bright 
yellow band at the top of the tube which was collected with a 21g butterfly needle as 
before. It was then dialysed for 24 hours with 10,000 molecular weight cut off dialysis 
tubing at 4◦C with 2 changes against phosphate-EDTA dialysis buffer (140 mM NaCl, 
8.1 mM Na2HPO4, 1.9 mM NaH2PO4, 0.1 mM EDTA, pH 7.4) to remove the heavy 
salts and impurities. The LDL is then filtered through a 0.22 µm filter and stored in 
the dark at 4◦C prior to protein concentration and oxidation. 
 
2.4.4 Oxidation of LDL 
Unlike in the body, where oxidation predominantly occurs as a result of cellular ROS, 
in vitro oxidation is initiated with the addition of copper ions (Naseem et al., 1997). 
Oxidation at 37◦C was used as predominantly oxysterol-rich LDL is produced by that 
method, whereas at 4◦C primarily hydroperoxide-rich LDL is produced (Gerry et al., 
2008). 
In this work for LDL oxidation, LDL was first dialysed against phosphate buffer (140 
mM NaCl, 8.1 mM Na2HPO4, 1.9 mM NaH2PO4, pH 7.4) for 4 hours at 4◦C with 3 
changes of buffer. The LDL was then dialysed against MOPS-Chelex buffer to 
remove EDTA (150 mM NaCl, 10 mM MOPS, 0.1% Chelex-100 w/v, pH 7.4) for 24 
hours at 4◦C with 2 changes of buffer. A small volume of MOPS-copper buffer was 
then added directly to the dialysis tubing (to ensure LDL concentration at oxidation 
was <2 mg/mL) and the LDL further dialysed against the MOPS-copper buffer (150 
mM NaCl, 10 mM MOPS, 10 µM CuSO4, pH 7.4) for 24 hours at 37◦C with 3 changes 
of buffer. Oxidation occurred within 4-6 hours indicated by a loss of yellow colouration 
of the LDL suspension as the β-carotene was broken down. Finally, oxidation was 
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halted through the addition of EDTA (1 mM) directly to the LDL. This was then 
dialysed against phosphate-EDTA dialysis buffer (140 mM NaCl, 8.1 mM Na2HPO4, 
1.9 mM NaH2PO4, 0.1 mM EDTA, pH 7.4) for 24 hours at 4◦C with 2 changes, filtered 
through a 0.22 µm filter and stored in the dark at 4◦C. 
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2.5 METHODS FOR THE STUDY OF PROTEINS 
2.5.1 Protein concentration 
Protein concentration was measured in both LDL and platelet lysates. BioRad 
Detergent Compatible Protein assay is an adaptation of the Lowry assay (Lowry et 
al., 1951), and was used as per manufacturer’s guidelines. In brief, protein standards 
were produced using BSA dissolved at a range of 0.2 - 2 mg/mL and loaded in 
triplicate in 96-well plates. The two-colour reagents, copper tartrate and Folin’s 
reagent were added to each well and mixed, and a blue colour developed, the 
intensity of which was indicative of protein concentration, and is measured by a plate 
reader at 750 nm and a standard curve produced. The concentrations of protein, LDL 
or platelet lysates were calculated from these standard curves. 
 
2.5.2 Relative electrophoretic movement assay 
The relative electrophoretic movement (REM) was used to determine the overall 
surface charge of each LDL preparation. Since LDL becomes increasingly negatively 
charged during the oxidation process it leads to increase migration towards the 
anode. A ratio is calculated by comparing the distance migrated by ox and nLDL 
measured from the start point and can be used to determine the extent of oxidation, 
typically a ratio of >3 is considered appropriate (Figure 19). In addition, the REM 
assay can be used to confirm the purity of the LDL preparation, since LDL should 
have only a single protein band, Apo B-100. The presence of additional bands would 
suggest contamination with other lipoproteins. 
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Figure 19. Schematic of relative electrophoretic movement assay. Differently 
treated LDL is loaded in an agarose gel and run towards the anode, the greater 
the level of oxidation the faster the speed of protein migration. 
 
Native LDL and oxidised LDL were both loaded onto an agarose gel (1% agarose, 
TAE buffer w/v) in a tank of TAE buffer (Tris base 40 mM, glacial acetic acid 0.1% 
v/v, EDTA 1 mM) and ran at 100 volts for 60 minutes. The gel is then rinsed in dH2O 
and proteins stained with Coomassie stain overnight. Excess stain is then washed 
off and the gel is imaged with a visible light scanner. 
 
2.5.3 Dot blot assay 
A dot blot is a simple but effective and high throughput method for assessing content 
of an antibody target within any suspension. In this case, it was used to detect 
oxidised phospholipids (oxPL) present in LDL preparations, as a marker of the levels 
of oxPL (Berger et al., 2019b). E06 is a murine IgM antibody raised against oxidised 
phospholipid (oxPL) and can therefore be used to differentiate between oxLDL and 
nLDL. A polyvinylidene fluoride (PVDF) membrane was activated in methanol and 
oxLDL and nLDL (2 µg) loaded. This was left to bind to the membrane (20 minutes) 
before blocking in BSA/Tris-base saline (5% BSA w/v, NaCl 150 mM, Tris-base 20 
mM, pH 7.6) for 30 minutes at room temperature. The blocking buffer was removed, 
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and the membrane probed overnight at 4◦C with E06 (1/1000 in 2% BSA/TBS), an 
antibody that recognises oxPL. The membrane was washed three times in Tris-base 
saline-Tween 20 (TBS-T, NaCl 150 mM, Tris-base 20 mM, Tween 20 0.1% v/v, pH 
7.6) and incubated with anti-mouse-HRP conjugate 1/10,000 TBS-T for 60 minutes 
at room temperature. Membrane was visualised by incubation with enhanced 
chemiluminescent (ECL) reagent for 90 seconds. For loading control, the membrane 
was counterstained with Coomassie stain and imaged on a visible light scanner. 
 
2.5.4 Immunoprecipitation 
Immunoprecipitation is used to isolate a protein from a mixture such as a cell extract. 
An antibody specific for a target protein is added to the mixture to form antibody-
antigen complexes. The complexes are then precipitated by adsorbing the antibodies 
to an insoluble matrix such as agarose or sepharose beads conjugated to protein A 
or G. The latter two proteins derive from bacteria and are stably bound by antibody 
constant regions. Using centrifugation, the beads are sedimented into a pellet and 
the supernatant containing unwanted proteins is aspirated and discarded. After 
several washes, the antibody-antigen complex is liberated from the beads by boiling 
in lysis (Laemmli) buffer (Laemmli, 1970). The isolated protein may be studied further 
using SDS-PAGE and Western blotting or by mass spectrometry. In addition to 
enriching the concentration of proteins that would otherwise be too scarce to detect 
through normal immunoblotting, the technique enables biochemical analysis of single 
proteins and interactions or post-translational modification states.  
Platelets were lysed with immunoprecipitation lysis buffer (150 mM NaCl, 10 mM Tris 
base, 1 mM EGTA, 1 mM EDTA, 1% Igepal (v/v)), which preserved protein: protein 
interactions and post-translational modifications. The lysed platelet suspension was 
then pre-cleared with protein A/G beads which were removed by centrifugation. The 
primary antibody targeted against the protein of interest was then added to the lysate 
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and incubated (4◦C, 60 minutes) prior to addition of protein A/G beads, which were 
then incubated overnight (4◦C). The lysate with beads now bound to antibodies which 
were bound to the desired protein were then isolated by centrifugation (1000 g, 10 
minutes). The lysate supernatant was then removed, and the beads were 
resuspended in Laemmli lysis buffer which released the proteins from the beads and 
bound antibodies. This enriched lysate could then be processed by SDS-PAGE. 
 
2.5.5 Gel electrophoresis and immunoblot 
Immune-specific detection of proteins separated using SDS-PAGE allows accurate 
detection of selected proteins against which specific antibodies are used. 
Electrophoresis allows the separation of charged macromolecules in an electric field. 
When applied to a porous matrix such as a gel it can be used to separate molecules 
based on their size and charges. SDS-PAGE uses a combination of SDS and the 
polyacrylamide gels to separate proteins according to their molecular masses by 
electrophoretic migration. Acrylamide molecules polymerise into long linear chains 
which are cross-linked by bisacrylamide. This polymerisation is accelerated by the 
presence of free radicals. Hence, ammonium persulphate (APS) is added when 
casting gels as it decomposes to release SO4- radical anions. 
Tetramethylethylenediamine (TEMED) is also included to catalyse the decay of APS. 
The percentage of the acrylamide used in these solutions determines the pore size 
and therefore the relative separation of the proteins within the mixture.  
To identify specific proteins separated from the mixture, Western blotting is routinely 
used. This involves transferring the proteins from a gel to an adhesive matrix such 
as nitrocellulose or polyvinylidene fluoride (PVDF) membranes under an electric field. 
Once transferred, the membranes are probed with specific primary antibodies against 
target proteins. A secondary antibody raised against the primary antibody species is 
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then added. Secondary antibodies are commonly conjugated to horseradish 
peroxidase (HRP) which allows visualisation of antibody detected protein bands. 
 
2.5.6 Sample preparation 
Platelet lysate was generated after treatment of washed platelets with the appropriate 
agonists or antagonists. Platelets (5-10 x 108/mL ) were lysed with Laemmli buffer 
(4% SDS (w/v), 10% 2-mercaptoethanol (v/v), 20% glycerol (v/v), 50mM Tris base, 
trace bromophenol blue, pH 6.8) and boiled at 95◦C for 5 minutes (Laemmli, 1970). 
SDS is an anionic detergent that binds and denatures proteins leaving them with 
similar, rod-shaped tertiary structure. Furthermore, it confers equal negative charge 
per unit protein mass (1.4g SDS per 1g protein). In the presence of a reducing agent 
such as 2-mercaptoethanol, disulphide bonds are broken, and proteins become fully 
denatured. 
All samples were run under discontinuous SDS-PAGE (Laemmli, 1970), using 
precast gels composed of a 4% stacking gel overlying a 10-18% gradient resolving 
gel. The more porous stacking gel containing wells for protein loading ensured that 
all the proteins entered the less porous resolving gel simultaneously. As the gels 
were buffered differently from each other and the running buffer, application of 
electric current caused a narrow band of high voltage to migrate down the stacking 
gel, compressing loaded proteins into a tight horizontal band. When the band reached 
the resolving gel, the proteins were dispersed as they passed through its pores. 
Protein lysates (30 µg) were loaded in each well and a biotinylated or visual molecular 
weight marker (Precision Plus) was also added. Gels were left to run at 120 V for 2 
hours, after which proteins were transferred to PVDF membranes using a BioRad 
turbo blotter for 7 minutes at 2.5 A and 25 V. Where own cast gels were used, a 1.5 
mm protocol was instead used which ran for 10 minutes to allow for the thicker gel’s 
slower transfer. 
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The membranes were blocked with 5% (w/v) BSA dissolved in TBS-T BSA (bovine 
serum albumin) w/v or 5% milk w/v in Tris-base saline + Tween-20 0.1% v/v (TBS-T) 
for 30 min and subsequently probed with primary antibody (at noted dilution in figure 
legends) diluted in 2% (w/v) BSA/TBS-T overnight at 4°C. The next day, the 
membranes were rinsed with TBS-T for 10 minutes, probed with HRP-conjugated 
secondary antibodies; anti-rabbit or anti-mouse (as appropriate, both 1:10000) and 
anti-biotin (1:2000) for 1 hour, washed with TBS-T (4 washes, 15 minutes each) and 
developed with ECL solution. 
 
2.5.7 Development of probed membranes 
Development of membranes was performed by either near infra-red (nIR) 
fluorescence detection with a LiCor CLX or by enhanced chemi-luminescence (ECL) 
using film in a dark room. For fluorescence detection, after incubation with nIR-
conjugated secondary antibodies, the membranes were further washed three times 
for 5 minutes each under orbital movement (30 RPM) in TBS, rinsed in dH2O and then 
imaged on a LiCor CLX system and analysed using Image Studio Lite (v.5.2.5). This 
system is a two-colour system and will allow multiplexed detection of two primary 
antibodies simultaneously provided they are from different species and therefore the 
secondary antibodies can distinguish between them. 
For ECL detection, after incubated with HRP-conjugated secondary antibodies, the 
membranes were incubated with 1 mL of SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate (ThermoFisher) for 1 minute, placed in a film cassette 
and developed under dark room conditions with exposures ranging from 0.2 – 30 
minutes. Films were then developed using an automatic silver developing and acetic 
acid fixation system. 
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In either instance, membranes can then be washed for 5 minutes under orbital 
movement (30 RPM) in TBS-T and stored for repeat development, stripping or re-
probing with further primary antibodies. 
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2.6 DATA PRESENTATION AND STATISTICAL ANALYSIS 
2.6.1 Data presentation 
Where raw value data was presented, GraphPad Prism (v.8) and/or Microsoft Excel 
(Office ‘16) were used. Where flow cytometry data was presented as histograms or 
scatter plots, FlowJo (v.10) or CytExpert (v.2) were used for analysis and graphics 
production. Data quoted in text is provided as XX ± standard deviation. 
 
2.6.2 Statistical analysis 
Statistical analysis was performed using GraphPad Prism (v.8). For single 
comparisons Students T-tests were used, however where multiple parameters were 
compared ANOVA tests were used. 
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Chapter 3 
Platelet regulation and subpopulations 
3.1 INTRODUCTION 
Platelet activation results in a series of dramatic changes to the surface of the cell, 
which are required to facilitate haemostasis, coagulation and inflammation. 
Degranulation results in the increased expression of numerous ligands or receptors 
stored within the granules, primarily within α-granules. These include but are not 
limited to CD62P (P-selectin), CD154 (CD40L), CD63 (LAMP-3) and integrin αIIbβ3. 
Cellular activation also causes conformational changes in the integrins, notably 
integrin αIIbβ3, converting them from a cryptic form to one that can bind protein 
ligands. In addition to changes to the protein receptors and associated ligands there 
is also a change in the surface lipid profile, with the increased externalisation of 
phosphatidylserine required to support coagulation. 
Fluorescent flow cytometry provides a platform for single cell analysis of multiple 
parameters. We sought to understand how multiple markers may be simultaneously 
changing across the platelet population and if the application of multiparameter 
assays in combination with multidimensional analysis could allow for identification of 
platelet subsets beyond the previously described procoagulant subpopulation and 
how the endothelial inhibitor PGI2 may regulate these procoagulant platelets (Agbani 
and Poole, 2017).  
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3.2 AIMS OF CHAPTER 
- Determine optimal conditions to measure platelet activity by flow cytometry 
- Develop multiparameter flow cytometry panels and apply multidimensional 
analysis to identify platelet subpopulations 
- Understand how PGI2 regulates the formation of platelet subpopulations 
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3.3 OPTIMISATION OF ANTIBODY CONCENTRATIONS 
Antibodies should be titrated to determine optimal doses. Correct titration can 
dramatically improve assay sensitivity and it can also allow for substantial reductions 
in antibody consumption per assay. In brief, each antibody dilution must be compared 
with a control or basal sample at a matched concentration, this comparison allows a 
comment on the sensitivity of each assay as opposed to simply the brightest 
stimulated condition, which will often be paired with excessive background binding 
and therefore anomalously high basal signal. Calculating fold over control allows the 
condition with the highest fold increase, and therefore optimal window for detection 
of changes, to be selected. 
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 3.3.1 CD62P 
CD62P was exposed on the platelet surface upon activation. Here we determined 
that 1.25 µL of anti-CD62P-PE is the optimal titre (Figure 20). 
 
 
Figure 20. Titration of anti-CD62P-PE. In whole blood drawn into sodium citrate, 
CD62P-PE was added at 6 dilutions ranging from 5 to 0 µL of antibody. Each 
sample was made in duplicate and half were stimulated with SFLLRN (10 µM) 
for 20 minutes, and the other half were maintained at basal, prior to fixation (1% 
PFA/PBS). CD42b-APC was used as a platelet marker which did not spectrally 
interfere with CD62P-PE. Samples were analysed for 10,000 platelet positive 
events and MFI and fold over relative basal are presented. 
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 3.3.2 Fibrinogen 
Fibrinogen is a ligand of activated platelets. Because the conformational change of 
the αIIbβ3 integrin is dependent on calcium, EDTA is used as a background 
fluorescence control. Here we determined that 1.25 µL of anti-fibrinogen-FITC was 
the optimal titre (Figure 21). 
 
 
Figure 21. Titration of anti-fibrinogen-FITC. In whole blood drawn into sodium 
citrate, fibrinogen-FITC was added at 6 dilutions ranging from 5 to 0 µL of 
antibody. Each sample was made in duplicate and half were stimulated with 
SFLLRN (10 µM) for 20 minutes, while half were maintained at basal, prior to 
fixation (1% PFA/PBS). CD42b-APC was used as a platelet marker which did 
not spectrally interfere with fibrinogen-FITC. Samples were analysed for 10,000 
platelet positive events and MFI and fold over relative basal are presented. 
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3.3.3 PAC1 
The monoclonal antibody PAC1 measures the same activity as the anti-fibrinogen 
antibody. PAC1 recognises the activated, but not inactivated, αIIbβ3 integrin which 
is vital for platelet homotypic aggregate formation (Frelinger, 2018). EDTA is used as 
a background fluorescence control. Here we determined that 5 µL of PAC1-FITC was 
the optimal titration (Figure 22). 
 
 
Figure 22. Titration of PAC1-FITC. In whole blood drawn into sodium citrate, PAC1-
FITC was added at 8 dilutions ranging from 20 to 0.5 µL of antibody. Each 
sample was made in duplicate and half were stimulated with SFLLRN (20 µM) 
for 20 minutes prior to fixation (1% PFA/PBS). CD42b-APC was used as a 
platelet marker which did not spectrally interfere with PAC1-FITC. Samples 
were analysed for 10,000 platelet positive events and MFI and fold over EDTA 
control are presented. 
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3.3.4 CD63 
CD63 (LAMP-3) is a lysosomal glycoprotein which is expressed in both platelet 
lysosomal and δ-granules and presented on the surface upon activation. Here we 
determined that 2 µL of anti-CD63-eF660 was the optimal dilution, where non-specific 
binding is at a minimum and the difference between IgG-eF660 control and CD63-
eF660 is maximal (Figure 23).  
 
 
Figure 23. Titration of anti-CD63-eF660. In whole blood drawn into sodium citrate, 
CD63-eF660 was added at 8 dilutions ranging from 16 to 0.5 µL of antibody. 
Each sample was made in duplicate and all were stimulated with SFLLRN (20 
µM) for 20 minutes prior to fixation (1% PFA/PBS). CD42b-FITC was used as 
a platelet marker which did not spectrally interfere with CD63-eF660. Samples 
were analysed for 10,000 platelet positive events and MFI and fold over 
matched IgG control are presented. 
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3.3.5 CD514 
CD154 (CD40L) is expressed in platelet α-granules and is important for platelet-
leukocyte interactions, when platelets degranulate some CD154 is maintained on the 
surface (Damien et al., 2015). Here we determined that 4 µL of anti-CD154-FITC was 
the optimal dilution over IgG-FITC control, although here all dilutions are similar, likely 
due to relatively low surface abundance of CD154 (Figure 24). As surface expression 
of CD154 was anticipiated to be low it was put in the relatively sensitive FITC channel. 
 
 
Figure 24. Titration of anti-CD154-FITC. In whole blood drawn into sodium citrate, 
CD154-FITC was added at 8 dilutions ranging from 16 to 0.5 µL of antibody. 
Each sample was made in duplicate all were stimulated with SFLLRN (20 µM) 
for 20 minutes prior to fixation (1% PFA/PBS). CD42b-APC was used as a 
platelet marker which did not spectrally interfere with CD154-FITC. Samples 
were analysed for 10,000 platelet positive events and MFI and fold over 
matched IgG control are presented. 
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3.3.6 TMRE 
TMRE is a dye which collects within mitochondria against an electrochemical 
gradient and is used as a marker of mitochondrial hyperpolarisation or depolarisation. 
TMRE is incompatible with whole blood and must be used with washed cells. Here 
we determined that 50 nM of TMRE dye staining 2 x 106 washed platelets for 20 
minutes was the optimal concentration over the mitochondrial uncoupler carbonyl 
cyanide-p trifluoromethoxyphenylhydrazone (FCCP) (20 µM) control (Figure 25). 
 
 
Figure 25. Titration of TMRE. 2 x 106 washed platelets were either treated or 
untreated for 10 minutes with FCCP (20 µM) and then duplicate pair was 
stained with TMRE (50 – 400 nM). At 10 (green) or 20 (red) minutes each 
sample was diluted 10x in PBS and analysed immediately for 10,000 platelet 
events and MFI and fold over matched FCCP control are presented. 
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3.4 PRE-ANALYTICAL CONDITIONS 
The quality of a flow cytometry experiment is underpinned by three main aspects; 
appropriate pre-analytical conditions, assay design with appropriate controls and 
accurate analysis incorporating MFI, percent positive cells and appropriate gating. 
Here we sought to understand the impact of several different pre-analytical variables 
which can affect assay output. Platelet activation was analysed using a four-
parameter assay for fibrinogen binding (FITC), CD62P (PE), annexin V (APC) and 
CD42b (BB700) under a variety of different conditions. Anti-coagulants were 
compared for; the effects of resting whole blood, reproducibility of the assay in 
different preparations of platelets and storage of samples for up to 4.5 hours. The 
four parameters which this assay measured provide a broad cross-section of the 
changes which platelet undergo upon activation, and therefore provides confidence 
that the pre-analytical conditions chosen as optimal, should be suitable for the 
measurement of many aspects of platelet biology. 
For all experiments, blood was drawn into the appropriate vacutainer, after a discard 
of the first draw to prevent artefactual activation. Stimulation was then carried out for 
20 minutes at 37◦C in the presence of calcium (1.8 mM) and Gly-Pro-Arg-Pro (GPRP; 
500 µM). Calcium is required to support annexin V binding (Gyulkhandanyan et al., 
2012) while GPRP is required to prevent fibrin polymerisation (Michelson, 1994). 
Activation was halted at 20 minutes by the addition of 450 µL of 1% 
paraformaldehyde/calcified modified Tyrodes buffer. Where storage was tested, 
samples were stored at 4◦C in the dark between re-acquisitions.  
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3.4.1 Optimal anti-coagulant 
Three anti-coagulants were investigated to examine and compare their effects on 
platelet activation. Discerning the best anti-coagulant for platelet activation is likely 
the most important pre-analytical step. The three anti-coagulants compared were; 
sodium citrate, sodium heparin and potassium EDTA, all pre-loaded into commercial 
evacuated tubes. All three anti-coagulants are routinely used in clinical laboratories, 
and as such, platelet researchers in collaboration with a clinic could potentially 
receive, or request to receive patient samples in either of these three anti-coagulants. 
ACD is an anticoagulant which is used universally in the platelet research laboratory, 
however this is predominantly for isolation of platelets where the reduction in pH is 
beneficial. In the context of whole blood activation assays, it is unlikely to be suitable, 
so we did not test this anticoagulant. To assess each anti-coagulant we measured 
fibrinogen binding, CD62P expression and annexin V binding. 
Platelets demonstrated the highest capacity for fibrinogen binding in citrate tubes and 
this was diminished in heparin and further diminished in EDTA (Figure 26a). CD62P 
expression was not affected by the anti-coagulants tested with both the capacity for 
expression and the number of positive events remaining the same for each anti-
coagulant. However there was a difference in the basal expression; with the lowest 
basal expression observed in citrate, followed by heparin and the highest at 40% 
positive in EDTA (Figure 26b). The binding of annexin V to phosphatidylserine was 
the most sensitive in heparin, followed by citrate and finally EDTA. Although the 
brightness of positive events when measuring annexin V was reduced, the number 
of positive events was consistent across the anti-coagulants, which is an important 
observation when annexin V is used a qualitative as opposed to quantitative marker 
(Figure 26c). Collating this data, it was possible to determine that the optimal anti-
coagulant to measure whole blood multiparameter platelet activation was determined 
to be sodium citrate as fibrinogen was most sensitive, CD62P basal was lowest and 
annexin V binding, as a qualitative marker, was effectively unchanged. 
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Figure 26. The major pre-analytical consideration for platelet activation assays 
is the anti-coagulant. Three anti-coagulants, sodium citrate, sodium heparin 
and potassium EDTA, were compared in whole blood for multicolour platelet 
activation and each is shown to affect activation markers differently. (A) 
Fibrinogen binding, MFI and percent positive over EDTA control. (B) CD62P, 
MFI and percent positive over IgG control. (C) Annexin V, MFI and percent 
positive over EDTA control. (n=3 for all experiments, error shown as standard 
deviation) 
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3.4.2 Optimal assay initiation 
The second issue which researchers working on primary cells, or clinical samples, 
must contend with is delays in receipt of samples. Consequently, the impact of assay 
initiation at either 0, 1.5 or 4.5 hours after blood was drawn was tested.  
Platelet binding to fibrinogen peaked at 0 hours, however this declined significantly 
after 1.5 hours and declined further still after 4.5 hours (Figure 27a). Although 
fluorescence intensity is reduced at 1.5 hours, percent positive cells retain some 
sensitivity but is severely compromised at 4.5 hours (Figure 27a). CD62P is a robust 
marker and is not significantly affected in terms of expression capacity or percent 
positive on stimulation, with only a minor decrease in capacity at the longest 
timepoint. However basal activation was shown to increase up to 2-fold across the 
time points tested, with the lowest at the immediate timepoint, and an increase in 
basal at 1.5 hours followed by further increases in basal degranulation at 4.5 hours 
(Figure 27b). Annexin V binding is a marker of cellular apoptosis as well as the 
procoagulant platelet subset. A longer rest increased the capacity for platelet annexin 
V expression with a small increase in basal expression (Figure 27c). The three 
studies would suggest that where possible, assays should be performed as soon as 
blood is drawn, however where this is not feasible, the degradation of sample quality 
over time must be appreciated during analysis of results and if carrying out multiple 
assay repeats these should be started at the same time point post-venepuncture 
wherever possible to eliminate artificial variation. 
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Figure 27. Resting citrated blood compromises assay sensitivity and drives 
basal expression of activation markers. Platelet activation was assayed in 
sodium citrated whole blood at 0 hours (freshly drawn), 1.5 and 4.5 hours. (A) 
Fibrinogen binding, MFI and percent positive over EDTA control. (B) CD62P, 
MFI and percent positive over IgG control. (C) Annexin V, MFI and percent 
positive over EDTA control. (n=4 for all experiments, error shown as standard 
deviation) 
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3.4.3 Optimal platelet preparation 
The third pre-analytical consideration for the platelet biologist is the media the 
platelets are suspended in, either; whole blood, PRP or washed platelets. In many 
situations, whole blood is ideal, as this is the more physiologically relevant milieu to 
examine platelet activation. However, in certain experimental situations the use of 
whole blood is not feasible. This is likely in situations where a chemical reagent loses 
specificity or activity in whole blood, and therefore a depleted system of platelet-rich 
plasma or a buffered system of washed platelets would be used. 
Whole blood and PRP from sodium citrate vacutainers were compared with ACD-A 
vacutainer washed platelets. Fibrinogen binding was most sensitive in whole blood, 
primarily as fibrinogen is removed in each stage of platelet isolation, presenting an 
anomalously high signal in washed cells. This anomalously high signal is represented 
by very bright MFI, indicative of strong antibody binding, but paired with low 
percentage positive, indicative of low antibody binding. As the percent positive cells 
is calculated over the EDTA control, and is low in signal, it suggests that the excess 
binding in MFI signal is likely non-specific (Figure 28a). The capacity for activation as 
measured by CD62P was again robust and not significantly affected by platelet 
isolation, although, the stress of isolation was indicated in the large increase in basal 
expression of CD62P, which correlated with longer isolation times and results in over 
60% of washed platelets being pre-activated (Figure 28b). Finally, annexin V was 
shown to increase in sensitivity in PRP and washed platelets, however this is at the 
cost of a minor increase in basal expression of phosphatidylserine (Figure 28c). 
Where feasible, and assay reagents do not require PRP or washed platelets to be 
effective, whole blood should be used for platelet activation assays, particularly if 
fibrinogen binding is to be measured. However, CD62P and annexin V binding remain 
robust in other platelet preparations. 
  
- 100 - 
 
Figure 28. Different preparations of platelets either whole blood, platelet-rich 
plasma or washed platelets impacts assay sensitivity. Whole blood drawn 
into sodium citrate, PRP isolated from sodium citrated blood and washed 
platelets isolated from ACD blood were compared. (A) Fibrinogen binding, MFI 
and percent positive over EDTA control. (B) CD62P, MFI and percent positive 
over IgG control. (C) Annexin V, MFI and percent positive over EDTA control. 
(n=3 for all experiments, error shown as standard deviation) 
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3.4.4 Storage of samples 
The final pre-analytical condition we considered was the durability of samples during 
routine 4◦C storage. Where feasible, it is expected that samples are processed for 
acquisition as soon as possible and then analysed. However, this is not always 
possible, therefore we re-ran selected samples at 90 minutes and again at 270 
minutes, storing samples at 4◦C in the dark between acquisitions to observe any 
differences in assay results.  
We compared the fluorescence intensity of the three activation markers from the 
initial processing with two later acquisitions of sample. Here we were able to show 
that fibrinogen binding remained robustly positive with no change in MFI (Figure 29a). 
However, both CD62P and annexin V binding demonstrated considerable decreases 
in fluorescence intensity in a time dependent manner (Figure 29b & Figure 29c). 
Whether this is due to degradation of the fluorophores, loss of epitope or antibody 
binding is unclear. Nevertheless, we can confirm that in the context of this four-colour 
assay, samples should be acquired as soon as possible, and it must be appreciated 
that any delay will result in a decrease in fluorescence intensity of both CD62P and 
annexin V. 
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Figure 29. Storage time negatively effects CD62P and annexin V binding 
however fibrinogen binding remains consistent. The effect of storing blood 
at 4◦C for each demonstrated timepoint was compared. (A) Fibrinogen binding, 
MFI and percent positive over EDTA control. (B) CD62P, MFI and percent 
positive over IgG control. (C) Annexin V, MFI and percent positive over EDTA 
control. (n=4 for all experiments, error shown as standard deviation) 
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3.4.5 Activation induced intracellular phosphorylated ERK1/2 
In conjunction with surface staining for activation markers, it is possible to link these 
changes in sensitivity in anti-coagulants to intracellular events by staining for key 
phosphorylation events using permeabilisation techniques (Spurgeon and Naseem, 
2018). We used phospho-ERK1/2 as an intracellular marker of platelet activation 
(Stalker et al., 2012). Stimulation with SFLLRN (20 µM) for 10 minutes led to 
increased platelet ERK1/2 phosphorylation in whole blood. We compared ERK 
phosphorylation in whole blood using sodium citrate, sodium heparin and potassium 
EDTA as anticoagulants. As calcium flux is vital for platelet activation, the potent 
chelator EDTA prevents ERK phosphorylation (0.94). However, consistent with the 
surface marker expression, phosphorylation was still evident in citrate (1.64) and 
heparin (1.68) (Figure 30). Furthermore, in conjunction with the previous observation 
of diminished response over time (Figure 27), phosphorylation capacity was shown 
to decline over time in both citrate (0 1.64, 60 1.46, 300 minutes 1.01) and heparin 
(0 2.68, 60 1.63, 300 minutes 1.36) anticoagulants (Figure 30). This experiment was 
performed with a standard phosphoflow protocol (Spurgeon and Naseem, 2018), 
using an AF647 conjugated pERK1/2. 
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Figure 30. Phosphorylation of ERK1/2 on stimulation with 20 µM SFLLRN 
compared across anti-coagulants. Whole blood drawn from indicated anti-
coagulants and at demonstrated time point was stimulated with SFLLRN (10 
µM) for 10 minutes prior to fixation in BD fix/lyse, permeabilisation and staining 
with pERK1/2-AF647. (n=1-2) 
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3.4.6 Antagonist induced intracellular phosphorylated VASP 
Platelet inhibition is a vital facet of platelet biology; however, it is more difficult to 
measure directly than activation, which can be measured by a multitude of surface 
markers. Although the effect of inhibition can be indirectly observed as a loss of 
activation, platelet inhibition can be directly measured through intracellular 
phosphorylation events which occur downstream of inhibition. The ability to measure 
platelet inhibition is a valuable tool in drug-screening studies (Spurgeon et al., 2014). 
Here we use the phosphoprotein VASP, an established target of both cAMP and 
cGMP signalling pathways (Butt et al., 1994). 
In a mirror experiment to the identification of optimal anti-coagulant for intracellular 
pERK1/2 measurement, pVASP-s157 in response to PGI2 was measured in sodium 
citrate, sodium heparin and potassium EDTA anticoagulated whole blood at multiple 
time points (0 – 300 minutes). The phosphorylation of VASP was not affected by 
anticoagulant choice (Citrate 8.69, Heparin 8.89, EDTA 8.31) (Figure 31). We found 
that after in vitro storage, platelet sensitivity to inhibition was diminished by 50% 
(Citrate 0 8.69, 60 6.47, and 300 minutes 4.47) (Figure 31). This experiment was 
performed with a standard phosphoflow protocol (Spurgeon and Naseem, 2018), 
using an AF647 secondary antibody against pVASP-s157. 
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Figure 31. Phosphorylation of pVASP-s157 on stimulation with PGI2 compared 
across time and anti-coagulants. Whole blood drawn from indicated anti-
coagulants and at demonstrated time point was stimulated with PGI2 (200 nM) 
for 5 minutes prior to fixation in BD fix/lyse, permeabilisation and staining with 
pVASP-s157. (n=1) 
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3.5 PLATELET ACTIVATION 
Having previously determined that freshly drawn whole blood into sodium citrate, are 
the optimal conditions for measuring multiparameter whole blood platelet activation, 
we proceeded to develop panels of antibodies and fluorophores to examine platelet 
activation in different contexts. We demonstrate measurement of platelet activation 
by both agonists and antagonists by changes in the surface protein expression and 
by measurement of intracellular phosphorylation of activation transducing enzymes. 
 
3.5.1 Activation induced surface antigens – fibrinogen, CD62P and 
CD42b 
Initially a three-colour assay was developed using antibodies which targeted 
fibrinogen, CD62P and CD42b. This combination allows two distinct measurements 
of platelet activation, fibrinogen binding (integrin activity/aggregation) and α-granule 
secretion (degranulation), and a constitutively expressed marker for platelet 
identification. The antibodies were tagged with fluorescent conjugates; fibrinogen-
FITC, CD62P-PE and CD42b-APC respectively. FITC and PE are both excited by 
the 488 nm laser and read in the 525/40BP and 585/42BP filters respectively and 
share overlapping spectral profiles. Due to this a compensation matrix was 
developed to allow for analysis of these parameters (Table 7). 
Table 7. Compensation matrix for three colour panel. 
Channel -FITC% -PE% -APC% 
525/40BP - 0.64 0.00 
585/42BP 27.62 - 0.00 
660/10BP 0.00 0.00 - 
 
The thrombin mimetic, SFLLRN (1 – 20 µM) induced a concentration dependent 
increase in both fibrinogen binding and CD62P expression (Figure 32). Where the 
data is analysed as percent positive cells, both markers reached near 100% 
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expression (fibrinogen 74.8±16% and CD62P 95.6±2%) at SFLLRN (5 µM) and do 
not increase significantly further as dose increased (fibrinogen 80.5±10% and CD62P 
98.1±1%) at SFLLRN (20 µM). This means that all platelets expressed the marker of 
activation at a level above the detection threshold, which is determined by either the 
use of EDTA or isotype control for fibrinogen and CD62P respectively. This provides 
a valuable illustration where despite percent positive cells not increasing further 
beyond SFLLRN (5 µM), MFI continued to increase; in fibrinogen binding, this 
increased from 844.7±76 (basal) to 9332.6±5009 (5 µM) peaking at 11,057.4±4673 
(20 µM). For CD62P expression, MFI increased dose dependently from 620.4±85 
(basal) to 13,314.6±3170 (5 µM) peaking at 17,099.9±2273 (20 µM). This experiment 
was performed with a standard surface staining protocol. 
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Figure 32. Platelet activation dose response to SFLLRN by three colour 
fluorescent flow cytometry. Whole blood was stimulated with SFLLRN (1 – 
20 µM) for 20 minutes prior to fixation in 1% PFA/PBS and subsequent 
fluorescent flow cytometry acquisition and analysis. (unpaired T-test, n=5, 
**<0.01 and ****<0.0001, error shown as standard deviation) 
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3.5.2 The influence of PKA signalling on platelet activation 
An outstanding caveat of most of the literature surrounding platelet activation, is that 
it is rarely carried out in the context of inhibition. Indeed, it is often measured in 
platelets which have been isolated from whole blood, plasma and any physiological 
milieu for some time. Work done in this hypo-inhibitory context suggests that platelets 
are hyper-sensitive to all stimuli, however, it must be considered that within the 
vasculature platelets are continually exposed to NO and PGI2. Therefore, we sought 
to perform analysis of platelet activation in the physiological milieu of whole blood 
and in the presence of PGI2, in order to more closely replicate activation in the blood 
to further understand how this affects the current beliefs surrounding the expression 
of markers of platelet activation. To do this, we applied fluorescent flow cytometry, 
as it allows an assessment of platelet function in whole blood without further sample 
processing. 
We first performed a dose response of PGI2 (1 – 100 nM) against a static dose of 
SFLLRN (5 µM) measuring fibrinogen-FITC, CD62P-PE and CD42b-APC 
simultaneously in the same samples (Figure 33). PGI2 caused a concentration 
dependent inhibition of both fibrinogen binding and CD62P expression. However, this 
approach allowed us to observe a difference in sensitivity of the markers to PGI2. 
Fibrinogen binding, and therefore integrin activation, was more sensitive to the 
effects of PGI2 with the marker returned to basal (5.3±3%) at maximal PGI2 (100 nM) 
treatment (5.9±3%). In contrast, CD62P remained significantly elevated over basal 
(10.1±6%) under the same conditions (33.1±18%) (Figure 33). 
We sought to further characterise this apparent dichotomy and repeated this 
experiment using a static maximal dose of PGI2 (1000 nM) against a dose response 
of SFLLRN (1 – 20 µM) (Figure 34). While kinetics of stimulation was similar across 
the two markers, with both fibrinogen and CD62P reaching near maximal percentage 
positivity at SFLLRN (5 µM) (74.6±16% and 95.6±2% respectively), the response to 
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activation in the context of inhibition was significantly different. Here, PGI2 maintained 
fibrinogen binding at basal regardless of agonist concentration, at maximal SFFLRN 
(20 µM) with PGI2, fibrinogen percentage expression was 3.7±3% and MFI was 
966.6±72, in comparison with fibrinogen basal at 2.2±3% and 844.72±76 
respectively. In contrast, CD62P expression remained elevated with PGI2 and 
SFLLRN at maximal dose (20 µM), percentage expression was 72.3±4% and MFI 
was 2948.6±741, and this remained significantly increased over basal at 24.3±10% 
(p<0.0001) and 620.4±85 (p<0.005) respectively (Figure 34). This reinforces the 
earlier finding (Figure 33), where PGI2 inhibited fibrinogen more than CD62P, and 
further confirms a dichotomy of response to PGI2 between the two markers of platelet 
activation, fibrinogen binding (integrin activation) and CD62P expression (granule 
secretion). 
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Figure 33. Dose response of PGI2 against a static dose of SFLLRN. Whole blood 
probed with fibrinogen-FITC, CD62P-PE and CD42b-APC treated with PGI2 (1 
– 100 nM) for 2 minutes and then treated with SFLLRN (5 µM) for 20 minutes 
prior to fixation in 1% PFA/PBS and subsequent fluorescent flow cytometry 
acquisition and analysis. (n=42, unpaired T-test, ns=non-significant and 
****<0.0001, error shown as standard deviation) 
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Figure 34. Dose response of SFLLRN against a static maximal dose of PGI2. 
Whole blood probed with fibrinogen-FITC, CD62P-PE and CD42b-APC treated 
with PGI2 (1000 nM) for 2 minutes and then treated with SFLLRN (1 – 20 µM) 
for 20 minutes prior to fixation in 1% PFA/PBS and subsequent fluorescent flow 
cytometry acquisition and analysis. (n=5, unpaired T-test, ns=non-significant, 
*<0.05, **<0.01, ***<0.005 and ****<0.0001, error shown as standard deviation) 
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3.5.3 pVASP-s157 phosphorylation is sustained 
In order to confirm that inhibitory signalling induced by PGI2 was sustained for the 
duration of the experiment (20 minutes) and these differences were not due to a 
significant loss of inhibitory signalling, we examined pVASP-s157. The levels of 
VASP phosphorylation at the initial time point of 2 minutes and the longer time point 
of 20 minutes were compared against a dose response of PGI2. Although there was 
a small reduction in phosphorylation over time, vitally the phosphoflow data 
confirmed that inhibitory signalling was sustained above basal by >4-fold for the 
duration of the time course tested (Figure 35). Hence CD62P remains expressed on 
the majority of cells despite elevated cAMP. 
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Figure 35. pVASP-s157 dose response of PGI2 at 2 and 20 minutes. Whole blood 
treated with PGI2 (1 – 100 nM) for 2 or 20 minutes prior to fixation in BD fix/lyse, 
permeabilisation, barcoding, washing and staining with pVASP-s157. (n=42) 
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3.6 MULTIPARAMETER SUBPOPULATION IDENTIFICATION 
Given that previous data (Figure 33 and Figure 34) demonstrated that fibrinogen 
binding and CD62P showed differing sensitivity to PGI2, we wanted to explore this 
concept of differential regulation using additional markers of platelet activation. The 
assay was adapted by adding in a fourth fluorescent parameter, annexin V-APC, 
which binds to phosphatidylserine (PS) and acts as a marker of platelet procoagulant 
activity (Gyulkhandanyan et al., 2012). In order to introduce this marker on an APC 
fluorophore, we used CD42b conjugated to a polymer BB700 dye, which is excited 
by the 488 nm laser and is detected in the 712/25BP channel. This increased the 
complexity of the compensation matrix required, as a greater number of fluorophores 
were emitting within a similar spectral range and overlapping within the detector 
bandpass array (Table 8). 
Table 8. Compensation matrix for four colour panel. 
Channel -FITC% -PE% -APC% -BB700% 
525/40BP - 0.64 0.00 14.11 
585/42BP 27.62 - 0.00 42.67 
660/10BP 0.00 0.00 - 10.24 
712/25BP 0.00 0.00 37.66 - 
 
 3.6.1 Multiparameter analysis platelet activation in the presence of PGI2 
In the four-parameter fibrinogen, CD62P, PS and CD42b assay we provided robust 
SFLLRN mediated PAR1 activation and cross-linked collagen related peptide (CRP-
XL) mediated GPVI activation. This dual stimulus drives platelet activation and 
phosphatidylserine exposure, which will induce the formation of the procoagulant 
platelet subpopulation (Sodergren and Ramstrom, 2018). 
Data from the four-parameter assay is presented here as percent positive cells over 
EDTA or IgG control respective to the conjugate and as fold MFI over basal. 
Fibrinogen binding was significantly increased over basal when treated with SFLLRN 
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(20 µM)/CRP-XL (10 µg/mL) for both percent positive (0.5±0.3% to 67.6±13.5%, 
p<0.0001) and fold MFI (1 to 8.6±3.9, p<0.05). CD62P was also significantly 
increased over basal in the same samples after stimulation in both percent positive 
(20.4±9.3% to 96.9±2.6%, p<0.0001) and fold MFI (1 to 37.4±5.9, p<0.0001). Again 
from the same cells, PS exposure was measured, and this was also increased over 
basal after stimulation in both percent positive (7.7±7.8% to 43.5±13.6%, p<0.0001) 
and fold MFI (1 to 9.8±3.8, p<0.01). However, pre-treatment of the whole blood with 
PGI2 (1 – 1000 nM) led to differences in sensitivity to inhibition becoming apparent in 
each marker measured on the same cells. In a recapitulation of previous data 
fibrinogen binding was shown to be significantly reduced in the presence of PGI2 
(1000 nM) in percent positive (67.6±13.5% to 10.62±6.9%, p<0.0001) and fold MFI 
(8.6±3.9 to 1.9±0.2, p<0.05). Again in support of previous findings, CD62P 
expression was shown to remain mostly independent of inhibition, with only a small 
reduction in percent positive (96.9±2.6% to 83.7±14.8%, p<0.05) and no significant 
reduction in fold MFI (37.4±5.9 to 23±13.6, ns). Finally, the third activation marker 
measured on these cells showed that PS exposure was also more sensitive to 
inhibition than granule secretion and demonstrated a significant reduction in percent 
positive (43.5±13.6% to 28.3±15.9%, p<0.01), although here percent positive cells 
appears to remain high the MFI data confirms that almost all signal is lost with a 
return to near basal (9.8±3.8 to 2.9±1.8, p<0.01). Furthermore, as a four parameter 
assay, CD42b expression was also measured here and shown to be decreased by 
stimulation (data not shown), but was protected from shedding by PGI2 treatment. In 
total this experiment demonstrates that three of four markers measured here are 
sensitive to PGI2 mediated inhibition of activation, but CD62P remains resistant to 
inhibition. 
Here we demonstrated an extension of the dichotomy between different markers of 
platelet activation in response to PGI2. Fibrinogen and phosphatidylserine both 
demonstrated markedly greater sensitivity to PGI2 than CD62P, which demonstrated 
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a significant resistance to PGI2. As this experiment was performed measuring four 
parameters simultaneously, this provides confidence in the dichotomy examined here 
between these markers as antagonists and agonists can be demonstrated to work in 
parallel markers, and further supports the previous observations made regarding the 
resistance of CD62P to inhibition. 
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Figure 36. Four parameter dose response of PGI2 against a static dose of 
SFLLRN/CRP-XL. Recalcified whole blood probed with fibrinogen-FITC, 
CD62P-PE, annexin V-APC and CD42b-BB700 treated with PGI2 (1 – 1000 nM) 
for 2 minutes and then treated with SFLLRN (20 µM)/CRP-XL (10 µg/mL) for 
20 minutes prior to fixation in 1% PFA/Ca2+ modified Tyrodes and subsequent 
fluorescent flow cytometry acquisition and analysis. (n=12 for percentage, 5 
matched for fold MFI, paired T-test, ns=non-significant, *<0.05, **<0.01 and 
****<0.0001, error shown as standard deviation) 
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3.6.2 FItSNE analysis of platelet subsets 
Here we applied multidimensional analysis to the four-parameter fibrinogen-FITC, 
CD62P-PE, annexin V-APC, CD42b-BB700 panel to distinguish unique subsets of 
platelets with an impartial clustering strategy. We applied a variant of t-SNE, FIt-SNE 
(Linderman et al., 2019). tSNE allows multidimensional (4D) data to be expressed on 
a 2D plot by the formation of clusters of related cells. These resulting “islands” of cells 
are related by their unique receptor expression profile. This analysis was performed 
on concatenated FCS files with 30,000 platelet positive events in each treatment 
category, which was drawn from 3 biological repeats. The islands formed through the 
algorithm were then pseudo coloured for expression of each marker so we could 
further understand the defining characteristics of each group. Where islands were 
distinct, they are manually gated to provide relative fluorescence intensities and 
population size of each island. In this case, blue represents negative populations, 
green-yellow interstitial expression, while red is indicative of high levels of 
expression. 
At basal we identified no distinct islands (upper, Figure 37), although the basal activity 
of CD62P was apparent. However this is a universally observed by platelet biologists 
(Frelinger et al., 2015), and is likely, but perhaps not exclusively, due to the physical 
trauma of venepuncture driving mild activation of platelets. When stimulated with 
SFFLRN (20 µM)/CRP-XL (10 µg/mL), 3 distinct islands emerged (mid, Figure 37). 
These cells were characterised primarily by distinct levels of PS exposure and 
fibrinogen binding. These are classified as; PSlo/FBhi (66.3%), PShi/FBlo (23.3%) and 
PShi/FBhi (9.5%). While the phenomena of PS+ and PS- platelet subpopulations have 
been previously described in many contexts, this is a novel observation suggesting 
that within PS+ platelets there are further unique subsets distinguished by a capacity 
to bind fibrinogen. In contrast to fibrinogen and PS, we found that within these 
populations there were minor differences in CD62P and CD42b expression.  
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However, as expected from our previous data, when pre-inhibited with PGI2 (100 nM) 
and then stimulated with SFFLRN (20 µM)/CRP-XL (10 µg/mL), there was a dramatic 
remodelling of the subpopulations previously described. We now identify 4 unique 
islands which have all undergone large changes in the presence of inhibition (lower, 
Figure 37). These subsets are characterised as; CD62Phi/FBlo (69.2%), CD62Phi/FBhi 
(20.8%), CD62Plo/FBlo (7.2%) and CD62Phi/PShi (2.9%). This is the first description 
of platelet subpopulations which emerge after potent stimulation in the physiological 
context of calcified whole blood and PGI2. 
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Figure 37. Static PGI2 against static SFLLRN/CRP-XL analysed by FIt-SNE. 
Recalcified whole blood probed with fibrinogen-FITC, CD62P-PE, annexin V-
APC and CD42b-BB700 treated with PGI2 (100 nM) for 2 minutes and then 
treated with SFLLRN (20 µM)/CRP-XL (10 µg/mL) for 20 minutes prior to 
fixation in 1% PFA/Ca2+ modified Tyrodes and subsequent fluorescent flow 
cytometry acquisition and analysis by FIt-SNE. (n=3) 
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 3.6.3 PGI2 protects mitochondria from depolarisation 
TMRE collects within mitochondria against an electrochemical gradient and is 
used as a marker of mitochondrial (de)polarisation. It has been previously 
suggested that mitochondrial depolarisation is a key event in the process of 
phosphatidylserine exposure (Agbani and Poole, 2017, Choo et al., 2017). We 
wanted to use this as a basis for asking where in the pathway PGI2 may target 
phosphatidylserine exposure. We demonstrate this data with fold MFI over 
controls (FCCP/EDTA respectively). Under basal conditions, TMRE measured 
2.3±0.8, which was reduced to 1.1±0.1 after activation with SFLLRN/CRP-XL. 
This decrease is indicative of mitochondrial depolarisation. The loss of 
mitochondrial polarisation under these conditions was associated with increased 
PS expression from 1.0±0 to 41.2±4 (upper, Figure 38). This is visually 
demonstrated by the biaxial plots examining the relationship between TMRE and 
Annexin V. Here it can be seen that under basal conditions platelets were high in 
TMRE, but low in PS. Stimulation leads to a loss of TMRE and increase in PS 
(lower, Figure 38).  
To understand if the inhibition of phosphatidylserine exposure was linked in any 
way to TMRE and the temporal order of events, we examined both markers in the 
presence of PGI2. PGI2 reduced annexin V events from 78.2% to 31.5%. The 
biaxial plots demonstrate that most of the platelet population (68.5%) that are PS 
negative also have normal TMRE staining (61.2%), this is an important 
observation, where a left shift alone would have shown that mitochondria are 
remaining depolarised, but PS is blocked from exposure. The shift is a return to 
polarised mitochondria, which confirms that depolarisation occurs upstream of 
PS exposure (Choo et al., 2017)and that PGI2 is either targeting mitochondria 
and protecting them or inhibiting the event prior to depolarisation, which in turn 
blocks mitochondrial depolarisation to prevent PS exposure. There was a dose 
responsive recovery of mitochondrial depolarisation and inhibition of PS 
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expression in the presence of PGI2, where at maximal dose mitochondria was 
rescued from depolarisation (TMRE, 1.1±0.1 to 2.0±0.7, SFLLRN/CRP-XL and 
PGI2 1000 nM respectively) (Figure 38). 
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Figure 38. Dose response of PGI2 against a static dose of SFLLRN/CRP-XL to 
examine mitochondrial membrane potential and phosphatidylserine. 2 x 
106 washed platelets were treated with PGI2 (1 – 1000 nM) for 2 minutes and 
then treated with SFLLRN (20 µM)/CRP-XL (10 µg/mL) for 20 minutes while 
staining for TMRE (50 nM) and annexin V-APC. Each sample was diluted 10x 
in PBS and analysed immediately for 10,000 platelet events, biaxial contour 
plots and fold over matched FCCP/EDTA control are presented. (n=3, ns=non-
significant, error shown as standard deviation) 
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3.6.4 Validation by PAC1 multiparameter panels 
To validate the previous observation with a parallel marker of integrin αIIbβ3, we 
repeated these experimental conditions with the monoclonal antibody PAC1. This 
antibody targets the integrin αIIbβ3 specifically in its active conformation, as opposed 
to the anti-fibrinogen antibody which targets fibrinogen bound to the integrin αIIbβ3, 
or indeed elsewhere on the platelet surface, and acts as a proxy for receptor 
activation. This allowed us to cross-validate and confirm our previous observations 
which suggested that fibrinogen binding was more sensitive to PGI2 mediated 
inhibition than CD62P expression. 
We first compared PAC1 and CD62P in a three-parameter assay including CD42b 
(Figure 39). Here, to compare inhibitory response, the two parameters are compared 
on the calculated percent inhibition. This demonstrated that in response to increasing 
doses of PGI2 (1 – 1000 nM), PAC1 inhibition was markedly more than that of CD62P 
and significantly increased when comparing minimal and maximal dose of PGI2 
(4.4±9% and 75.7±15%), whereas there was no significant difference when 
comparing CD62P (10.0±3% and 34.7±17%) (Figure 39).  
To then further validate our findings regarding the two PShi subsets, we used PAC1 
as an alternative marker of integrin αIIbβ3 activity and performed a four parameter 
assay also including CD62P, annexin V and CD42b. Here we could show that upon 
treatment with the dual stimulus of SFLLRN and CRP-XL, three subsets were formed; 
PS-PAC1+, PS+PAC1- and PS+PAC1+ (Figure 40). These corroborate with the three 
subsets formed when observed with fibrinogen as the primary marker of integrin 
αIIbβ3 activity (Figure 37). 
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Figure 39. PAC1 and CD62P dose response of PGI2 against a static dose of 
SFLLRN/CRP-XL. Whole blood probed with PAC1-FITC, CD62P-PE and 
CD42b-APC treated with PGI2 (1 – 1000 nM) for 2 minutes and then treated 
with SFLLRN (20 µM)/CRP-XL (10 µg/mL) for 20 minutes prior to fixation in 1% 
PFA/PBS and subsequent fluorescent flow cytometry acquisition and analysis. 
(n=3, paired T-test, ns=non-significant and **<0.01, error shown as standard 
deviation) 
 
 
 
Figure 40. Four parameter PAC1 assay with a static dose of SFLLRN/CRP-XL 
for subpopulation identification. Recalcified whole blood probed with PAC1-
FITC, CD62P-PE, annexin V-APC and CD42b-BB700 treated with SFLLRN (20 
µM)/CRP-XL (10 µg/mL) for 20 minutes (+/- EDTA 10 mM) prior to fixation in 
1% PFA/Ca2+ modified Tyrodes and subsequent fluorescent flow cytometry 
acquisition and analysis. (n=1) 
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3.6.5 Validation by multiparameter granule secretion panel 
While we have been able to establish that CD62P demonstrates resistance to 
inhibition in the context of robust stimulation and show this in multiple assays, we 
sought to provide further validation and further explore this phenomenon. Here using 
an additional four-marker panel using CD154-FITC, CD62P-PE, CD63-APC and 
CD42b-BB700 we aimed to validate and explore our observations on these additional 
markers of platelet degranulation. By using 3 markers of granule secretion, we hoped 
to be able to confirm the resistance demonstrated to PGI2 by CD62P would also be 
conferred onto other markers of granule secretion, thereby validating the 
independence of CD62P (and granule secretion) to cAMP-mediated inhibitory 
signalling. 
These markers were all shown to be significantly increased in the presence of robust 
stimulation (SFLLRN/CRP-XL) (CD154 28.1±7%, CD62P 98.7±0.2%, CD63 
98.5±0.3%), but also demonstrated significant resistance to inhibition, shown as a 
continued significant difference to basal in the presence of maximal PGI2 (1000 nM) 
(CD154 22.8±11%, CD62P 96.1±4%, CD63 96.0±3%) (Figure 41). This validates our 
previous observations surrounding CD62P and further suggests that it is platelet 
degranulation itself that may retain resistance to cAMP signalling in the context of 
robust stimulation. 
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Figure 41. Dose response of PGI2 against a static dose of SFLLRN/CRP-XL to 
measure granule secretion. Whole blood probed with CD154-FITC, CD62P-
PE, CD63-eF660 and CD42b-BB700 treated with PGI2 (1 – 1000 nM) for 2 
minutes and then treated with SFLLRN (20 µM)/CRP-XL (10 µg/mL) for 20 
minutes prior to fixation in 1% PFA/PBS and subsequent fluorescent flow 
cytometry acquisition and analysis. (n=5, unpaired T-test, **<0.01, ***<0.005 
and ****<0.0001, error shown as standard deviation) 
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 3.6.6 Inhibitory signalling by phosphoflow with surface CD62P 
Having previously confirmed the partial resistance of agonist induced CD62P 
expression to PGI2 through three different assays, we next wanted to further confirm 
that the resistance was not due to diminished cAMP signalling over the course of the 
experimental 20-minute incubation. To explore this, we developed a novel assay 
which for the first time in platelet biology combined intracellular phosphoflow with 
measurement of surface markers of activation. This assay requires a stimulation, 
surface probe, fix, permeabilise and intracellular probe protocol to allow for optimal 
recognition and detection of all markers. 
Treatment with PGI2 (10 – 1000 nM) resulted in a robust phosphorylation of pVASP-
s157 (6.3±0.1, 7.5±0.5 and 7.6±1.1 at 10, 100 and 100 nM respectively), at higher 
doses of PGI2 (100 – 1000 nM) this was not diminished in the presence of SFLLRN 
(20 µM) (8.3±1.8 and 9.0±3.0 respectively), but was reduced with weaker PGI2 
stimulation (10 nM) from 6.1±0.1 to 2.4±0.5 respectively (Figure 42). Examining 
CD62P on the same cells demonstrated that CD62P was expressed in the presence 
of both PGI2 and SFLLRN, and SFLLRN alone at all doses, as prior, at the lower dose 
of PGI2 (10 nM) the opposite observation than for pVASP-s157 was made where 
CD62P expression was greater than at higher doses of PGI2 (100 – 1000 nM) 
16,637.3±5495 vs. 8969.4±3613 and 8316.8±3007 at 10, 100 and 1000 nM 
respectively. This suggests there is some capacity for CD62P inhibition but it remains 
expressed independent of robust cAMP signalling driven by excess PGI2 (Figure 42). 
By also demonstrating this data as a biaxial contour plot of pVASP versus CD62P, 
we can confirm that all cells positive for CD62P (97.1%) retain robust VASP-s157 
phosphorylation and there is no subset of inhibition resistant platelets (Figure 42), 
therefore confirming that the CD62P expression is independent of intact inhibition 
signalling and is not due to diminished inhibition.  
  
- 131 - 
 
 
Figure 42. Dose response of PGI2 against a static dose of SFLLRN/CRP-XL to 
measure inhibitory signalling. Whole blood probed with CD62P-PE and 
CD42b-APC treated with PGI2 (10 – 1000 nM) for 2 minutes and then treated 
with SFLLRN (20 µM) for 20 minutes prior to BD fix/lyse, permeabilisation and 
staining with pVASP-s157 followed by fluorescent flow cytometry acquisition 
and analysis. Within biaxial contour plots, the line indicates IgG-PE background 
fluorescence. (n=3, unpaired T-test, ns=non-significant and *<0.05, error 
shown as standard deviation) 
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 3.6.7 Platelet monocyte aggregates 
Given that CD62P and CD154 are known to be as key mediators of platelet-leukocyte 
interactions (Rossaint et al., 2016, Stokes et al., 2009), and we had shown that these 
were independent of platelet inhibitory signalling, we assessed the effect of PGI2 on 
platelet-monocyte aggregates (PMA). We hypothesised that PMA may be 
independent of PGI2-cAMP signalling under the same experimental conditions of 
robust activation and inhibition where the previous observations had been made. 
Here, monocytes (CD14+) were analysed for expression of the platelet marker 
CD42a. PMA were significantly increased after co-stimulation of whole blood with 
SFLLRN (20 µM) and CRP-XL (10 µg/mL) from 1508.6±177 at basal to 6819.7±1835 
when stimulated (p<0.005). Exposure of whole blood to PGI2 prior to platelet 
activation led to a modest reduction in PMA (5093.6±705), but this was not 
statistically significant (Figure 43). To further confirm that fibrinogen binding was 
inhibited by PGI2 and did not mediate PMA, we employed the specific αIIbβ3 integrin 
blocker Tirofiban. We showed that Tirofiban did not potentiate PGI2 (1000 nM) 
inhibition (4664.1) and that alone it could mimic the effects of PGI2 alone 
(5673.4±1574) (Figure 43). This suggests that PMA do not depend on platelet-bound 
fibrinogen and can occur independently of fibrinogen binding and are probably 
mediated by platelet granule proteins which are resistant to inhibition. Therefore, 
residual PMA in the presence of the vascular inhibitor PGI2 is independent of 
fibrinogen binding and occurs in a context where inhibition independent CD62P and 
CD154 expression is upregulated. 
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Figure 43. Platelet monocyte aggregates continue to form in the context of 
inhibition and are not dependent on fibrinogen. Platelet monocyte 
aggregates are induced by SFLLRN (20 µM) and CRP-XL (10 µg/mL) and in 
some cases pre-treated with PGI2 (1000 nM) or Tirofiban (1 µg/mL). CD42a 
fluorescence measured with anti-CD42a-Peridinin Chlorophyll Protein Complex 
(PerCP). (n=5, Two-tailed unpaired T-tests; ns=non-significant and ***<0.005, 
error shown as standard deviation). 
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3.7 DE-ACTIVATION OF PLATELETS BY PROSTACYCLIN 
Previously, we examined the effects of PGI2 on platelet activation when added prior 
to stimulation, which most likely presents the real scenario in vivo. However, we also 
sought to understand if platelet activation markers could be modulated by PGI2 post-
stimulation, which had been shown previously in a static adherent model (Yusuf et 
al., 2017). In vivo, it is also likely that activated platelets may continue to be exposed 
to endothelial inhibitors. Our own data previously suggested there is some capacity 
for a reduction in activation markers, this was observed as part of the pVASP-
s157/CD62P assay where basal expression of CD62P was shown to be lost when 
treated with PGI2 (Figure 42). Therefore, we sought to specifically pursue this 
question. 
 
 3.7.1 Reversal of platelet activation 
First, we designed a four-colour flow cytometry experiment to assess several aspects 
of platelet activation. Here we applied fibrinogen-FITC, CD62P-PE, CD63-EF660 and 
CD42b-BB700. whole blood was stimulated for 20 minutes followed by 2 minutes of 
PGI2 treatment. Two matched controls were included, one of which was a mock 
treatment with 2 minutes of modified Tyrode’s buffer and the second fixed at 20 
minutes, which provided a snapshot of activation at both 20- and 22-minutes allowing 
comparisons to the effects of post-activation inhibition. Here mock treated then fixed 
is presented for comparison. 
Remarkably, we were able to observe reductions in all examined markers of 
activation, although to different extents. Fibrinogen binding, CD62P and CD63 were 
all reduced by treatment with PGI2 (1000 nM) and the effect was strongest on those 
samples which had been stimulated with the lower doses of SFLLRN (1 µM). At the 
lower dose of SFLLRN (1 µM) fibrinogen binding was reduced from 10,553.7 to 
1465.4, CD62P from 25743.6 to 9965.4 and CD63 from 1825.8 to 1028.0 (Figure 44). 
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Again, in reference to our previous observation that fibrinogen binding/ integrin αIIbβ3 
was more sensitive to PGI2 than granule secretion, at maximal SFFLRN (10 µM), 
fibrinogen binding was reduced from 40,966 to 19,886.8 while the granule markers 
remained essentially unchanged; CD62P from 66,293.7 to 52,241.7 and CD63 from 
6470.3 to 5571.1. CD42b presented an important control in this experiment. As 
previously shown (Figure 37), expression of CD42b was decreased by stimulation, 
from 11,375.7 to 4857.5 (basal and SFLLRN 10 µM respectively). Therefore, as 
CD42b was shed after stimulation, unlike the other markers, it could not be recovered 
(4407.6, SFLLRN 10 µM + PGI2 1 µM) despite the post-activation inhibition. 
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Figure 44. Dose response of SFLLRN against a static dose of PGI2 added post 
activation. Whole blood probed with fibrinogen-FITC, CD62P-PE, CD63-
eF660 and CD42b-BB700 treated with SFLLRN (1 – 10 µM) for 20 minutes prior 
to addition of PGI2 (1000 nM) for 2 minutes or mock treated and then fixed in 
1% PFA/PBS. (n=2) 
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3.8 DISCUSSION 
Platelet activation and inhibition measured by fluorescent flow cytometry provides a 
platform for robust, reproducible and data rich interpretation of the platelet status. In 
this chapter, we have demonstrated the use of traditional surface markers of platelet 
activation, intracellular markers of inhibition and markers for surface 
phosphatidylserine and mitochondrial depolarisation. With the application of unique 
combinations of markers, we have been able to demonstrate the potential for 
discovery which this technique provides. We have revealed novel platelet 
subpopulations and shown how these are remodelled in the presence of activated 
PKA and also shown how fluorescent flow cytometry can be used to link surface 
markers to intracellular signalling events within platelets. 
 
3.8.1 Pre-analytical considerations 
Although there have been several platelet flow cytometry guidelines published to date 
(Spurgeon and Naseem, 2019, Harrison et al., 2011, Harrison, 2009, Linden et al., 
2004) which comprehensively examine pre- and post-analytical considerations of 
platelet flow cytometry, they have not examined multicolour platelet flow cytometry in 
recalcified whole blood. Therefore, an important element of this chapter was to 
assess the major pre-analytical considerations which may impact this study. A four-
colour assay was designed with the marker’s fibrinogen-FITC, CD62P-PE, Annexin 
V-APC and CD42b-BB700, which allows the researcher to comment on αIIbβ3 
integrin activity, α-granule secretion and procoagulant activity on cells confirmed as 
platelets, all simultaneously. Applying this assay, we then examined and assessed 
the impact of the pre-analytical considerations including; anti-coagulant, assay 
initiation, platelet medium (whole blood, PRP or washed platelets) and impact of 
storage of samples post-fixation. 
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The three anti-coagulants tested here are all commonly used in clinical laboratories 
and all blood was drawn into vacutainers. The recent work of others on whole blood 
flow cytometry has confirmed the suitability of vacutainers for platelet biologists 
(Welch et al., 2018). The use of vacutainers carries several inherent advantages over 
manually prepared syringes. Primarily, it creates standardisation across laboratories, 
but it also allows rapid translation of assays to clinical samples, where the standard 
is evacuated tubes. We decided to determine the optimal anti-coagulant based on 
optimal sensitivity in each marker. We found that sodium citrate was the optimal anti-
coagulant for platelet activation by flow cytometry. Previously, citrate, heparin and 
hirudin anti-coagulants were compared with markers PAC1, CD62P and LAMP1 
(Ramstrom et al., 2016), or CD62P alone was assayed (Golanski et al., 1996) and in 
agreement with our study, citrate tubes were determined as optimal for platelet flow 
cytometry. We determined sodium citrate as optimal, as fibrinogen binding was most 
sensitive in this anti-coagulant, and CD62P remained sensitive and was not 
dependent on changes in anti-coagulant. Furthermore, in citrated blood fluorescence 
intensity of annexin V binding was reduced in comparison to sodium heparin, but as 
a qualitative marker, the percent positive remained unchanged and therefore 
sensitivity to determine the procoagulant platelet subset was not compromised. In 
support of this observation we were also able to measure ERK1/2 phosphorylation, 
which can be used as a marker of platelet activity (Stalker et al., 2012), and 
demonstrated that this was most sensitive in heparin and citrate, but not EDTA anti-
coagulants. This signalling defect in EDTA mirrors the functional defects observed in 
EDTA anti-coagulated blood. 
In a research laboratory prompt instigation of assays is optimum, however when 
working on clinical samples where medical intervention must be the first concern, 
delay in obtaining blood samples may be unavoidable. We rested blood at room 
temperature (Harrison et al., 2011), and compared results from each time point. 
Surprisingly we observed an almost total loss of fibrinogen binding at the longest time 
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point, with a large reduction in assay sensitivity. Work from others has suggested that 
this reduced fibrinogen binding is unlikely to be due to the αIIbβ3 integrin losing 
capacity to bind fibrinogen, as PAC1 binding does not significantly decrease over 
storage time (Huskens et al., 2018), nor is it likely degradation of the ligand, as 
fibrinogen levels have also been shown to increase at 8 hours of ambient temperature 
storage (Kemkes-Matthes et al., 2011). As part of assay design and to limit variation 
across time points, staining solutions were made up at 0-hours and stored on wet ice 
in the dark throughout the experiment. To eliminate the potential of this inducing error, 
duplicate samples with fresh stain at 4.5 hours were also analysed and the reduction 
in fibrinogen was again observed (data not shown). Therefore, it is probable that it is 
the addition of GPRP to the whole blood at 0 hours and subsequent storage with this 
peptide that caused this effect, indeed it has previously been shown that excess 
GPRP is able to block some fibrinogen binding to platelets (Plow and Marguerie, 
1982). Nevertheless, the addition of GPRP is vital in a calcified whole blood system 
to prevent fibrin formation and clotting, but the consistent reduction in fibrinogen 
binding, suggests a long-term incompatibility with GPRP treated stored samples. 
Consequently either the addition of GPRP should be delayed, a non-calcified system 
used (meaning annexin V could not be used (Gyulkhandanyan et al., 2012)), or PAC1 
substituted as an alternative marker of integrin αIIbβ3 activation where sample 
resting is likely to occur (Frelinger, 2018). The robust marker of CD62P remained 
sensitive to activation over the time points tested, although basal expression 
significantly increased over time. This highlights that when comparing donors, it is 
vital assays are initiated at the same time point to minimise basal activation, which 
could be misinterpreted as having clinical significance, where basal activation could 
be considered a clinical biomarker. This increase in basal CD62P suggests that some 
platelets are degranulating, by both a small amount (noting small MFI increases) and 
not all cells (noting percentage positive). Both annexin V basal and stimulated 
expression increased over time, but this is likely due to reduction in the inhibition of 
- 140 - 
the apoptotic pathways at 4.5 hours ex vivo, if longer time points were examined it is 
probable more platelets would become apoptotic and functional responses continue 
to decline (Sperling et al., 2019, Sodergren et al., 2016). 
The platelet medium which assays will be performed in is an important consideration. 
The data presented here suggested that for activation, whole blood is optimal. 
However, contradictions for the use of whole blood may include fluorescent dyes, 
chemical inhibitors or agonists which are incompatible with any system other than 
washed cells in a buffered suspension. Fibrinogen binding, counter-intuitively, 
appears to substantially increase on the surface of washed platelets, however when 
MFI is compared with percent positive cells, it is apparent that there is a significant 
loss of sensitivity. This is clearly demonstrated by the EDTA control which can no 
longer prevent binding, suggesting that most of the signal appears to be non-specific 
binding or no longer calcium dependent/integrin αIIbβ3 mediated. Where washed 
platelets might regularly be assayed, it would be practical to exchange anti-fibrinogen 
for PAC1, which would detect integrin activation without the need for fibrinogen to be 
present and eliminate this anomaly and restore assay sensitivity (Frelinger, 2018). 
Although CD62P retains capacity for activation within washed platelets, there is a 
high basal activation from the physical stresses of isolation, as a result percent 
positive cells loses sensitivity as a marker of activation. Finally, annexin V binding to 
phosphatidylserine appears to increase in PRP and further in washed platelets. It 
appears that in washed platelets, platelets are pre-disposed to become procoagulant, 
this could be due to increased agonist availability, however as it has previously been 
demonstrated that the number of phosphatidylserine positive cells should not change 
based on agonist availability (Sodergren and Ramstrom, 2018). In support of this, 
this phenomena was also observed in later experiments when annexin V and TMRE 
were assayed together, again the number of PS positive cells exceeding the typically 
accepted ~35%. 
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Finally, we considered the effect of storage of fixed and probed samples. In many 
instances, it is not feasible to acquire samples immediately, although based on our 
findings we recommend that samples are acquired promptly. Notably here, and in 
contrast to our other results presented here, fibrinogen binding remains robust but 
both CD62P and annexin V are diminished by storage. Previous work by Atar et al. 
has suggested CD62P is stable up to 5 days, however they used different 
concentrations of paraformaldehyde (2% versus 0.9%) and based their observations 
on basal expression whereas our samples were stimulated, greatly increasing the 
window to detect a decrease (Atar et al., 2010). Furthermore, although there is a 
considerable decrease in CD62P MFI in our data, the number of positive cells 
remained consistent (data not shown). Where samples are required to be stored, it 
may be prudent to freeze samples immediately to add further protection against 
degradation. Regardless, we recommend that where possible samples are run for 
cytometry acquisition as soon as feasible, or in cases where this is not possible 
delays are universally applied to all samples to reduce any errors within data. 
Here we have described several comparisons of pre-acquisition parameters within 
the control of the platelet biologist. In summary, we determined that when performing 
platelet activation assays in re-calcified systems, assays should be performed on 
citrated blood drawn into evacuated tubes; sample preparation should be begun 
immediately after the blood is drawn or when this is not possible started at a 
consistent time point after blood acquisition, and samples must be acquired 
immediately or stored for standard time frames. As a result, we followed these 
strictures in subsequent studies. 
 
3.8.2 PGI2 and platelet subpopulations 
Signalling downstream of elevated cAMP is known to regulate multiple aspects of 
platelet function including calcium mobilisation, integrin αIIbβ3 activity and the actin 
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cytoskeleton (Raslan and Naseem, 2014). The aim of this series of experiments was 
to determine if distinct platelet functions showed differential sensitivity to inhibition by 
PGI2, using multiparameter fluorescent flow cytometry as a model assay. A pro-
coagulant platelet subpopulation has been characterised and the three-dimensional 
structure, stimulation conditions and functions of the pro-coagulant PS positive 
platelet subpopulation has been previously described (Heemskerk et al., 2013, 
Agbani and Poole, 2017). However, several unresolved discrepancies between 
studies are evident, in particular, the difference in the expression of active integrin 
αIIbβ3 or fibrinogen binding on PS positive platelets has remained unresolved, 
despite publications on this subject (Agbani and Poole, 2017, Topalov et al., 2012, 
Choo et al., 2017). A combination of multicolour flow cytometry assays, validated with 
the pre-analytical considerations study, was used and multidimensional data analysis 
algorithms applied, variants of which have been previously applied to CyTOF platelet 
data (Blair et al., 2018) but not fluorescent flow cytometry data, and this facilitated 
both a novel and objective approach. 
Using a four-parameter assay, fibrinogen-FITC, CD62P-PE, annexin V-APC and 
CD42b0BB700 we identified two subsets within the larger subpopulation of 
procoagulant platelets that could be differentiated by their ability to bind fibrinogen 
(PShi/FBhi and PShi/FBlo). This suggests that both sides of this ongoing discussion as 
to whether PS positive platelets bind to fibrinogen are correct. This PShi 
characterisation supports a previous study that also identified two PS populations, 
which were distinguished primarily by Ca2+ signalling, this group also demonstrated 
a difference in PAC-1 binding, but intriguingly they suggested there were no 
differences in fibrinogen binding (Topalov et al., 2012), in direct disagreement with 
our study. However, we further validated our findings using PAC1. The analytical 
approach with FIt-SNE allowed us to evaluate how these subsets were linked to other 
platelet surface markers. Under potent activatory conditions, CD62P was expressed 
on all platelets, but the highest expression of CD62P was concentrated in the 
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PShi/FBhi subset, indicating that these platelets were “super-activated”. Given the 
functional dichotomy of procoagulant and aggregatory platelets, the role of the 
intermediate subset that expresses both markers are unclear. However, they may 
represent a group of cells that act to integrate the two arms of platelet function or 
indeed may change in disease and represent a hyperactive/thrombotic platelet 
subset which can facilitate both platelet-rich thrombus formation and thrombin 
generation alone. 
Having established the presence of three subsets of platelets upon strong activation, 
we wanted to understand how they were affected by cAMP signalling. First, in a 
screening experiment, we found that PGI2 failed to fully inhibit mild agonist-induced 
CD62P expression on the blood platelets of 42 healthy individuals despite robust 
inhibition of fibrinogen binding. Further exploration with the subpopulation defining 
four colour assays revealed that PGI2 prevented fibrinogen binding and PS exposure 
despite potent activation, ameliorating the generation of any procoagulant subsets. 
What emerged was a novel platelet population that was characterised by high CD62P 
expression (CD62Phi/PSlo/FBlo). Further investigation using a separate multicolour 
assay for independent validation showed that this subset of platelets was also 
enriched in the expression of CD154 and CD63. To understand the wider 
physiological relevance of these findings we measured platelet-monocyte aggregates 
(PMA) in whole blood, as it is established to occur through CD62P-CD162 and 
potentially CD154-CD40. In these experiments, PMA was confirmed to be fibrinogen 
independent, and it was not significantly inhibited by PGI2. This suggests that the 
resistant CD62P on the platelet surface is competent to support heterotypic cell-cell 
interactions. Thus, under physiological conditions of elevated cAMP, procoagulant 
and aggregatory subsets are diminished, yet an immunocompetent phenotype is 
maintained. This could represent a model for platelet monocyte aggregate formation 
without associated thrombotic activity. 
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The mechanism underpinning the ability of PGI2 to modulate subset formation 
remains unclear. It is now established that the formation of PShi platelets requires a 
sustained increase in Ca2+ and subsequent mitochondrial depolarisation (Agbani and 
Poole, 2017). PGI2 has been shown to regulate intracellular Ca2+ flux (Fung et al., 
2012), which accounts for both PS exposure and integrin activation, there is a 
component of Ca2+ signalling that is resistant to PGI2. We found that TMRE 
fluorescence, where a loss is associated with mitochondrial depolarisation (Choo et 
al., 2017), is protected by treatment with PGI2, confirming that another component of 
the pathway driving the generation of procoagulant platelets is blocked by cAMP. 
This data also suggests that granule secretion under these conditions is independent 
of mitochondrial dysfunction and not wholly reliant on flux of Ca2+. Previous studies 
have shown that cAMP-elevating agents can inhibit CD62P expression in weakly 
activated platelets, leading us to believe that cAMP causes global inhibition of platelet 
function. However, it has previously been shown that elements of Ca2+ in platelets 
are unaffected by supraphysiological concentrations of PGI2 (Fung et al., 2012). 
Recently, clear differences in agonist-dependent platelet sensitivity have been shown 
in the presence of gradient doses of PGI2 (Macwan et al., 2019). Indeed, in the cited 
study CD62P expression showed far greater resistance to PGI2-mediated inhibition 
than fibrinogen-mediated aggregation in paired samples that were stimulated with 
only CRP-XL (Macwan et al., 2019), a finding that we are able to support and expand 
on using single cell analysis. In the context of our current study, CD62P resistance is 
not related to a difference in overall cAMP signalling in platelets as pVASP-s157 
phosphorylation was elevated to the same degree in all subsets. Thus, our data, and 
that of others, suggests that a more nuanced mechanism must explain the inhibition 
of platelets by cAMP.  
One caveat of non-imaging flow cytometry is that it cannot reveal the localisation of 
signalling molecules (Cossarizza et al., 2017). In many cells, cAMP modulates 
distinct aspects of cell function through the selective coupling of its signalling 
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complexes to specific substrates or regions within the cell (Raslan et al., 2015). 
However, much of the data regarding the role of cAMP in platelet function, including 
CD62P expression (Libersan et al., 2003), has been gained from in vitro studies using 
mimetics that act as global cAMP modulators or bypass AC, as well as 
pharmacological inhibitors that have off-target effects (Yan et al., 2009, Libersan et 
al., 2003). Previously there has been evidence of compartmentalisation of cAMP 
signalling (Raslan and Naseem, 2015, Raslan et al., 2015), with individual PKA 
isoforms targeting distinct components of activatory machinery and elements of Ca2+ 
signalling demonstrating resistance to PGI2. Therefore, it is possible that cAMP 
signalling preferentially targets signalling mediators which lead to PS exposure and 
integrin activation, while secretory mechanisms are only partially inhibited in highly 
activated platelets. Thus, platelets could retain their immunomodulatory properties 
and continue to regulate vascular inflammation, or wound healing, despite the 
elevations in cAMP they experience during routine circulation, but this concept 
requires further study and we have only been able to hint at its existence. 
Our data provides a novel glimpse into the complex regulation of platelets that occurs 
within the vasculature, where despite the constant barrage of inhibitory endothelial 
PGI2 and nitric oxide (Mitchell et al., 2008), platelets can become activated and form 
thrombi. Our model may initially suggest that PGI2 is able to fully block haemostasis, 
but several points must be considered. Firstly, haemostasis will often occur outside 
the direct effect of endothelial-derived PGI2 (Cho and Allen, 1978). Furthermore, in 
vivo, the core and shell model of thrombus formation would promote platelet 
activation at the core, where PGI2 is excluded leading to a reduction in cAMP 
signalling (Stalker et al., 2013). Additionally, a recent model of platelet adhesion 
resolved with microfluidic studies proposed that thrombus formation was initiated by 
the GP1b(CD42)-IX-V complex binding to vWF in conjunction with CD62P interacting 
with endothelial PSGL1 prior to subsequent arrest and activation via integrin outside-
in signalling, GPVI and thromboxane synthesis (Coenen et al., 2017). This suggests 
- 146 - 
that the CD42 complex and CD62P may be enough to initiate haemostasis and 
promote tethering, a model which supports our findings of expression of CD42 and 
resistant CD62P in the presence of vascular inhibition. 
The observation that granule secretion is resistant to PGI2 may have importance in 
the context of cardiovascular disease. Platelet hyperactivity in several cardiovascular 
diseases manifests as increased circulating levels of platelet-monocyte complexes, 
sCD62P, sCD154 (Wang et al., 2007) and PF4 (Gresele et al., 2011), all of which are 
granule-dependent processes. However, it has been difficult to explain the 
observations in patients, since short-lived haemostatic agonists are unlikely to mimic 
sustained levels of activation in platelets that circulate in patients with cardiovascular 
diseases. Where perhaps what is happening, is that short-lived haemostatic agonists 
are inducing granule secretion with the majority of thrombotic activity suppressed by 
tonic inhibition. Furthermore, many platelet studies do not look at activation in 
physiological conditions, where platelets are continually bathed in PGI2 and NO. Our 
data might suggest that PS and integrin αIIbβ3 are maintained at near basal levels 
by exposure to PGI2 after transient platelet activation, but CD62P remains elevated 
where it can then mediate heterotypic cellular interactions that are important for 
vascular inflammation, and degranulation permits the release of soluble ligands such 
as sCD62P or sCD154, and the secretion of growth factors that contribute to the 
resolution of injury. It may be important to determine if the level of CD62P resistance 
or indeed the ratio of PShi/FBlo and PShi/FBhi subsets change in disease cohorts, as 
this might prove to be a valuable clinical biomarker of platelet hyperactivity. Such an 
approach may be particularly pertinent since many states of cardiovascular disease 
are associated with hyposensitivity to PGI2 (Magwenzi et al., 2015, Knebel et al., 
2015, Hishinuma et al., 2001). 
In summary, we have identified and characterised novel platelet subsets, which 
reveal themselves only in the presence of both activatory and inhibitory agonists. 
Stimulatory conditions lead to the generation of PSlo/FBhi, PShi/FBlo and PShi/FBhi 
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subsets. After PGI2 treatment, however, these subsets are replaced primarily by 
platelets expressing CD62P, which we demonstrate allows the continued interaction 
of platelets with monocytes. 
 
 3.8.3 Reversible platelet activation 
The previous work focussed on examining platelet activation post-inhibitory 
stimulation, which drives a potent remodelling of the activated platelet phenotype. 
However, what is less well understood is the effect of inhibition post-activation. 
Although this has previously been explored in static systems, as opposed to systems 
in suspension, there is evidence of a phenotype which is predominantly remodelling 
of the actin cytoskeleton by endothelial inhibitors after activation (Atkinson et al., 
2018, Yusuf et al., 2017). Therefore, we sought to replicate this finding in our models. 
The physiological relevance of this question can be justified, as, within the 
vasculature, there will be regions of the vascular system, likely capillary beds, that 
have reduced endothelial surface area and are at much lower shear and therefore 
produce less inhibitory PGI2 and NO. Platelets will circulate through these capillary 
beds and return to the venous and finally arterial vasculature where they will then 
again be exposed to greater levels of PGI2 and NO, suggesting platelets may have 
to respond to fluctuations in inhibitory signalling in the circulation. Therefore, we 
hypothesise that within the healthy controls tested here, platelets will have the 
capacity to reduce expression of activation markers. We applied four-parameter 
whole blood fluorescent flow cytometry to this question. 
We adapted our previously used four-colour assay to measure fibrinogen binding, 
CD62P, CD63 and CD42b expression and stimulated platelets for 20 minutes prior 
to 2 minutes treatment with PGI2, followed by fixation. Under these conditions, we 
found a marked reduction in expression of all markers when compared to mock 
treated. Critically, we found no recovery of CD42b expression, which was already 
- 148 - 
shed and could not be returned to the surface (Bodnar et al., 2002). The reduction in 
marker expression was most significant with transient expression at lower doses of 
SFLLRN. While CD42b did not change with post-inhibition, fibrinogen binding 
demonstrated the largest post-activation inhibition mediated reduction, suggesting 
that integrin αIIbβ3 may be able to be turned back off, although this experiment 
requires further repeats and validation by PAC1, to confirm this observation. It would 
also be valuable to examine both the cAMP response after 20 minutes of stimulation 
and the calcium flux, both can also be performed by fluorescent flow cytometry. The 
granule markers CD62P and CD63 demonstrate small decreases with post-activation 
inhibition, whether this is recycling or shedding we cannot currently comment, 
although fractionation experiments could be used to determine if membrane bound 
receptors return to the cytoplasm, or fluorescence live cell microscopy could be used 
to track the movement of these receptors when stimulated with an inhibitor. 
In addition to this, a further observation was made from the pVASP-s157, CD62P 
and CD42b assay we performed as part of the previous study. Here we were able to 
demonstrate that basal CD62P expression was consistently inhibited and returned to 
background by the addition of PGI2. While not designed to examine this question 
initially, it was a model of addition of PGI2 post (basal) stimulation, of note this was a 
reversion from very weak stimulation where CD62P positive cells was <20%. This 
may well further support the hypothesis that platelets are able to not only be 
prevented from activation by pre-exposure to PGI2, but also have some capacity to 
be “switched off” with post-activation exposure to PGI2, the pVASP-s157 experiments 
would be a valuable addition to measuring cAMP-PKA activity in cells treated with 
PGI2 post stimulation. Although only a small exploration of this hypothesis, it suggests 
that there is some flexibility within platelets to reverse or diminish their activatory state 
post-stimulation. This provides a novel insight into how thrombi may be resolved once 
haemostasis has occurred, where weakly or transiently activated platelets at the 
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margin of the thrombus (Stalker et al., 2013) may return to circulation, or how 
platelets in the vasculature may respond to fluctuations in tonic inhibition. 
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Chapter 4 
NLRP3 inflammasome activation and expression 
4.1 INTRODUCTION 
The inflammasomes are a broad group of large multimeric protein complexes with 
enzymatic activity which are related in their ability to drive an inflammatory response 
(Schroder and Tschopp, 2010). NLRP3 is a relatively unique inflammasome as it 
appears to play a role in many diseases, notably in several sterile inflammatory 
diseases including gout (Martinon et al., 2006), systemic lupus erythematosus (SLE) 
(Kahlenberg et al., 2013), cardiovascular disease (Yang et al., 2017b) and 
rheumatoid arthritis (Mathews et al., 2014). NLRP3 has been shown in vitro to 
respond to many agonists including the bacterial toxin nigericin, bacterial membrane 
component LPS, cellular stress signal ATP, gout derived monosodium urate crystals, 
atherosclerotic plaque cholesterol crystals, oxLDL and amyloid-β protein (Sheedy et 
al., 2013, Agostini et al., 2004). NLRP3 is suggested to respond to the wide variety 
of ligands as they are assumed to share common signalling node, where they 
converge on a regulator of activity, which is proposed to be mitochondrial ROS 
production (Zhou et al., 2011). While there is literature demonstrating other cells 
types respond to oxLDL and this drives NLRP3 activity, and that platelets respond to 
oxLDL which drives other pathways and that platelet NLRP3 can be activated by 
other agonists, there has been no exploration yet surrounding oxLDL and NLRP3 
platelet activity. Here we attempt to characterise the platelet NLRP3 inflammasome 
and explore if oxLDL can drive inflammatory platelet activity mediated by this 
complex. 
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4.2 AIMS OF CHAPTER 
- To measure platelet caspase-1 cleavage through the FLICA dye and 
fluorescent flow cytometry 
- To assess expression of NLRP3 inflammasome components by biochemical 
analysis 
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4.3 FLUORESCENT MEASUREMENT OF CASPASE-1 ACTIVITY 
Caspase-1 cleavage and subsequent activity can be used as a direct measure of 
NLRP3 inflammasome activity. This can be measured by immunoblotting for cleaved 
caspase-1 (P20/P10 subunits) (Lin et al., 2015) or by proprietary methods which rely 
on the specificity of caspases to unique amino acid sequences. Caspase-1 primarily 
targets, and has a high specificity for, the amino acid YVAD motif (Garcia-Calvo et 
al., 1998).  
The assay employed here uses a cell permeable construct of the YVAD motif 
sandwiched between a fluorophore, FAM or a far-red 660nm dye and a FMK which 
forms a covalent bond with the enzyme once within close enough proximity (Bedner 
et al., 2000). This assay has been termed as fluorochrome-labelled inhibitors of 
caspases (FLICA) and for caspase-1 are based on the fluorophore-YVAD-FMK 
design. Therefore, FLICA assays allow specific activated caspases to be targeted, 
bound to covalently, and tagged with a fluorescent probe. 
Here, the FLICA assay was set up to detect caspase-1 cleavage in human and 
murine washed platelets to assess their NLRP3 inflammasome activity in a high 
throughput and quantitative manner. 
 
4.3.1 Calcium is required for detection of caspase-1 cleavage 
This assay was established using washed platelets to allow activation of platelets in 
an otherwise cell and plasma free system, as initial attempts in whole blood appeared 
to be not compatible with the FLICA dye (data not shown). Experiments using washed 
platelets are normally performed in modified Tyrode’s buffer, which does not contain 
calcium. We first examined whether the inclusion of extracellular calcium was 
required to detect caspase-1 cleavage. At the time, this was based on the single 
previous report of detection of caspase-1 cleavage by FLICA in platelets in a 
complete media, M199, which included extracellular calcium (Hottz et al., 2013). 
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Calcium was also assumed to be required for NLRP3 activation due to previous 
biochemical studies that determined that the influx of calcium from extracellular pools 
was vital for NLRP3 inflammasome activity and therefore caspase-1 cleavage 
(Murakami et al., 2012). 
In a single experiment, we were able to reproduce these previous findings and 
demonstrate a significant increase in fluorescent signal. Washed platelets were 
incubated with nigericin (20 µM) in the presence or absence of extracellular calcium 
(2 mM). In the absence of extracellular calcium nigericin failed to increase FLICA 
signal above basal (Figure 45). In contrast the presence of Ca2+ led to a significant 
increase in signal (p=<0.005). As a result, all subsequent assays were performed 
with the inclusion of calcium (2 mM). 
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Figure 45. FLICA in human washed platelets +/- calcium. Human washed 
platelets (2x106/well) in the presence and absence of CaCl2 (2 mM) treated with 
or without nigericin (20 µM) for 30 minutes then incubated with 1x FLICA-green 
for 60 minutes followed by fixing, washing and acquisition. (One-way ANOVA 
vs. relative basal, ***<0.005, error shown as standard deviation, n=3) 
  
- 155 - 
4.3.2 FLICA titrations and optimal conditions 
As the basis for this assay is a cell-permeant fluorescent dye, we performed titrations 
to determine optimal dose and incubation time. Each dilution and time point were 
compared with a basal sample at a matched concentration and time, this comparison 
allows a comment on the sensitivity of each assay condition as oppose to asking 
simply which dye condition is brightest, which often leads to excessive background 
binding and therefore anomalously high basal signal. Calculating fold over control 
allows the condition with the highest fold increase, and therefore optimal window for 
detection of changes, to be selected. 
Data are presented as fold increase over relative basal (same 
concentration/timepoint) to account for the additional background signal that more 
dye will induce. All 60-minute timepoints induced only a 2-fold increase, while at 40 
minutes the increases ranged from 2 to 4-fold. 40 minutes incubation with 1x dye 
presented a fold increase of 4 over relative control (Figure 46). Therefore, we 
determined that 1x dye, or 5 µM, incubated for 40 minutes post stimulation then 
followed by fixation provided the optimal window for signal to be measured. 
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Figure 46. FLICA in human washed platelets at a range of dye doses and 
incubation times. Human washed platelets (2x106/well) + 2 mM CaCl2 treated 
with or without nigericin 5 µM for 15 minutes then incubated with designated 
dose of FLICA-green for designated time followed by fix, wash and acquisition. 
(error shown as standard deviation, n=2-5) 
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Beyond optimal dye dose and incubation time, we also optimised the conditions for 
appropriate fixation and washing of the samples. Fixation can both improve 
adherence and stability of a probe or conversely mask epitopes and diminish signal. 
Washing samples should generally improve signal: noise ratio, however in the case 
of weakly bound probes positive signal may also be lost. Therefore, we confirmed 
optimal conditions for this assay. 
First, we compared three different fixation conditions; fixed and washed, unfixed and 
washed, unfixed then washed and fixed. In each instance we compared basal with a 
dose response of nigericin (2, 5 and 10 µM) and there was a dose dependent 
increase in signal in all conditions. Comparing the three conditions at maximal 
treatment (nigericin 10 µM) the MFI values were 6364.8, 4771.5 and 4133.6 for 
fixed/washed, unfixed/washed and unfixed/washed/fixed respectively. There was a 
reduced basal signal when washing pre-fix 824.8 but not post-fix 1237.7, suggesting 
that early fixation does drive some increase in background signal, however the 
increased retention of positive signal outweighed this caveat. From this we 
determined that fixation prior to washing provided the largest signal (Figure 47). 
Fixing of the samples has the additional advantage of providing a distinct halt point 
in time course experiments. 
Secondly, we compared fixed and washed platelets with unwashed platelets. Here 
we demonstrated that washing after fixation significantly reduced excess binding of 
the dye and increases resolution and sensitivity of the assay. After washing the 
increase in MFI from basal to nigericin treatment (10 µM), there was a 2.6-fold 
increase, compared to 1.6-fold increase without washing (Figure 47). Therefore, we 
determined that fixed and then washed cells are optimal for signal resolution and 
sensitivity in the FLICA assay when measured by flow cytometry. 
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Figure 47. FLICA fixed versus unfixed and washed versus unwashed. Human 
washed platelets (2 x 106/well) + 2 mM CaCl2 treated with or without nigericin 
(2 – 10 µM) for 20 minutes followed by 1x FLICA-green for 40 minutes followed 
by varied combinations of fixation and washing protocols followed by 
acquisition. (n=1) 
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4.3.3 Nigericin dose response 
Nigericin is a potassium ionophore (Perregaux and Gabel, 1994, Estradao et al., 
1967), and is a known canonical activator of the NLRP3 inflammasome (Tang et al., 
2017). It was used as a positive control ligand in all FLICA experiments. To validate 
assay sensitivity and determine the optimal concentrations of nigericin a dose 
response experiment was performed using concentrations surrounding those 
commonly cited in the literature (Liu et al., 2017). 
Incubation of platelets with nigericin (2, 5 and 10 µM) led to a concentration 
dependent increase in FLICA signal. While there was a response at all doses of 
nigericin, it was significantly different to basal (987.4±61) at 5 µM (3531.2±1495, 
p<0.01) and 10 µM (4445.5±1972, p<0.005), but not at 2 µM (2396±1137) (Figure 
48). This data further demonstrated the natural variation within the assay, assumed 
to be due to variation across a normal cohort of healthy donors, mixed in age, gender, 
ethnicity, BMI and other lifestyle factors. This variation suggests that within a normal 
population, platelets are primed for NLRP3 inflammasome activity at varying states 
and therefore demonstrates a wide variety of responses. Nevertheless, it is important 
to note that while all donors and treatments do demonstrate an increase over basal, 
it is solely the size of increase which is variable. 
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Figure 48. FLICA in human washed platelets, nigericin dose response. Human 
washed platelets (2 x 106/well) + 2 mM CaCl2 treated with or without nigericin 
(2 – 10 µM) for 20 minutes followed by 1x FLICA-green for 40 minutes followed 
by fix, wash, wash and acquisition. (One-way ANOVA vs. basal, **<0.01 and 
***<0.005, error shown as standard deviation, n=7) 
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4.3.4 OxLDL and caspase-1 cleavage 
Typically, NLRP3 inflammasome activity is considered in the context of various 
diseases, both sterile and unsterile, with priming and activation driven by DAMPs and 
PAMPs dependent on the disease in question. We have previously published that 
platelets respond to oxLDL, a DAMP which is known to be significantly upregulated 
in cardiovascular disease (Berger et al., 2019a, Berger et al., 2019b, Magwenzi et 
al., 2015, Wraith et al., 2013). Furthermore, oxLDL has been shown to drive NLRP3 
inflammasome activity in other cells types including macrophages (Liu et al., 2014). 
Hence the aims of this section were to examine if oxLDL could drive caspase-1 
cleavage alone or potentiate caspase-1 cleavage following stimulation with nigericin 
at a low dose (2 µM), since we previously showed a low dose induces a consistent 
but small increase over basal which provides a suitable window to observe 
potentiation of signal (Figure 48). 
Basal caspase-1 cleavage was demonstrated to be low (968.0±63), and in response 
to nigericin (2 µM) there was a small but statistically non-significant increase in signal 
(2566.4±1346). Incubation of platelets with oxLDL and nLDL did not cause a 
significant increase in FLICA response above basal (724.9±31 and 845.4±32 
respectively). However, pre-treatment of platelets with oxLDL (50 µg/mL) for 10 
minutes, but not nLDL, significantly potentiated nigericin (2 µM) induced caspase-1 
cleavage from 8116.9±7092 vs. 1399.9±364 (p<0.01) (Figure 49). Interestingly we 
found that only 3 of 5 platelet donors were sensitive to the effects of oxLDL. 
Given the variability of the response, we repeated these experiments with different 
batches of ox/nLDL, but also employed a distinct FLICA-red dye. Here we were able 
to demonstrate findings consistent with those previously observed, nigericin (2 µM) 
induced a significant increase in MFI over basal (12,588.8±1513 and 3133.0±1309 
respectively, p<0.001), while oxLDL significantly potentiated the response induced 
by nigericin (2 µM) (31,941.1±5139, p<0.0001). Vitally nLDL (12,194.2±3048) was no 
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different to nigericin (2 µM) (12,588.8±1513). We included an additional condition of 
maximal dose nigericin (10 µM) and found the level of caspase-1 cleavage induced 
by this strong stimulus was substantially exceeded by nigericin (2 µM) when pre-
treated with oxLDL (50 µg/mL) (18,910.7±4606 and 31,941.1±5139 respectively) 
(Figure 49). Here we again demonstrate a significant potentiation of caspase-1 
cleavage induced by oxLDL treatment, confirming our prior observations with 
different donors, LDL preparations and dye conjugate. 
This data also suggests that FLICA-red is potentially more sensitive than FLICA-
green, although the same trends were observed in both assays. The significant 
difference between basal and nigericin (2 µM) observed in FLICA-red but not green 
is indicative of this improvement in assay sensitivity. 
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Figure 49. LDL treatment of human washed platelets. Human washed platelets 
(2 x 106/well) + 2 mM CaCl2 treated with or without ox/nLDL (50 µg/mL) for 10 
minutes, then incubated with or without nigericin (2 µM) for 20 minutes followed 
by 1x FLICA-green (upper) or 1x FLICA-red (lower) for 40 minutes followed by 
fix, wash, wash and acquisition. (One-way ANOVA vs. basal, ns=non-
significant, **<0.01, ****<0.0001, error shown as standard deviation; Green 
n=5; Red n=3 with LDL conditions in 2 duplicates with different LDL 
preparations) 
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4.3.5 oxLDL potentiation, CD36 inhibitors and ROS scavenger screen 
Following on from our previous key observation that oxLDL primes the NLRP3 
inflammasome for activation in washed platelets, we sought to understand the 
pathway through which this process may occur. Here we applied several inhibitors 
and scavengers/chelators to investigate this pathway. We primarily targeted ROS, 
which oxLDL is known to induce in platelets (Berger et al., 2019b), calcium which our 
previous observations suggested was vital and then the primary platelet oxLDL 
receptor CD36 and downstream signalling apparatus (Wraith et al., 2013). N-acetyl-
cysteine (NAC) was used as a ROS scavenger, BAPTA-AM as an intracellular 
calcium chelator, EDTA as an extracellular calcium chelator, FA6-152 as a CD36 
blocking antibody with control IgG, BAY61 to block Syk, PP2 to block Src family 
kinases, PP3 as an analogue control and a DMSO vehicle control. 
Treatment with nigericin (2 µM) increased FLICA MFI to 3568.4±1290 which was 
potentiated by oxLDL to 29,287.4±4980, this was again a large increase over 
nigericin alone or nigericin pre-treated with nLDL. We were then able to demonstrate 
that NLRP3 inflammasome activation and potentially oxLDL priming were ablated 
completely by the addition of the ROS scavenger NAC, as was the nigericin and nLDL 
control. In the oxLDL experiments, FLICA MFI was reduced from 29,287.4±4980 to 
1060.75±313 (p<0.0001) by the presence of the antioxidant NAC (Figure 50). We 
again reiterated our previous observation of the requirement of calcium for caspase-
1 cleavage in platelets with the chelators BAPTA-AM (intracellular) and EDTA 
(extracellular), these reduced FLICA MFI from 29,287.4±4980 (oxLDL/nigericin) to 
2372.7 and 2474.8 respectively. Finally, blockade of CD36, Src family kinases or Syk 
had no effect (Figure 50). This suggests that other receptors may be involved. While 
we were unable to explore these here, there is literature evidence that oxLDL can 
drive NLRP3 through CD36/TLR4/6 complexes in other cells, and evidence that 
oxLDL can ligate CD36/TLR2/TLR6 on platelets driving hyperactivity (Stewart et al., 
2010, Biswas et al., 2017).  
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Figure 50. FLICA-red in human washed platelets +/- LDL, scavengers, chelators 
and CD36 signalling inhibitors. Human washed platelets (2 x 106/well) + 2 
mM CaCl2 treated with or without designated inhibitors (NAC 5 mM, BAPTA 20 
µM, EDTA 10 mM, Fa6/IgG 5 µg/mL, BAY61 5 µM, PP2/PP3 20 µM, DMSO 
0.1% (v/v)) for 20 minutes, then incubated with or without ox/nLDL (50 µg/mL) 
for 10 minutes then nigericin (2 – 10 µM) for 20 minutes followed by 1x FLICA-
red for 40 minutes followed by fix, wash, wash and acquisition. (One-way 
ANOVA vs. inhibited sample, *<0.05 and ****<0.0001, error shown as standard 
deviation, n=1(CD36 signalosome), 3(all other measurements)) 
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4.3.6 NLRP3 inhibition by MCC950 
While previous results have highlighted a novel role for oxLDL in the potentiation of 
NLRP3 inflammasome activity measured by caspase-1 cleavage, the FLICA assay 
has lacked a negative control peptide or a control to specifically target and block 
NLRP3. To measure this we sought to apply the highly specific compound inhibitor 
of NLRP3, MCC950 (Coll et al., 2015). This inhibitor has been widely applied both in 
vitro and in vivo (Coll et al., 2019, van der Heijden et al., 2017) and has also been 
used in platelets to some effect (Vogel et al., 2018a). We stimulated washed platelets 
with a mid-range dose of nigericin (5 µM) and compared this against a range of doses 
of MCC950 pre-treated samples (Figure 51). On stimulation with nigericin (5 µM) MFI 
increased to 1281±1562 from 168.8±51 at basal, although there was large error in 
these experiments primarily to a very strong responder. When treated with maximal 
dose of MCC950 (10 µM) MFI remained comparable to nigericin alone at 603±412 
due to the error (Figure 51). We were not able to demonstrate any significant 
differences in treated samples, however the variability in the nigericin alone treated 
samples results in it not being significantly different to the basal condition (which 
mimics 100% inhibited) either, a lower dose of nigericin was used here to prevent 
there being excessive activation preventing the inhibitor functioning, however 
repetition with a higher dose of nigericin may provide a larger window of observation. 
In order to pursue that possibility, this was later repeated on oxLDL potentiated 
samples where the window for inhibition considerably exceeds any nigericin alone 
treatments (Figure 55, Figure 56). Nevertheless, there are not any significant trends 
of inhibition emerging, while the literature suggests this inhibitor has a high efficacy 
(Coll et al., 2015). 
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Figure 51. FLICA-green in human washed platelets +/- MCC950. Human washed 
platelets (2 x 106/well) + 2 mM CaCl2 treated with or without MCC950 (1 nM – 
10 µM) for 30 minutes, then incubated with nigericin (5 µM) for 20 minutes 
followed by 1x FLICA-green for 40 minutes followed by fix, wash, wash and 
acquisition. (One-way ANOVA vs. basal, ns=non-significant, error shown as 
standard deviation, n=1-5) 
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4.3.7 Correlation of FLICA signal with CD62P 
To further understand mechanist elements of what may be occurring within the 
platelets concurrent to caspase-1 cleavage, we developed an assay to 
simultaneously measure both FLICA-green and a marker of α-granule secretion 
(CD62P-PE) against a dose response of nigericin (1 – 10 µM) and a low/high dose 
of the thrombin mimetic and PAR1 peptide agonist SFLLRN (1 and 10 µM). These 
two agonists act as positive controls for each marker respectively and allow a 
comparison of how each marker responds to a specific agonist targeted against the 
other pathway. 
Incubation of platelets with nigericin (0 – 10 µM) led to a concentration dependent 
increase in caspase-1 cleavage. However, this was associated with increased 
expression of CD62P on the platelet surface, suggesting the platelets are activated 
and have undergone degranulation (Figure 52). Although this cannot be the exclusive 
conclusion, as loss of membrane stability would allow antibody entry into the platelet, 
similar to a detergent permeabilisation step, and therefore intracellular staining of 
pools of CD62P would be detected. While the expression of CD62P at maximal dose 
of nigericin (10 µM) (28,043) was similar only to low dose SFLLRN (1 µM) (32,094.7), 
it was increased over basal (784.4). Furthermore, SFLLRN (10 µM) (4216.3) was 
shown to induce caspase-1 cleavage to a similar level compared to low dose nigericin 
(2 µM) (3922.1) over basal (1329.4) (Figure 52).  
We also explored if nigericin is able to induce platelet aggregation by LTA, as the 
prior indication was that it did possibly drive platelet activation. However, nigericin did 
not induce aggregation up to 15 minutes, only a linear decrease in turbidity, 
potentially agglomeration or platelet death (Figure 53). Notably there was no shape 
change or aggregates in the nigericin treated cuvette (19%) and tirofiban an inhibitor 
of the integrin αIIbβ3, did not attenuate the effect of nigericin (22%) suggesting it is 
not typical platelet aggregation and is independent of any fibrinogen: integrin 
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interactions. In support of this inducing platelet death, samples treated with nigericin 
analysed by flow cytometry also consistently demonstrated a reduced concentration 
of cells when compared with basal despite all tubes being initially loaded with 2 x 106 
platelets (data not shown). 
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Figure 52. Correlation of FLICA-green binding with platelet activation. Human 
washed platelets (2 x 106/well) + 2 mM CaCl2 incubated with nigericin (1 – 10 
µM) or SFLLRN (1 or 10 µM) for 20 minutes followed by co-staining with 1x 
FLICA-green and CD62P-PE for 40 minutes followed by fix, wash, wash and 
acquisition. (n=2) 
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Figure 53. Nigericin induces linear clearance of platelet solution that is 
aggregation independent. Human washed platelets (2.5x108/mL) were 
stimulated with 0.1U/mL or 10 µM nigericin +/- 1 µg/mL tirofiban and trace was 
observed for aggregation for up to 15 minutes by light transmission 
aggregometry. (Thrombin alone and nigericin alone are representative of n=3) 
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4.3.8 Transgenic murine caspase cleavage 
Our previous observations suggested a wide variation across healthy human donors 
with respect to caspase-1 activation. Having also demonstrated that oxLDL can 
potentiate this response, we sought to assess if basal activity changed with 
cardiovascular disease, where oxLDL has been shown to be increased (Ramos-
Arellano et al., 2014). To do this we translated the FLICA assay into a murine model 
to allow further exploration with genetically modified or diet induced models of 
obesity. We first repeated our previous experiment, to demonstrate extracellular 
calcium was required for the FLICA assay to detect caspase-1 cleavage in murine 
samples. Calcium was reconstituted to 2.5 mM, to mirror the calcium concentrations 
found within murine blood (Otto et al., 2016). This basic question was first explored 
as it fulfils two early questions, namely; does the assay translate to murine models, 
and is the mechanism conserved with human platelets, i.e., calcium dependent. Here 
we were able to reiterate our previous findings from humans in a murine model and 
confirm that calcium is a requirement for murine platelet caspase-1 cleavage (Figure 
54). 
Due to the variation in response to nigericin we saw across the normal human 
population, we hypothesised this could be a phenotype driven by lifestyle and 
environmental changes which may be commonly observed within a normal cohort of 
individuals. To explore this question, we tested this theory in wild type C57/Bl6 and 
ApoE-/- murine platelets. ApoE-/- models are known to progress to early 
atherosclerosis and demonstrate a strong phenotype of vascular inflammation on 
chow diet (Getz and Reardon, 2006). Wild type (WT) mice alone showed an increase 
over basal (318.3) when treated with nigericin (5 µM) (1344.8) but not with ATP (5 
mM) (229.7). Basal caspase-1 cleavage was not different between the two groups 
and unexpectedly when stimulated with a mid-dose of nigericin (5 µM) the C57/Bl6 
platelets demonstrated a greater caspase-1 cleavage than the platelets from the 
ApoE-/- animals (1344.8 compared to 944.2). We also stimulated with ATP, which is 
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another canonical stimulator of NLRP3 activity, and this showed no increase in MFI 
above basal at a maximal dose (Figure 54). Therefore, assuming parallels between 
murine models of atherosclerosis and human cardiovascular disease, this is not 
regulating NLRP3 activity of platelets in these models and suggests that factors 
beyond hyperlipidaemia must be inducing the natural variation. 
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Figure 54. FLICA in murine washed platelets +/- calcium. (Upper) Murine washed 
platelets (2x106/well) +/- 2.5 mM CaCl2 treated with or without nigericin 10 µM 
for 15 minutes then incubated with 1x FLICA-green for 60 minutes followed by 
fix, wash and acquisition (n=1). (Lower) As prior but cells were treated with or 
without nigericin 5 µM or ATP 5 mM for 15 minutes. (n=2) 
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4.3.9 Specificity and validation of the FLICA assay 
Although we had made several novel and extremely reproducible observations 
including; (i) oxLDL is able to significantly potentiate caspase-1 cleavage, (ii) the 
requirement for ROS and (iii) requirement for extracellular calcium for caspase-1 
cleavage in platelets, a key inhibitor of NLRP3, MCC950 (Coll et al., 2015), was 
unable to this block signal. This led to several concerns of the specificity of the FLICA 
dye, as without a negative control the signal could not be confirmed as a true marker 
of caspase-1 cleavage. This was further supported by literature that has previously 
demonstrated that FLICA will bind with a low specificity to apoptotic cells and cannot 
be outcompeted by unlabelled peptide controls, although these studies were not 
performed in platelets (Pozarowski et al., 2003, Darzynkiewicz and Pozarowski, 
2007). A series of experiments were performed to explore the specificity of the dye 
and events which occur concurrently to FLICA dye binding in platelets. 
Using mirrored conditions across four assays we explored other events occurring 
simultaneously to caspase-1 cleavage. The assays applied included; (i) mitoSOX to 
detect mitochondrial superoxide, (ii) Annexin V binding to detect apoptosis or 
coagulant platelet formation, (iii) TMRE to measure mitochondrial polarisation and 
formation of mitochondrial pores, and (iv) FLICA-red. MitoSOX at basal gave an MFI 
of 486 and when treated with nigericin (2 µM) alone or with oxLDL (50 µg/mL) this 
increased to 1962.6 and 1534.3 respectively. The positive control of antimycin A (100 
µM) (1188.9) surprisingly produced less mitochondrial superoxide than nigericin 
alone. Annexin V binding at basal was low (1011) and when treated with nigericin (2 
µM) alone or with oxLDL (50 µg/mL) this increased to 4680.1 and 4161.1 
respectively, the positive control of SFLLRN/CRP-XL (20 µM/10 µg/mL) was 
comparable at 4014.2. TMRE binding at basal was bright (1859.1) suggesting 
normally polarised mitochondria, when treated with nigericin (2 µM) alone or with 
oxLDL (50 µg/mL) this decreased to 357.7 and 407.7 respectively. FLICA bound as 
previously demonstrated, with low basal, a mild increase with low dose nigericin (2 
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µM) and significant potentiation with oxLDL (50 µg/mL) from 10,335.3 to 35,278.9 
respectively. The inhibitor MCC950 (1000 nM) did not drive a large reduction in the 
signal when cleavage was induced with nigericin and oxLDL together (31,787.3) 
(Figure 55). Through comparisons across each assay, we were able to determine 
that concurrent to caspase-1 cleavage detected by the FLICA-red assay, 
mitochondrial superoxide is significantly increased, PS is exposed on the outer leaflet 
of the phospholipid membrane and the mitochondria are depolarised (Figure 55). 
These are many hallmarks of apoptotic cells and suggests that the FLICA-red assay 
may be binding non-specifically to apoptotic platelets – potentiated by oxLDL and 
driven by nigericin. 
To further understand if the binding of FLICA-red mirrored PS exposure we tested 
these two parameters with a series of inhibitors; basal, nigericin alone, nigericin pre-
treated with MCC950, glyburide (Lamkanfi et al., 2009), mitoTEMPO, NAC, EDTA or 
vehicle control. As expected nigericin (2 µM) increased FLICA-red binding (2402.0 to 
5899.5), and consistent with previous data was blocked by the ROS scavenger NAC 
(2291.4), and calcium chelator EDTA (2791.9) (Figure 56). In contrast, NLRP3 
inhibitors MCC950, the ATP channel inhibitor glyburide and the mitochondrial 
superoxide scavenger mitoTEMPO were without effect and all showed comparable 
values to nigericin alone (5795.5, 9772.0 and 7102.5 respectively). Importantly, these 
effects were almost identical to PS exposure measured by annexin V binding, where 
nigericin (2 µM) induced a significant increase in surface PS over basal (1432.9 to 
14,698.1) and only NAC and EDTA reduced signal (2369.0 and 255.8 respectively) 
(Figure 56). In conjunction, this may suggest that this treatment is killing the platelets, 
but in a calcium and ROS dependent manner, which suggests mitochondria may be 
the common node here. Finally, the specificity of the FLICA-dye was validated with 
z-YVAD-FMK, an identical peptide to FLICA’s FAM-YVAD-FMK, but without a 
fluorophore conjugate (Pozarowski et al., 2003). Using concentrations ranging from 
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50x less to 200-fold excess no demonstrable competitive inhibition of FLICA-green’s 
binding to nigericin stimulated platelets across two donors (Figure 57).  
Taken together, we used two different dyes and a range of inhibitors that have been 
shown to modulate the activity of the NLRP3 inflammasome and were unable to see 
any change in response. While the numbers of experiments are not high, the data 
suggested that the signal measured by FLICA may indeed be non-specific to 
apoptotic cells and so further experiments in this system were not pursued.  
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Figure 55. Specificity of the FLICA reagent to caspase-1 cleavage, marker 
screen. Four assays in washed human platelets were performed under 
identical conditions on the same donor to understand what events may occur 
simultaneous to FLICA dye binding. mitoSOX was used to detect mitochondrial 
superoxide, Annexin V to detect phosphatidylserine exposure, TMRE to detect 
mitochondrial membrane potential and FLICA-green to detect caspase-1 
cleavage. All assays used human washed platelets (2 x 106/well) + 2 mM CaCl2. 
All dyes were used as described. oxLDL was pre-incubated for 10 minutes prior 
to nigericin addition for a total time course of 60 minutes prior to sample 
acquisition or fixation (n=1) 
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Figure 56. Specificity of the FLICA reagent to caspase-1 cleavage, inhibitor 
screen. Two assays were performed under identical conditions on the same 
donor to understand the relationship between phosphatidylserine exposure and 
FLICA binding. All assays used human washed platelets (2 x 106/well) + 2 mM 
CaCl2. All dyes were used as described, FLICA-red was used, and inhibitors 
were incubated for 30 minutes prior to addition of nigericin (2 µM) for a total 
time of 60 minutes. (n=1) 
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Figure 57. Inability to outcompete FLICA dye binding by unlabelled z-YVAD-
FMK peptide. Human washed platelets (2 x 106/well) + 2 mM CaCl2 treated 
with or without z-YVAD-FMK (100 nM – 100 µM) for 30 minutes, then incubated 
with nigericin (10 µM) for 20 minutes followed by 1x FLICA-green for 40 minutes 
followed by fix, wash, wash and acquisition. (n=2, plotted as individual data 
sets) 
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4.4 PROTEIN EXPRESSION, IMMUNOBLOTS AND IMMUNOPRECIPTATIONS 
In order to perform cross validation of FLICA data, immunoblotting experiments were 
performed for components of the NLRP3 inflammasome including NLRP3, ASC, 
caspase-1, gasdermin D and IL-1β (Schroder and Tschopp, 2010). Although NLRP3 
activity in platelets has been measured, primarily by FLICA it is worth noting, there 
has been little convincing evidence of expression in any published papers to date, 
with the majority relying on immunofluorescence (Vogel et al., 2018a) or flow 
cytometry (Hottz et al., 2013), with the first report of detection by immunoblot 
appearing in 2019 (Vats et al., 2019). 
 
4.4.1 NLRP3 immunoblot and immunoprecipitation 
Here we immunoprecipitated (IP) NLRP3 from human washed platelet lysate using 
two antibodies raised against NLRP3, monoclonal (anti-cryopyrin 6F12) and 
polyclonal (anti-cryopyrin H66). Whole cell lysate, immunoprecipitated monoclonal 
antibody (mAb), immunoprecipitated polyclonal antibody (pAb), IgG and inputs were 
immunoblotted using both anti-cryopyrin 6F12 and H66 antibody. The IP using anti-
cryopyrin H66 led to the detection of bands at 110 kDa and 140 kDa respectively 
(Upper, Figure 58). The proposed molecular weight of NLRP3 is 110 kDa, suggesting 
that NLRP3 was potentially identified under these conditions. In contrast, no NLRP3 
was detected in the whole cell lysate or immunoprecipitating with anti-cryopyrin 6F12, 
which made this less conclusive, where typically a second antibody would act to 
validate findings. The lack of a positive control sample and potential PBMC 
contamination in a standard washed platelet preparation also weakens the possibility 
of expression. Intriguingly the Coomassie stain of the same membrane suggests the 
presence of a 110 kDa band in both immunoprecipitate elutions. 
We also immunoblotted for NLRP3 on human washed platelet lysate with the 
extensively published CRYO-2 antibody clone. As part of this study, we validated the 
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antibody against positive control lysates from immortalised THP1 and HL60 cell lines. 
While a band was detected in both positive controls at ~110 kDa, the predicted 
molecular weight of NLRP3, no band was detected at that weight in the platelet 
lysates from three separate donors although we were able to detect the ~140 kDa 
band which was immunoprecipitated previously alongside several other protein 
bands at <100 kDa (Figure 58). 
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Figure 58. Immunoprecipitation and immunoblot of NLRP3. (Upper) NLRP3 was 
immunoprecipitated from human washed platelet lysate with either a 
monoclonal (6F12) or polyclonal (H66) anti-cryopyrin (Santa Cruz) antibody as 
shown. The immunoprecipitate was washed, lysed and underwent SDS-PAGE 
and western blot. The blot was probed with anti-NLRP3 (6F12) mAb 1/1000 in 
5% milk followed by anti-mouse-680nm 1/20,000 and anti-NLRP3 (H66) pAb 
1/1000 in 5% milk followed by anti-mouse-800nm 1/20,000. The blot is 
composite of both secondary detections, NLRP3 only detected in pAb lysate by 
pAb probe. Detection was by fluorescence using an Odyssey LiCor. (Lower) 
Immunoblot, human washed platelet lysate was separated with SDS-PAGE and 
probed with anti-NLRP3 (CRYO-2, Adipogen) at 1/1000 in 5% milk followed by 
anti-mouse-HRP 1/10,000. Detected by ECL. Representative of 3 blots. 
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4.4.2 ASC immunoblot and immunoprecipitation 
ASC is a 22 kDa protein which bridges NLRP3 and caspase-1 through its pyrin 
domain and CARD domain respectively (Matsushita et al., 2009). ASC forms 
filaments which amplify the signal from NLRP3 and results in caspase-1 recruitment 
(Dick et al., 2016). In the first instance, ASC was detected by immunoblot of whole 
cell lysates of multiple human and murine donors and was demonstrated to be 
expressed in 3 human and 3 murine donors at 20 kDa (Upper, Figure 59). In the 
second instance ASC was immunoprecipitated from human washed platelet lysate 
using a monoclonal antibody raised against ASC, note that the dominant bands in 
the IP are immunoglobulin heavy and light chain (50 and 25 kDa respectively) (Lower, 
Figure 59). In both sets of experiments, the detected ASC band was clear, suggesting 
this is specific antibody recognition, but at 20 kDa rather than 22 kDa, as typically 
described in the literature and also demonstrated here as blotted from THP1 and 
HL60 cells. Of note, ASC was immunoblotted and immunoprecipitated from multiple 
donors exclusively at a molecular weight of 20 kDa. However, there are shortened 
isoforms of ASC previously described in other cells which may lack a hinge domain 
and therefore be constitutively active (Matsushita et al., 2009), and are known to be 
20 kDa. Here we have described, that human and murine platelets predominantly 
express a shortened isoform of the NLRP3 adaptor protein ASC. 
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Figure 59. Immunoblot and immunoprecipitation of ASC. (Upper) human washed 
platelet lysate was separated with SDS-PAGE and probed with anti-ASC (F9, 
mAb) at 1/250 in 5% milk followed by anti-mouse-HRP 1/10,000, representative 
of 3 blots. (Lower) the ASC (F9, mAb) immunoprecipitate was washed, lysed 
and underwent SDS-PAGE and western blot. The blot was probed with anti-
ASC (F9, mAb) 1/250 in 5% milk followed by anti-mouse-HRP 1/10,000. 
Developed by ECL onto x-ray film. 
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4.4.3 Identification of caspase-1 and cleavage products 
Caspase-1 is a thiol protease which belongs to the inflammatory caspases sub-group 
(Miao et al., 2011). Upon inflammasome activation, recruited caspase-1 undergoes 
self-cleavage which forms two subunits, P20 and P10, these form an active 
enzymatic tetramer which cleaves at the amino acid motif YVAD (Garcia-Calvo et al., 
1998). 
Here, using two antibodies, we first try to determine the presence of caspase-1 in 
washed platelet lysate and compare these with two leukocyte lysates THP1 and HL-
60 used as positive controls. We validated that the antibody detects bands between 
50 and 40 kDa, which covers the range of major caspase-1 isoforms; α (50 kDa), β/γ 
(40-45 kDa) and δ (<40 kDa) (Alnemri et al., 1995) (Upper left, Figure 60). Using the 
HL-60 as a positive control we next immunoblotted platelet lysates and detected a 
dominant band at 45 kDa, which would suggest that platelets may express primarily 
a caspase-1 β isoform (Upper right, Figure 60). 
When caspase-1 is activated, it undergoes cleavage, therefore we sought to 
immunoblot for cleavage products, ranging from 10-20 kDa, encompassing P20 and 
P10 subunits (Broz et al., 2010). Washed platelets were stimulated with thrombin (10 
U/mL), ATP (5 mM) or nigericin (1 and 10 µM) for 15 and 30 minutes and caspase-1 
cleavage evaluated. Under these conditions, only nigericin was able to induce 
cleavage with a band detected at 15 kDa (Lower, Figure 60). This is consistent with 
previous FLICA data, which detected caspase-1 cleavage was optimal after 
treatment with nigericin (Figure 48), with only a mild increase for the thrombin mimetic 
SFLLRN (Figure 52). 
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Figure 60. Immunoblots of caspase-1. Human washed platelet lysate untreated or 
treated as indicated was separated with SDS-PAGE and probed with anti-
caspase-1 CST2225S (upper 2 blots) or SCBT mAb (16F468) (lower blot) in 
5% milk followed by anti-rabbit-HRP (upper blots) or anti-mouse-IR800 (lower 
blot) and then developed by enhanced chemi-luminescence onto x-ray film or 
fluorescence on Odyssey LiCor respectively. Cleavage blot representative of 
n=4. 
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4.4.4 Identification of Gasdermin D 
Gasdermin D is a 55 kDa protein cleaved by caspase-1. In canonical inflammasome 
activation it is responsible for pore formation which induces pyroptosis and releases 
IL-1β (Liu et al., 2016) and in non-canonical activation it is part of the caspase-11 
feedback loop leading to potassium efflux dependent NLRP3 activation (Ringel-Scaia 
et al., 2016). 
Here gasdermin D was detected by immunoblot from three human donors washed 
platelet lysate using a monoclonal antibody raised against gasdermin D. Comparing 
THP1 lysate to human washed platelet lysate from three separate donors, there was 
a prominent band at the predicted 55 kDa and a second band at 40 kDa which is 
shared by both cell lines (Figure 61), suggesting it may be non-specific or a cleavage 
product of the pore forming domain or repressor domain. This novel observation 
confirms that human platelets express gasdermin D and may represent a novel 
pathway for secretion of intracellular cargo. To examine this further, gasdermin D 
cleavage products after caspase-1 activation should be immunoblotted for, where 
they should represent a pore-forming domain and repressor domain. 
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Figure 61. Immunoblot of Gasdermin D. Human washed platelet lysate was 
separated with SDS-PAGE and probed with anti-gasdermin D (mAb) at 1/500 
in 5% milk followed by anti-mouse-HRP 1/10,000. Developed by enhanced 
chemi-luminescence onto x-ray film. 
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4.4.5 Interleukin 1-beta immunoblot 
IL-1β is the final cleavage product of NLRP3 inflammasome activation and is the 
systemic effector of the pathway. On an initial signal, pro-IL-1β (p37) is produced via 
transcriptional priming and accumulates within the cell, prior to cleavage by caspase-
1 into bio-active IL-1β (p17) which can then act beyond the cell and drive 
inflammation (Perregaux and Gabel, 1994, Grebe et al., 2018). 
Here we screen human washed platelet lysate treated with several agonists for 
expression of IL-1β using two separate antibodies, anti-IL-1β P420B pAb and 5C10 
mAb to ensure confidence in findings. Using the HL-60 lysate both clones bound to 
a distinct band at approximately 40 kDa. In contrast, this was not detected in THP1 
lysate. This discrepancy is likely as the HL60 lysate is generated from cells pre-
treated with LPS while the THP1 was not, and as described LPS acts as a priming 
signal and drive IL-1β accumulation within the cell. There is also a remarkable 
difference in specificity of antibody when comparing the pAb with the mAb. Even with 
the highly specific mAb, from this donor, the washed platelets demonstrated no 
detectable IL-1β under any of the conditions of stimulation or priming used (Figure 
62). 
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Figure 62. Immunoblot of IL-1β. Human washed platelet lysate was left untreated 
or treated with the indicated agonist (30 minutes) and was separated with SDS-
PAGE and probed with anti-IL-1β (SCBT 5C10 mAb or TF P420b pAb) at 1/500 
in 5% milk followed by anti-mouse/rabbit-HRP 1/10,000. Developed by ECL 
onto x-ray film. 
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4.5 DISCUSSION 
 4.5.1 FLICA and NLRP3 inflammasome activity 
The first section of data in this chapter concerned the FLICA assay, which 
fluorescently labels active caspase-1 (Bedner et al., 2000). We used this to attempt 
to pull apart mechanistic elements and novel ligands which may drive activation of 
the platelet NLRP3 inflammasome, first described in 2013 (Hottz et al., 2013). Initially 
we were able to show that the canonical NLRP3 activating ligand, nigericin 
(Perregaux and Gabel, 1994), could drive a significant increase in FLICA signal in 
the presence of (plasma levels of) calcium (Murakami et al., 2012), this was an 
important basis for the study, as it suggested that known aspects of NLRP3 biology 
described in other cells was reproducible in platelets. We next sought to understand 
if oxLDL may drive or potentiate caspase-1 cleavage in platelets, as it has been 
shown to have other effects on platelets including ROS production (Berger et al., 
2019b), disinhibition (Magwenzi et al., 2015, Berger et al., 2019a) and activation 
(Wraith et al., 2013, Yang et al., 2017a) and in macrophages, oxLDL has been shown 
to drive NLRP3 activation (Liu et al., 2014). While we were unable to demonstrate an 
increase in FLICA signal when treated with oxLDL alone, oxLDL significantly 
potentiated a sub-maximal dose of the canonical activator nigericin. Vitally this effect 
was not observed if treated with nLDL. This suggests that in platelets, rather than 
directly activating the NLRP3 inflammasome, oxLDL may be functioning as a primer 
of complex recruitment, allowing for greater activation when stimulated. This 
hypothesis is in agreement with the literature, where oxLDL is proposed to have both 
a priming effect (transcriptional activity) and also an activatory effect via ROS 
production (Liu et al., 2014). Considering the potential for oxLDL to be present not 
only in atherosclerotic plaque, but in circulation (Ramos-Arellano et al., 2014), we 
can suggest that circulating oxLDL may priming platelets for NLRP3 activity. 
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Having demonstrated that oxLDL potentiated the effects of nigericin on caspase-1 
cleavage as measured by FLICA, we sought to understand the mechanisms through 
which this occurs. In platelets, there are many studies which show oxLDL signals 
primarily through CD36 (Podrez et al., 2007, Wraith et al., 2013), which is highly 
expressed by human platelets (Burkhart et al., 2012). However, it is also known that 
other receptors may be involved in driving platelet-oxLDL interactions. To look at 
other mechanisms through which this effect could be transduced we included the 
general ROS scavenger N-acetyl cysteine (NAC) and the calcium chelators EDTA 
(extracellular) and BAPTA (intracellular). OxLDL is known to induce ROS in platelets 
(Magwenzi et al., 2015), and also induce calcium release via PLCγ2 (Berger et al., 
2019b), which is a key mediator of both platelet activation (Begonja et al., 2005) and 
also NLRP3 (Ye et al., 2017, Liu et al., 2014). Interestingly we were able to 
demonstrate both that this increase in signal was wholly reliant on ROS, and again 
reiterated the importance of calcium. As the inhibitors also blocked the positive 
control of nigericin alone, it cannot be confirmed if they also selectively inhibit oxLDL 
potentiation or instead block all nigericin driven NLRP3 activity. Since NAC also 
completely blocks the activation of caspase-1 by high dose nigericin (10 µM) 
suggesting it blocks an upstream event, it cannot be assumed that NAC is targeting 
only downstream of oxLDL rather it is either only blocking all NLRP3 activity or 
simultaneously blocking the potentiation caused by oxLDL. To dissect the role of 
CD36 in the transduction of the oxLDL signal, we applied inhibitors against several 
aspects of the pathway targeting the receptor itself and downstream kinases using 
previously published inhibitors (Magwenzi et al., 2015, Wraith et al., 2013). We 
applied FA6-152 as a CD36 blocking antibody, BAY61 to block Syk and PP2 to block 
Src family kinases. These inhibitors were shown to not have any significant effects 
on the FLICA signal after treatment with nigericin and oxLDL. There was a minor 
decrease in signal after treatment with BAY61, which based on Fa6 and PP2 not 
inhibiting response would suggest it was not affecting CD36 signalling, therefore as 
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Syk has been previously shown to be involved in the regulation of ASC recruitment, 
this may be the pathway through which this reduction was mediated (Lin et al., 2015). 
Nevertheless, together this suggests that oxLDL is not signalling through CD36 to 
potentiate caspase-1 activity. However, as these studies on the CD36 signalosome 
lack repeats, it is important that the experiments are later repeated to validate these 
observations. 
Having found a reproducible phenotype, where oxLDL heavily potentiated the 
cleaved caspase-1 signal, we wanted to verify this, as it was a larger increase than 
anticipated. Therefore we adjusted our strategy to attempt to blockade NLRP3 with 
the specific inhibitory compound MCC950, which has been shown to inhibit the 
NLRP3 inflammasome with a high specificity (Coll et al., 2019, Coll et al., 2015). We 
chose to pursue this method, as the FLICA assay does not have an intrinsic control 
to account for non-specific binding and a well published inhibitor (MCC950) could 
provide a negative control for this purpose. As was demonstrated several times, this 
inhibitor, at a wide range of doses failed to inhibit FLICA signal. This surprising result 
suggested that; (i) NLRP3 is not present in platelets and the caspase-1 cleavage 
being measured is downstream of an alternative mediator, or (ii) the FLICA dye is 
binding non-specifically and potentially an alternative event is being measured. 
Platelet proteomic studies have demonstrated no other inflammasome complexes 
present in human or murine platelets, bar NLRX1 (Burkhart et al., 2012, Zeiler et al., 
2014), which does not signal through caspase-1 as it lacks both a pyrin domain to 
recruit ASC, or a CARD domain to recruit caspase-1 (Allen, 2014). We were therefore 
concerned that we were inducing platelet apoptosis and pursued several assays to 
measure events which are hallmarks of death pathways. 
Having demonstrated that the signal we induce is insensitive to MCC950, we sought 
further validation of the assay. We pursued the use of a competitive unlabelled 
YVAD-motif control and screened our optimal stimulation conditions against assays 
for mitochondrial ROS, mitochondrial membrane potential and phosphatidylserine 
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exposure. Here we were able to demonstrate, in agreement with previous literature 
(Pozarowski et al., 2003), that an unlabelled peptide cannot outcompete FLICA 
binding at large molar excess. We further demonstrated that under identical 
conditions, where FLICA binding is high, that apoptotic hallmarks such as PS 
exposure, loss of mitochondrial membrane potential and mitochondrial ROS are all 
induced. Critically MCC950 was confirmed as unable to block FLICA binding, but the 
data also suggested that PS exposure may not be downstream of inflammasome 
activation, which was similarly unperturbed by the inhibitor, again indicative of 
apoptosis. While pyroptosis, or inflammatory cell death (Miao et al., 2011) is a well 
described phenomena of NLRP3 activity the inability of blockade of FLICA signal by 
specific inhibitors and the relative similarities to apoptosis observed suggest the 
peptide may be binding non-specifically to apoptotic/pyroptotic platelets (Pozarowski 
et al., 2003, Darzynkiewicz and Pozarowski, 2007). Potassium efflux is also 
suggested to be vital to NLRP3 activation, we tested whether an excess of 
extracellular potassium could block FLICA binding (Tang et al., 2017) but again, we 
could demonstrate no blockade of signal (data not shown). Further to this, we tested 
nigericin on the classical platelet assay of LTA. This demonstrated no aggregation 
but did induce a linear clearance of platelet suspension which was not dependent on 
fibrinogen binding, suggesting this may be cell death. This was also supported by an 
observation in cellular concentrations when samples were analysed by flow 
cytometry, where those samples treated with nigericin took considerably longer to 
acquire an equivalent number of cells in comparison to basal samples. While LTA 
demonstrated no functional response CD62P expression did appear to be induced 
by nigericin treatment. This observation is in agreement with literature suggesting 
that NLRP3 activity in platelets can be induced by traditional platelet agonists 
thrombin and collagen, of which SFLLRN is a thrombin mimetic (Murthy et al., 2017). 
Furthermore, we can show that the K+ ion flux driven by nigericin is possibly able to 
induce α-granule secretion, however confirmation with additional marker PAC1 would 
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provide validation that this is complete activation. PAC1 would be insensitive to 
changes in membrane permeability, as CD62P staining might be, as it instead detects 
the active conformation of the integrin αIIbβ3. There is a likelihood that if the cells are 
truly becoming apoptotic, the CD62P antibody may be simply entering the cell to 
detect total CD62P rather than exposure of the protein on the surface. 
While there are concerns over the specificity of FLICA as a readout of NLRP3 activity 
within the literature (Darzynkiewicz and Pozarowski, 2007), we have applied several 
control experiments to our model in washed human platelets. We can summarise that 
FLICA signal is robustly increased by the known NLRP3 activator nigericin and we 
show that oxLDL significantly potentiates this and nLDL does not, however, we are 
unable to block this effect with MCC950 (Coll et al., 2015), glyburide (Lamkanfi et al., 
2009), competitive peptide controls (Pozarowski et al., 2003) or potassium efflux 
blockade (Tang et al., 2017). Remarkably the ROS scavenger NAC (Ye et al., 2017) 
and calcium (Murakami et al., 2012) are shown to be vital to this signal, but the FLICA 
signal also co-exists with several apoptotic markers. The importance of ROS and 
calcium concurrent with markers of apoptosis and mitochondrial dysfunction may 
suggest that nigericin is perturbing mitochondrial stability leading to apoptosis. 
Ultimately, while we may be reading caspase-1 cleavage, under the current 
conditions we cannot be sure that this is the case and several factors point to the 
treatment inducing platelet death, although again this may be pyroptosis (Miao et al., 
2011). This study requires further validation, preferably by alternative methods such 
as immunoblot for cleaved caspase-1 or ELISA for secreted IL-1β. Additionally the 
use of NLRP3 knockout murine models to avoid relying on chemical inhibition would 
significantly enhance the study and overcome the limitations of biochemical 
inhibitors. 
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 4.5.2 NLRP3 inflammasome expression 
Another important consideration is the expression of NLRP3 and associated 
components in platelets. The human platelet proteome reports the presence of only 
ASC and gasdermin D (Table 9), with copy numbers of both proteins presumed not 
to exceed 1500 per cell (Burkhart et al., 2012), the murine platelet proteome also 
reports that only ASC and gasdermin D are present (Table 10) (Zeiler et al., 2014). 
However, it must be noted that these proteomic studies were performed on healthy 
donors, or wild type mice, and there is a strong argument for inflammatory protein 
complexes being upregulated in a diseased state, and therefore not present in 
healthy donors. However, it is of some concern to this argument of inflammatory 
reprogramming, that in individuals with dengue virus infection, where platelet NLRP3 
activity was initially described (Hottz et al., 2013), the same group later reported no 
NLRP3 detectable by proteomics (Trugilho et al., 2017). In contrast with this, the 
transcriptome of both human and murine platelet RNA reports the presence of all 
components; NLRP3, ASC, caspase-1, IL-1β and gasdermin D (Table 11), although 
none are ranked within the 3000 most common transcripts (Rowley et al., 2011). 
These negative reports could be attributed to a lack of protein presence in the healthy 
donors assayed or low copy numbers of these proteins or transcripts, below detection 
thresholds. In support of this, the human proteome does not detect the presence of 
TLRs, but their expression has been evidenced by traditional biochemistry and 
functional studies both in vivo and in vitro (Biswas et al., 2017, Fung et al., 2012, 
Damien et al., 2015, Vogel et al., 2018a, Vogel et al., 2018b, Rex et al., 2009).  
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Table 9. Protein name, accession code, confidence of signal and estimated copy 
number for each component of the NLRP3 inflammasome in human platelets 
(Burkhart et al., 2012). 
Protein Accession Confidence (%) Copy number 
NLRP3 Q96P20 - - 
ASC Q9ULZ3 100 1,000 
Caspase-1 P29466 - - 
Gasdermin D P57764 100 1,500 
IL-1β P01584 - - 
 
 
Table 10. Protein name, accession code and estimated copy number for each 
component of the NLRP3 inflammasome in murine platelets (Zeiler et al., 2014). 
Protein Accession Copy number (+/- variation) 
NLRP3 Q8R4B8 - 
ASC Q9EPB4 3,743 +/- 1,375 
Caspase-1 P29452 - 
Gasdermin D Q9D8T2 308 +/- 111 
IL-1β P10749 - 
 
 
Table 11. Protein name, genecard symbol and relative expression rank in the 
transcriptome for each component of the NLRP3 inflammasome (Rowley et al., 
2011). 
Protein Symbol Human rank Murine rank 
NLRP3 NLRP3 5913 10955 
ASC PYCARD 3005 4178 
Caspase-1 CASP1 3365 6354 
Gasdermin D GSDMD 4114 9645 
IL-1β IL1B 4972 5773 
 
We attempted to assess the expression of NLRP3 inflammasome components by 
protein biochemistry; immunoprecipitation and immunoblot. We were able to 
immunoprecipitate a clear NLRP3 band, however this migrated at a molecular weight 
different to that predicted from the literature by roughly 30 kDa. The data indicated 
that immunoblotting confidently detected three potential components of this complex 
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including ASC, caspase-1 and gasdermin D. While efforts to detect caspase-1 
cleavage, IL-1β and NLRP3 were challenging. 
The above data was then compared and summarised in a single table to compare 
expression of NLRP3 inflammasome complex proteins by different methods including 
open access proteomics, transcriptomics and our own protein biochemistry of platelet 
lysates. In summary, only ASC and gasdermin D are present across all three studies 
(Burkhart et al., 2012, Zeiler et al., 2014, Rowley et al., 2011), including our own 
(Table 12). 
 
Table 12. NLRP3 inflammasome complex components presence based on 
proteomic data (Burkhart et al., 2012), transcriptomic data (Rowley et al., 
2011) and own immunoblots and immunoprecipitations. += present, -=not-
present, ~=further validation and X=not tested. 
Protein Proteom
e (h) 
Transcri
pt (h) 
Lysate 
(h) 
Proteom
e (m) 
Transcri
pt (m) 
Lysate 
(m) 
NLRP3 - + ~ - +  
ASC + + + + + + 
Caspase-1 - + + - +  
Gasdermin D + + + + +  
IL-1β - + - - +  
 
A novel finding made here was that platelets express primarily a spliced transcript of 
ASC (Matsushita et al., 2009), which is suggested to be constitutively active or play 
regulatory roles in NLRP3 activity depending on the spliced variant expressed (Bryan 
et al., 2010). What is known is that ASC recruitment is a vital step in NLRP3 activity 
(Dick et al., 2016), one could hypothesise, that if ASC is able to oligomerise without 
NLRP3, NLRP3 itself may not be required in platelets to activate ASC CARD domains 
and recruit caspase-1, potentially explaining why the MCC950 did not work in this 
model. Further studies are required on the capacity of platelet ASC to oligomerise, 
and this can be pursued by both CHAPS cross-linked immunoblotting for oligomers 
or light microscopy for ASC puncta (Dick et al., 2016). We also identified that platelets 
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express gasdermin D, a novel finding that has not previously been described but 
which requires further work, as if confirmed, gasdermin D pore formation could well 
represent a novel node of cargo trafficking available to platelets (Liu et al., 2016), 
particularly if as some literature suggests platelet NLRP3 is activated by typical 
platelet agonists (Murthy et al., 2017, Qiao et al., 2018). The fact that several 
components of the pathway are present would suggest that; (i) there is some capacity 
to enact NLRP3 like activity via a novel pathway, (ii) an alternative and as of yet 
undetected NLR complex exists, where a recent proteomic study detected NLRP2 
(Trugilho et al., 2017), (iii) the NLRP3 inflammasome is present in platelets and 
detection and inhibition remains a challenge. However, without the confirmation of 
the NLRP3 inflammasome in this study, these suggested points currently remain 
speculation. 
Our findings here raise some discrepancies when compared with the literature 
currently surrounding the NLRP3 inflammasome in platelets. Where several platelet 
NLRP3 papers all provide functional evidence of NLRP3 activity (Hottz et al., 2013, 
Murthy et al., 2017, Qiao et al., 2018, Vogel et al., 2018a, Vogel et al., 2018b) and 
there is also prior evidence of platelets cytokines downstream of NLRP3, IL-1β 
(Brown et al., 2013, Nhek et al., 2017), or IL-18 (Allam et al., 2017). Furthermore, 
activation of the inflammasome in platelets, in our study and others, has been 
measured primarily using the FLICA assay. In comparison with our own work, the 
effects of MCC950 on platelet inflammasome activity have been small in the literature 
(Vogel et al., 2018a). However, there has been little evidence of protein expression 
by immunoblot of NLRP3 bar a single report (Vats et al., 2019), which has routinely 
been shown in leukocytes, and indeed in almost all leukocyte NLRP3 papers since 
the field was started (Agostini et al., 2004). Instead, platelet studies have typically 
used fluorescent flow cytometry (Hottz et al., 2013) or fluorescent microscopy (Vogel 
et al., 2018a), which intrinsically have fewer controls than traditional protein detection 
by immunoblot.  
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Chapter 5 
Mitochondrial dysfunction under lipid stress 
5.1 INTRODUCTION 
Platelets are metabolically active cells and demand for energy production increases 
on activation (Aibibula et al., 2018). Therefore a decreased mitochondrial activity 
leads to platelets which are hyporesponsive (Baaten et al., 2018). Beyond the 
requirement of functional mitochondria for effective platelet haemostatic activity, 
mitochondria have been implicated as key regulators of NLRP3 activity in other cell 
types (Zhou et al., 2011) and also in platelets (Hottz et al., 2013). Platelet 
mitochondria also regulate the procoagulant platelet phenotype – where 
mitochondrial depolarisation driven by sustained calcium signalling is a key event in 
the pathway leading to phosphatidylserine exposure (Choo et al., 2017, Choo et al., 
2012). 
Mitochondrial superoxide anion (O2•-) is produced from the electron transport chain 
and is reduced by manganese superoxide dismutase (Mn+ SOD) to H2O2 which can 
leave the mitochondria into the cytoplasm. In the cytoplasm, H2O2 is broken down by 
catalase to produce H2O and O2 (Collins et al., 2012). Mitochondrial membrane 
potential can be diminished by excess mitochondrial ROS, and when membrane 
potential is lost, this further increases the rate of mitochondrial ROS production, 
leading to a snowball effect of mitochondrial dysfunction. These mitochondrial ROS 
can leak out of the mitochondria if the mitochondrial permeability transition pore is 
formed (Schulz et al., 2014). Mitochondria play a key role in many cellular signalling 
pathways (Tait and Green, 2012) and by measuring markers of mitochondrial stress 
we aim to link mitochondrial dysfunction to a functional platelet phenotype.  
Mitochondrial function in platelets has previously been measured and shown to be 
implicated in several aspects of platelet function, including activation, ageing and 
necrosis (Gyulkhandanyan et al., 2012, Fidler et al., 2017, Zhao et al., 2017, Baaten 
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et al., 2018, Obydennyi et al., 2019, Zhang et al., 2019). Collagen-GPVI mediated 
platelet activation has been shown to be potentiated by hyperglycaemia driven by 
mitochondrial superoxide production (Yamagishi et al., 2001). In aged mice, 
mitochondria are changed in circulating platelets by parent megakaryocytes which 
are suggested to drive an age-associated hyperactivity phenotype (Davizon-Castillo 
et al., 2019). Furthermore, in Wiscott-Aldrich syndrome patients, platelets are shown 
to undergo mitochondrial-dependent necrosis on activation (Obydennyi et al., 2019). 
Understanding there is a key role for mitochondria in the regulation of many facets of 
platelet function, we sought to understand how oxLDL or lipid stress may be affecting 
platelet mitochondrial function. In other cell types oxLDL has been shown to affect 
mitochondrial function having several effects; driving mitochondria-dependent 
apoptosis in endothelial cells (Vindis et al., 2005), mitochondrial ROS production in 
endothelial cells (Chowdhury et al., 2010, Zmijewski et al., 2005), mitochondrial ROS 
production in macrophages (Asmis and Begley, 2003) and hyperpolarisation in 
enterocytes (Giovannini et al., 2002). This suggests a clear effect of oxLDL on 
metabolism in cells from multiple lineages, however, the effects of oxLDL on platelet 
or megakaryocyte metabolism has not been previously explored. Nevertheless, we 
have previously shown that ROS are produced in platelets in response to oxLDL 
(Magwenzi et al., 2015, Berger et al., 2019b), and that ROS signal from oxLDL 
treatment is sustained over several hours (Berger et al., 2019b), which is in contrast 
with the spike of ROS on GPVI activation (Walsh et al., 2014), suggesting that this 
divergence in ROS kinetics may control different platelet function. 
To further understand the mechanisms of this pathway, several known pathways 
could be targeted to determine how oxLDL is transducing a signal to the mitochondria 
leading to the observed dysfunction. The first and most well described pathway 
through which oxLDL signals in platelets is via CD36. CD36 ligation with oxLDL has 
been shown to drive platelet activation via; Spleen tyrosine kinases (SYK) and Rho 
(Wraith et al., 2013), PLCγ2 and ROS (Berger et al., 2019b), disinhibition of NO via 
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NOX2 (Magwenzi et al., 2015), disinhibition of PGI2 via PDE3a (Berger et al., 2019a), 
JNK (Chen et al., 2008) and ERK5 (Yang et al., 2017a). Recent studies in platelets 
have also now demonstrated a role for CD36 signalling in conjunction with other 
receptors, primarily Toll-like receptors (TLRs). This was first described in 
macrophages as being a CD36, TLR4 and TLR6 (Stewart et al., 2010) heteromeric 
complex, however it was then further described as a CD36, TLR2 and TLR4 (Chavez-
Sanchez et al., 2014) complex. In platelets, oxLDL signalling has been suggested to 
be via a different heteromeric complex to that detailed above; CD36, TLR2 and TLR6 
(Biswas et al., 2017). Other receptors on the platelet surface which may bind to 
oxLDL alongside CD36 include LOX1 and SRB1 (Levitan et al., 2010) and TLR2/4 in 
a heteromeric complex with CD36 (Biswas et al., 2017, Chavez-Sanchez et al., 
2014). LOX1 has been shown to be expressed on the platelet surface downstream 
of activation (Chen et al., 2001). Importantly for this study, LOX1 has also been 
shown to directly drive mitochondrial dysfunction and release of mtDNA – in turn 
activating the NLRP3 inflammasome (Christ and Latz, 2014). Additionally, LOX1 has 
been suggested to target the mitochondrial enzyme arginase II (ARG2) via ROCK 
(Touyz, 2014). Furthermore, and in support of LOX1 activation related to modified 
LDL and metabolic defects, a recent clinical study has identified circulating soluble 
LOX1 as a marker of the metabolic syndrome (MetS) which further correlates with 
another modified LDL, carbamylated LDL (cLDL) (Stankova et al., 2019). 
Therefore, within our system, we sought to understand how oxLDL, a key ligand in 
atherogenic lipid stress (Podrez et al., 2002a), may modulate mitochondrial biology, 
particularly in the context of mitochondrial superoxide production and mitochondrial 
membrane potential. We hypothesised that these observations may provide a 
functional link between oxLDL and the potentiation of FLICA/caspase-1 cleavage 
signal. 
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5.2 AIMS OF CHAPTER 
- To measure platelet mitochondrial function in response to lipid stress 
- To understand if platelet mitochondrial function changes in a model of diet-
induced hyperlipidaemia 
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5.3 PLATELET MITOCHONDRIAL SUPEROXIDE 
Previous FLICA findings suggested the potentiation of caspase-1 cleavage was 
driven by oxLDL but not by the control, nLDL. Furthermore, the data from section 
4.3.5 (Figure 50) indicated that these effects were mediated by ROS and calcium. 
Both calcium and ROS are intrinsically related to modulating mitochondrial function 
and ROS are additionally produced by mitochondria (Tait and Green, 2012, Schulz 
et al., 2014). Therefore, we chose to examine whether oxLDL modulated 
mitochondrial biology, specifically mitochondrial superoxide production, a potent 
source of intracellular ROS. 
A cell-permeant fluorescent probe assay which fluoresces when oxidised in 
mitochondria, mitoSOX, was established. This dye has previously been applied to 
measure platelet superoxide production (Hottz et al., 2013, Fidler et al., 2017), but 
platelet mitochondrial dysfunction in the context of lipid stress has not previously 
been measured.  
 
5.3.1 MitoSOX titrations 
The basis for this assay is a cell-permeant dye which fluoresces upon oxidation, and 
cell loading titrations were performed using the positive control antimycin A (AA; 100 
µM), which blocks complex 3 of the electron transport chain leading to superoxide 
leak. Each dilution was compared with a basal sample at a matched concentration, 
this comparison allows a comment on the sensitivity. As before calculating fold over 
control allows the condition with the highest fold increase, and therefore optimal 
window for detection of changes to be selected. There was a consistent signal in 
basal samples which did not change when incubated with increasing amounts of 
mitoSOX dye. Antimycin A (100 µM) caused increased signal as a function of dye 
concentration and it was determined that 5 µM dye provided the optimal window for 
positive signal to be measured (Figure 63). This is a dose of the dye that has 
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previously been loaded into washed platelets to measure mitochondrial superoxide 
(Fidler et al., 2017). 
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Figure 63. MitoSOX dye titration. Washed human platelets (2 x 106) were treated 
with or without antimycin A (100 µM) for 20 minutes prior to incubation with or 
without mitoSOX (1 – 5 µM) for 10 minutes. Samples were then diluted 10x in 
PBS and analysed by fluorescent flow cytometry. (n=1) 
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5.3.2 Antimycin A dose and time response 
Antimycin A targets and blocks complex 3 of the mitochondrial electron transport 
chain (Potter and Reif, 1952). Blocking complex 3 is known to induce superoxide leak 
from the electron transport chain, therefore we can use this agonist as a positive 
control ligand for mitoSOX (Park et al., 2007). Here in washed human platelets, time 
and dose responses against antimycin A were performed to determine the sensitivity 
of the assay. At 0 minute basal, fluorescent signal was low, suggesting basal 
mitochondrial superoxide production in platelets was also low (569.1±23), and this 
was increased after 60 minutes of resting (730.4±86). Antimycin A (10 – 100 µM) 
caused a concentration dependent increase in superoxide generation when 
incubated for 60 minutes, with a significant increase over time matched basal 
observed at 50 and 100 µM (1229±374 and 1345±355 (p<0.05) respectively) (Figure 
64). Antimycin A (50 µM) also increased superoxide production in a time-dependent 
manner and outstripped basal at 60 minutes (730.4±86) after just 15 minutes with 
antimycin A (810.8±159) with maximal effects seen at 60 minutes (1117±263, 
p<0.005, longest time tested) (Figure 64). This suggested the assay was sensitive to 
small changes in superoxide production at short time points and did not only detect 
changes at maximal dose/time. 
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Figure 64. MitoSOX antimycin A dose and time response. Washed human 
platelets (2 x 106) were treated with or without antimycin A (10 – 100 µM) for 60 
minutes or with or without antimycin A (50 µM) for 1 – 60 minutes prior to 
incubation with mitoSOX (5 µM) for the final 10 minutes of incubation. Samples 
were then diluted 10x in PBS and analysed by fluorescent flow cytometry. (One-
way ANOVA vs. basal sample, *<0.05, **<0.01 and ***<0.005, error shown as 
standard deviation, n=3-4)  
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5.4 OXIDISED LDL AND MITOCHONDRIAL SUPEROXIDE 
5.4.1 OxLDL dose and time response 
Having determined that the assay is sensitive over a wide range of time points and 
several doses of the positive control antimycin A, we next performed dose and time 
responses with oxLDL comparing it to basal and nLDL treated platelets. The mitoSOX 
probe was added 10 minutes prior to analysis, the assay was designed like this to 
avoid continued kinetic activation of the dye and false amplification of the signal. 
However, as part of this study we also explored if pre-incubation of the samples with 
the dye for 10 minutes followed by incubation with the agonist could improve the 
sensitivity of the assay through the amplification of superoxide signal (Figure 65). 
Performing the assay with dye incubated for only 10 minutes prior to analysis, we 
used antimycin A as a positive control which was significantly increased over basal 
(1840±412 vs. 634.9±29, p<0.0001) and confirmed the assay was functioning 
appropriately. We were then able to show that oxLDL (6.25 - 200 µg/mL) induced a 
dose-dependent increase in mitochondrial superoxide with maximal effects observed 
at 200 µg/mL (1055±198, p<0.05). In contrast, the signal at maximal dose of nLDL 
(617.6 ±49) was not significantly different from basal. Although the difference in signal 
was not statistically significant at all doses of oxLDL, there was an obvious trend that 
as the concentration of added oxLDL increased so did the level of superoxide (Figure 
66). There was also a time-dependent increase in mitochondrial superoxide when 
the concentration of added oxLDL was a constant (50 µg/ml). Again, increases in MFI 
were not statistically significant for all time points but nonetheless increase was seen 
after the shortest time point (674.7±37), and significant increases were then observed 
after at 90 minutes (894.4±115, p<0.05) and 180 minutes (1037.0±172, p<0.01). 
Crucially, the control nLDL at 180 minutes was again not different from basal (634.6± 
38) (Figure 66).  
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Figure 65. Timeline of two mitoSOX dye loading strategies. Two mitoSOX 
staining strategies were used in this study. Protocol one was used in Figure 66, 
and protocol two in Figure 67. A total oxLDL incubation of 90 minutes is used 
but the incubation of mitoSOX was varied. 
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Figure 66. MitoSOX oxLDL dose and time response. Washed human platelets (2 
x 106) were treated with oxLDL or nLDL (6.25 – 200 µg/mL) for 60 minutes or 
with oxLDL or nLDL (50 µg/mL) for 15 – 180 minutes prior to incubation with 
mitoSOX (5 µM) for the final 10 minutes of incubation. Antimycin A (100 µM, 30 
minutes) was used as a positive control and stained in the same way. Samples 
were then diluted 10x in PBS and analysed by fluorescent flow cytometry. (One-
way ANOVA vs. basal, ns=non-significant, *<0.05, **<0.01and ****<0.0001, 
error shown as standard deviation, n=3-11) 
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We repeated the previous experiment and explored if pre-incubation of the samples 
with the dye for 10 minutes followed by the agonist incubation would affect sensitivity 
(Figure 65). Under these conditions antimycin A (100 µM) again increased the MFI 
from 590.2±37 to 2111.2±623 (p=<0.0001) (Figure 67). Interestingly, the increase in 
MFI was not that different to that observed when mitoSOX was added at the assay 
endpoint (634.9±29 to 1840±412) (Figure 66), suggesting that assay performance 
was not affected by longer incubations with the dye and that the effects of antimycin 
A were likely maximal. In agreement with our previous findings oxLDL increased the 
level of superoxide in both a time and dose-dependent manner. OxLDL (200 µg/mL) 
increased MFI over nLDL (200 µg/mL) from 898.3±116 to 1498.7±78 (p=<0.05). 
Furthermore, at 120 minutes, oxLDL (50 µg/mL) increased MFI signal over nLDL (50 
µg/mL) from 988.0±209 to 1576.0±296 (p=<0.05) (Figure 67). In comparison, when 
the dye was added for 10 minutes post agonist treatment (Figure 66), oxLDL (200 
µg/mL) increased MFI over nLDL (200 µg/mL) from 617.6±49 to 1054.6±198 and at 
120 minutes, oxLDL (50 µg/mL) increased MFI signal over nLDL (50 µg/mL) from 
634.6±38 to 1037.2±172. Therefore, it was concluded that the differences between 
nLDL and oxLDL were greater when the dye was incubated for the duration of the 
experiment suggesting that this approach provided a better window of sensitivity. An 
additional advantage to using this incubation approach, is that it allows for the basal 
accumulation of superoxide to be assessed, here the basal superoxide signal was 
590.2±37, 1025.0±282 and 1130.6±264 at 0, 90 and 120 minutes respectively, for 
reference background unstained signal was 487.0±2, importantly these basal signals 
were exceeded in all cases by oxLDL signal at the relative time points (Figure 67). 
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Figure 67. MitoSOX oxLDL dose and time response with assay redesign. 
Washed human platelets (2 x 106) were loaded with mitoSOX (5 µM) for 10 
minutes and then treated with oxLDL or nLDL (12.5 – 200 µg/mL) for 60 minutes 
or with oxLDL or nLDL (50 µg/mL) for 15 – 120 minutes. Antimycin A (100 µM, 
30 minutes) was used as a positive control and stained in the same way. 
Samples were then diluted 10x in PBS and analysed by fluorescent flow 
cytometry. (One-way ANOVA vs. nLDL, ns=non-significant, *<0.05 and 
****<0.0001, error shown as standard deviation, n=3) 
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Having shown that using an assay design whereby the dye was incubated for the 
duration of the experiment is permissible and allows basal signal to be measured; 
the increased basal signal observed prompts the question of whether this assay 
design would allow the dye to be used as a kinetic measurement rather than the 
standard approach whereby single tubes are read at x time point and then discarded. 
Consequently, we compared a time response of oxLDL set up using single tubes for 
each condition, which were then read at x time point and discarded, against tubes 
read repeatedly for each increasing time point. Consistent with previous single tube 
with dye incubated throughout the time course, oxLDL (50 µg/mL) increased 
superoxide over time (30 – 120 minutes) which was elevated over matched basally 
treated time points (120 minutes) from 1130.6±264 to 1576±296 (Figure 68). Kinetic 
tubes also demonstrated an increase in MFI when comparing basal and oxLDL (50 
µg/mL, 120 minutes) from 843.1±50 to 1526.4±143 respectively (Figure 68). The 
comparison between single and kinetic tubes demonstrated a similar increase in 
oxLDL treated superoxide signal, but the use of kinetic tubes also removed/reduced 
the increase in basal signal over time, where basal (120 minutes) in single tubes was 
1130.6±264 and in kinetic tubes was 843.1±50. 
This demonstrated that the assay could be used in a kinetic manner without the need 
for multiple tubes for each condition and suggested that a kinetic read ablates the 
error in increasing basal signal and also reduces intrinsic assay error as single tubes 
are read repeatedly eliminating tube-tube error. As a result, the sensitivity to measure 
an increase in superoxide stimulated by oxLDL was increased. Ultimately, we have 
shown that when dye is pre-loaded into the assay (protocol 2) and a kinetic process 
of measurements is used then optimal conditions are obtained. 
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Figure 68. Single tubes versus kinetic reading. Washed human platelets (2 x 106) 
were loaded with mitoSOX (5 µM) for 10 minutes and then treated with oxLDL 
or nLDL (50 µg/mL) for 30 – 120 minutes. Antimycin A (100 µM, 30 minutes) 
was used as a positive control and stained in the same way. Samples were 
then diluted 10x in PBS and analysed by fluorescent flow cytometry, kinetic 
samples were single tubes from the earliest time point for each treatment that 
were then re-read at each subsequent time point. (Error shown as standard 
deviation, n=3) 
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5.4.2 ROS scavenger screen against oxLDL induced superoxide 
The demonstration that oxLDL, but not nLDL, drove a time and dose-dependent 
increase in platelet mitochondrial superoxide is a novel finding. To understand this 
further and explore the mechanisms driving the process we used several 
pharmacological inhibitors to confirm the source of ROS. 
We used oxLDL at a fixed dose and time point (50 µg/mL & 90 minutes) and pre-
treated samples with two scavengers, the mitochondrial superoxide scavenger 
mitoTEMPO (mT, 100 µM) and the cytoplasmic ROS scavenger NAC (5 mM). 
Antimycin A (100 µM) caused a significant increase in MFI from 634.9±29 to 
1839.7±412 which was significantly reduced to 952.9±107 by the presence of 
mitoTEMPO (p<0.0001), and therefore confirmed mitoTEMPO was an effective ROS 
scavenger (Figure 69). OxLDL (50 µg/mL, 90 minutes), caused a significant increase 
in MFI (894.4±115) over basal (634.9±29) (p<0.05) but this was not seen for nLDL 
(614.4±40) (Figure 69). In contrast to the effect of mitoTEMPO on antimycin A, 
attempts to scavenge oxLDL mediated superoxide demonstrated no significant 
decreases in MFI for oxLDL (894.4±115) compared to oxLDL + mitoTEMPO 
(774.5±125), with just a trend of reduction observed. Furthermore, the addition of 
NAC with oxLDL showed no difference in MFI (853.5±177), but as NAC scavenges 
cytoplasmic ROS and not mitochondrial superoxide this may mean it does not have 
access to the mitochondria. The inability of mitoTEMPO to cause a marked return to 
basal could be interpreted in several ways; (i) the superoxide signal from the oxLDL 
is false signal; (ii) the scavenging capacity of the mitoTEMPO is limited (superoxide 
is not returned to basal even with effective scavenging in antimycin A samples), or 
(iii) the mitoSOX assay is not sensitive enough to determine such subtle changes, 
where the increase over basal is already small (+260 a.u). However, with increased 
repetition of the experiment, the scavenging of oxLDL mediated superoxide would 
likely become more distinct. Considering the clear effects of oxLDL when compared 
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to the control nLDL and the non-return to basal of scavenged antimycin A superoxide, 
an informed assumption suggests the issue is a combination of points ii and iii. 
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Figure 69. MitoSOX treated with ROS scavengers. Washed human platelets (2 x 
106) were treated with oxLDL or nLDL (50 µg/mL) for 90 minutes prior to 
incubation with mitoSOX (5 µM) for the final 10 minutes of incubation. Antimycin 
A (100 µM, 30 minutes) was used as a positive control and stained in the same 
way. In some cases, samples were pre-incubated with mitoTEMPO (mT) (100 
µM, 20 minutes) or N-acetyl-cysteine (5 mM, 20 minutes) prior to agonist 
addition. Samples were then diluted in PBS 10x and analysed by fluorescent 
flow cytometry. Individual donors are shown as superimposed points over each 
bar. (One-way ANOVA vs. shown, ns=non-significant, *<0.05 and ****<0.0001, 
error shown as standard deviation, n=3-11) 
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5.5 MURINE MITOCHONDRIAL SUPEROXIDE 
5.5.1 Murine antimycin A dose and time 
Having confirmed that superoxide production in mitochondria mediated by oxLDL is 
increased in human platelets, we next sought to replicate this study using a murine 
model. Here we wanted to validate the mitoSOX assay in murine platelets, so that 
we could later screen transgenic or diet-fed murine platelets. In washed wild type 
murine platelets, we performed time and dose responses against antimycin A. 
Antimycin A (1 – 10 µM), caused a dose dependent increase in MFI, with maximal 
effects over basal observed at 10 µM (2016.2±137 vs. 1244.6±310, 10 µM vs. basal). 
Using a constant 10 µM concentration of antimycin A, a time dependent increase in 
superoxide production was observed with MFI increasing from 622.7±25 at basal to 
931.9±65 after 1 minute (p<0.05) and 2295±159 after 60 minutes (p<0.0001) (Figure 
70). The increase in superoxide occurred rapidly after just 1 minute of treatment and 
the MFI measured at every treated time points were significantly different to the basal 
at 0 minutes (Figure 70). Specifically, for time-matched comparison, the MFI at 60 
minutes basal was 1244.6±310 and after 60 minutes of antimycin A treatment had 
increased to 2294.8±159 (Figure 70). 
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Figure 70. Murine mitoSOX antimycin A dose and time response. Washed 
murine platelets (2 x 106) were loaded with mitoSOX (5 µM) for 10 minutes and 
then treated with or without antimycin A (1 – 10 µM) for 60 minutes or with or 
without antimycin A (10 µM) for 1 – 60 minutes. Samples were then diluted 10x 
in PBS and analysed by fluorescent flow cytometry. Individual mice are shown 
as superimposed points over each bar. (One-way ANOVA vs. basal, *<0.05, 
**<0.01 and ****<0.0001, error shown as standard deviation, n=4) 
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5.5.2 Platelet mitochondrial superoxide in murine models of 
atherosclerosis 
Having validated the applicability of the mitoSOX assay in wild type murine platelets 
we tested if platelet superoxide generation was altered in genetically instigated 
hyperlipidaemia. For this, we first compared wild type animals against the transgenic 
ApoE-/- model, where mice are spontaneously hyperlipidaemic, inflammatory and 
develop early atherosclerotic plaques (Getz and Reardon, 2006). MFI for mitoSOX 
increased from 710.2±78 for wild type murine platelets to 1135.8±308 for the ApoE-
/- platelets (p<0.01) (Figure 71). Further investigation using a double knockout model 
deficient in GP91 a component of NOX2, ApoE/GP91-/- confirmed that basal 
superoxide was derived from mitochondrial sources, and not the cytoplasmic ROS 
generator NOX2 (Magwenzi et al., 2015). Similar to the ApoE, and in support of that 
observation, this double knockout also had increased platelet mitochondrial 
superoxide above wild type (1110.5±151) (p<0.05), indicating that NOX2 was not 
responsible for superoxide production under these conditions but the effects of ApoE 
knockout were conserved (Figure 71). This demonstrated that platelets from mice 
under lipid and inflammatory stress demonstrate increased basal superoxide. 
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Figure 71. MitoSOX basal superoxide in murine models of atherosclerosis. 
Washed murine platelets (2 x 106) were loaded with mitoSOX (5 µM) for 10 
minutes. Samples were then diluted 10x in PBS and analysed by fluorescent 
flow cytometry. Individual mice are shown as superimposed points over each 
bar. (One-way ANOVA vs. basal, *<0.05 and **<0.01, error shown as standard 
deviation, n=3-8) 
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5.6 PLATELET MITOCHONDRIAL MEMBRANE POTENTIAL 
Mitochondrial membrane potential can be used as a measure of the hyper-, normo- 
or hypopolarisation of the mitochondria (Joshi and Bakowska, 2011). 
Hypopolarisation is a collapse of the gradient across the mitochondria, this is often a 
pre-cursor to apoptosis. Hyperpolarisation describes an increase in the mitochondrial 
electrochemical gradient and may drive mitochondrial hyperactivity. Both events are 
likely to lead to an increased production of mitochondrial superoxide. Having shown 
that oxLDL can induce changes in mitochondrial function and drive superoxide 
production, we explored other measures of mitochondrial dysfunction to confirm 
these findings and further understand the involvement of oxLDL in mitochondrial 
superoxide formation. Specifically, we explored the effects of lipid stress on 
mitochondrial membrane polarisation. 
 
 5.6.1 TMRE titrations 
TMRE is a dye which collects within mitochondria against an electrochemical 
gradient, therefore it can be used as a marker of mitochondrial hyperpolarisation or 
depolarisation (Joshi and Bakowska, 2011). TMRE is incompatible with whole blood 
and therefore must be used with washed cells. To optimise assay design for accurate 
discrimination between normally polarised platelet mitochondria and depolarised or 
hyperpolarised platelet mitochondria the dye was titrated to determine the optimum 
staining concentration. Here we determined that 50 nM of TMRE dye, staining 2 x 
106 washed platelets was the optimum concentration compared to the FCCP (20 µM) 
control (Figure 72). This was determined based on the largest fold-decrease between 
the stained and the FCCP treated sample, where FCCP was used to induce 
depolarisation and therefore prevent TMRE accumulation and drive a decrease in 
TMRE signal (Toninello and Siliprandi, 1982). At 20 minutes incubation with 50 nM 
of dye, there was a 3-fold decrease in fluorescence. Comparatively, at excess levels 
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of dye, the higher concentration drove increased accumulation of the dye which then 
became insensitive to changes in mitochondrial membrane potential. For example, 
using 400 nM over 20 minutes resulted in only a 1.1-fold decrease. 
In order to translate these findings to murine models of obesity, dyslipidaemia or 
genetic knockouts as previously used in mitoSOX studies, TMRE was also titrated in 
murine platelets. We determined that, in similarity to human samples, 50 nM of TMRE 
dye staining 2 x 106 washed platelets for 20 minutes was the optimal concentration 
over FCCP (20 µM) control demonstrating a 3-fold decrease in fluorescence when 
treated with FCCP (Figure 73). 
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Figure 72. Titration of TMRE. Washed human platelets (2 x 106) were pre-treated 
with or without FCCP (20 µM) for 20 minutes and then stained with TMRE (50 
– 400 nM) for 10 or 20 minutes. Samples were then diluted 10x in PBS and 
analysed by fluorescent flow cytometry. Total MFI and fold over matched 
control are shown. (n=1) 
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Figure 73. Murine TMRE titration. Washed murine platelets (2 x 106) were pre-
treated with or without FCCP (20 µM) for 20 minutes and then stained with 
TMRE (50 – 400 nM) for 10 or 20 minutes. Samples were then diluted 10x in 
PBS and analysed by fluorescent flow cytometry. Total MFI and fold over 
matched control are shown. (n=1) 
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5.6.2 OxLDL and mitochondrial membrane potential 
Having confirmed that TMRE is an assay which is sensitive to changes in 
mitochondrial membrane potential in platelets, the next step was to identify if oxLDL 
influenced mitochondrial membrane potential in addition to superoxide production. 
Platelets (2x106 cells) were treated with oxLDL and nLDL (50 µg/ml) and changes in 
membrane potential were measured over time, including a 90-minute time point, 
which is comparable with the time point at which the majority of mitoSOX studies 
were performed. 
FCCP (20 µM) caused a significant decrease in MFI, from 5451.5 to 580.1 after 90 
minutes, which indicated a clear shift from normopolarised to hypopolarised 
mitochondria and loss of TMRE signal. This was observed for all time points where 
FCCP induced depolarisation of the platelet mitochondria. Furthermore, across the 
course of the experiment (0 – 180 min) basal polarisation decreased – although this 
did not reach the level of staining indicated as depolarised (FCCP treated) across 
time points tested (Figure 74). This steady loss of mitochondrial membrane potential 
could be explained by, or explain the short half-life of the washed platelet which 
typically begin losing function beyond 360 minutes of 37̊C storage. 
In contrast to FCCP, oxLDL significantly increased the TMRE signal at all time points 
measured over both basal (5451.5 to 9861.8, 90 minutes) and the control nLDL 
treated samples (5222.8), which suggests that oxLDL is driving significant 
mitochondrial hyperpolarisation in platelets. A key control was the dual FCCP/oxLDL 
treated sample, which demonstrated a total loss of fluorescent signal indicating that 
the increased MFI was neither autofluorescence of the LDL particles or binding of 
TMRE to LDL. After treatment with nLDL, polarisation remained consistent with time 
matched basal at 90 minutes but increased against time matched basal after 180 
minutes. This suggested that at the longer time points nLDL could be maintaining 
some mitochondrial membrane potential, but vitally it did not exceed the initial basal 
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(0 minutes) MFI reading, which demonstrated nLDL does not drive hyperpolarisation 
while oxLDL convincingly does (Figure 74). 
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Figure 74. TMRE oxLDL time course. Washed human platelets (2 x 106) were pre-
treated with or without FCCP (20 µM) for 20 minutes and/or treated with oxLDL 
or nLDL (50 µg/mL) for 0 – 180 minutes. Samples were then stained with TMRE 
(50 nM) for the final 20 minutes. Samples were then diluted 10x in PBS and 
analysed by fluorescent flow cytometry. Individual donors are shown as 
superimposed points over each bar. (n=1-2) 
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5.7 MURINE PLATELET MITOCHONDRIAL FUNCTION IN DIET-INDUCED 
OBESITY 
In sections 5.4, 5.5 and 5.6, we concluded that oxLDL causes increased 
mitochondrial superoxide and mitochondrial membrane polarisation. Therefore, we 
sought to examine if western diet-induced obesity influenced murine platelet 
mitochondrial function. 8-week old C57/Bl6 mice were fed for up to 16 weeks with 
either normal chow or a western diet (WD) (45% fat). Several parameters were 
measured from these mice including; systemic changes such as weight, insulin 
resistance and glucose tolerance, and platelet function; mitochondrial superoxide, 
mitochondrial membrane potential, activation and platelet-monocyte interactions 
(activation and PMA data not shown). This approach allowed a deep phenotyping of 
the effects of obesity in C57/Bl6 mice caused by a prolonged western diet. 
 
5.7.1 Systemic characteristics 
We were able to measure several features to characterise the systemic phenotypes 
of these animals prior to platelet phenotyping. These included weight, post-prandial 
hyperglycaemia and insulin tolerance. This range of tests allowed an evaluation of 
the animal and diagnoses of obesity and/or type 2 diabetes which are both conditions 
likely to be induced by a western diet. C57/Bl6 mice fed a western diet put on weight 
at a greater rate than normal chow-fed animals and this was significantly different 
(p<0.005) at 11 weeks of feeding (Figure 75, weight). A test for post-prandial 
hyperglycaemia induced by fasted glucose bolus, or a glucose tolerance test (GTT) 
is a typical test for type 2 diabetes used in human diabetes and endocrine clinics. 
After 13 weeks of being fed a western diet (WD), fasting blood glucose was 7.7±1.3 
mmol/L which was significantly higher than for normal chow (NC) fed mice (4.7±0.6 
mmol/L). In addition WD showed a diminished reduction over time and remained 
more different to 0 minute basal at 120 minutes (14±1.8 mmol/L WD 120 minutes vs. 
8±0.7 mmol/L NC 120), indicating that the mice are in a state of pre-diabetes (Figure 
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75, GTT). Insulin tolerance is another hallmark of cardiometabolic disease (Golia et 
al., 2014), and can be tested by an insulin tolerance test (ITT), where an injection of 
insulin is provided and response in blood glucose measured. After 13 weeks of 
feeding, the resting blood glucose was again demonstrably different between the two 
feeding regimes, with 10.6±1.3 mmol/L for NC and 13.6±1.6 mmol/L for the WD fed 
mice (p<0.005). However, there was no significant difference in response to insulin 
suggesting the mice are likely not diabetic (Figure 75, ITT). 
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Figure 75. Analysis of systemic changes in a murine model on western diet. 
Murine delta (∆) weight measured over 16 weeks of western diet feeding. 
Glucose tolerance test and insulin tolerance test, both done at 13 weeks 
western diet feeding. (Multiple T-tests with Holm-Sidak multiple comparisons, 
***<0.005 and ****<0.0001, error shown as standard deviation, Weight NC n=3, 
WD n=4; GTT n=5; ITT NC n=4, WD n=5) 
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5.7.2 Platelet mitochondrial function in hyperlipidaemic mice 
Platelet mitochondrial function was examined in both WD and normal chow fed mice 
after 8 and 16 weeks of feeding using the optimised mitoSOX and TMRE assays. 
There were no differences in mitoSOX at basal levels or in response to antimycin A 
(10 µM) between the two feeding regimes at 8 weeks (Figure 76, 8-week mitoSOX). 
After 16 weeks there was a trend that platelets from WD fed mice had a greater 
response to antimycin A, where NC platelet response was 2495.8±417 compared to 
2906.4±465 from WD platelets, but this was not statistically significant (Figure 76, 16-
week mitoSOX). Whilst a phenotype had been anticipated but not observed we can 
be confident in these results, since mitoSOX increased when treated with antimycin 
A and was scavenged by mitoTEMPO indicating the assay was functioning correctly. 
When platelet mitochondrial polarisation was measured by TMRE, we again found 
no significant difference in fluorescence between the feeding regimes after 8 weeks 
(Figure 76, TMRE). At 16 weeks there was evidence of a small increase in basal 
mitochondrial membrane potential for the WD fed mice, from NC at 3668.5±643 to 
WD at 4129.5±456, but again this was not significant (Figure 76, 16-week TMRE). 
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Figure 76. Mitochondrial superoxide and membrane potential in an 8 and 16-
week fed DIO murine model. Grey bars, NC. Pink bars, WD. MitoSOX and 
TMRE staining were performed on murine washed platelets at 2x106 per tube 
as previously described, mitoSOX was loaded prior to agonist addition. 
Treatments included positive control antimycin A, negative controls 
mitoTEMPO and FCCP for mitoSOX and TMRE respectively. Individual mice 
are shown as superimposed points over each bar. (Error shown as standard 
deviation, NC n=3, WD n=4)  
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5.8 DISCUSSION 
While we did not pursue the NLRP3 inflammasome directly any further, primarily due 
to assay limitations and the requirement of murine knockout models, we were able to 
demonstrate that oxLDL had a distinct effect over nLDL on FLICA signal which was 
dependent on calcium and ROS (chapter IV). Calcium is key to the regulation of many 
cellular processes including mitochondrial function itself, and ROS are produced in 
platelets from several sources, but predominantly NADPH oxidases and the 
mitochondria (Schulz et al., 2014). Mitochondria are also involved in the regulation of 
inflammasome activity (Zhou et al., 2011) and were implicated in the initial 
observation regarding the platelet inflammasome (Hottz et al., 2013). Therefore, we 
explored what effects oxLDL may be having on mitochondrial metabolism and 
homeostasis in platelets, to this end we specifically measured mitochondrial 
superoxide production and mitochondrial membrane potential. 
OxLDL, but not control nLDL, was found to induce platelet mitochondria to produce 
superoxide, detected by fluorescent mitoSOX. This is a novel finding and has never 
been observed before in platelets. Furthermore, a second new observation 
demonstrated that oxLDL stimulated increased mitochondrial membrane potential 
detected by fluorescent TMRE and maintained this polarisation over basal and 
control nLDL for up to 3 hours (longest time point measured). While not definitive, 
these two observations could suggest that the increased superoxide production is 
linked to the ability of oxLDL to induced mitochondrial hyperpolarisation. To 
determine the kinetics of the relationship between polarisation and superoxide 
production, co-incubation with oxLDL and mitoTEMPO followed by measurement of 
polarisation would suggest if polarisation occurred prior to superoxide production 
(and is therefore unaffected by scavenging) or is driven by changes in superoxide 
production (and is therefore protected by scavenging).  
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To explore the mechanistic aspects of oxLDL on mitochondrial superoxide 
production, we first applied the general ROS scavenger NAC and the mitochondrial 
specific scavenger mitoTEMPO. Here we were able to show that mitoTEMPO 
significantly reduced the superoxide produced by the positive control antimycin A, 
however it did not drive a significant reduction in oxLDL mitochondrial superoxide, 
although there was a trend towards a reduction in signal. It was possible that these 
observations were due to the small margin of increase induced by oxLDL, which 
reduced the opportunity to detect a significant inhibition of signal. Interestingly, 
mitoTEMPO never fully decreased the maximal effects of antimycin A of superoxide 
generation, and there is also the possibility that the scavenger is not able to fully 
deplete the mitochondria of superoxide. In a second approach, we found that oxLDL 
consistently induced hyperpolarisation of the mitochondria. Together we were able 
to confirm that oxLDL, through a currently unknown mechanism drives mitochondrial 
superoxide production and hyperpolarisation. The functional consequence of this 
mitochondrial dysfunction downstream of oxLDL remains unclear. However, there 
are suggestions in the literature that mitochondrial dysfunction is key to regulating 
NLRP3 inflammasome activity (Zhou et al., 2011, Hottz et al., 2013). Furthermore, 
oxLDL driven mitochondrial dysfunction is perhaps unlikely to affect platelet function 
itself, as several pathways for oxLDL driven platelet hyperactivity have been 
described and phenotypes rescued with no reference to mitochondrial superoxide 
(Berger et al., 2019a, Magwenzi et al., 2015, Wraith et al., 2013). In addition to this, 
a recent study has shown that platelet function is not perturbed by a superoxide 
dismutase 2 (SOD2/Mn+ SOD) platelet specific knockout model either in vitro or in 
vivo (Fidler et al., 2017). These data in conjunction with the results described in this 
chapter suggest platelet mitochondrial dysfunction likely controls aspects of platelet 
function beyond (oxLDL-mediated) haemostatic function. In the future however, this 
work must all be repeated using the now optimised mitoSOX conditions, namely pre-
loading of cells with the permeant superoxide dye followed by kinetic reading of each 
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treatment condition over time, as this has been shown to increase the sensitivity of 
the assay. A striking finding was the effect of oxLDL on mitochondrial membrane 
potential, therefore this study must be pursued and repeated, firstly to validate these 
findings and then to explore the pathways leading to this effect and also the outcomes 
of the mitochondrial hyperpolarisation. 
While we were able to demonstrate that extracellular oxLDL treatment in vitro could 
drive a mitochondrial phenotype, we wanted to ask if this phenotype was also 
apparent in platelets from mice which were both inflammatory and hyperlipidaemic – 
a suitable environment for the production of circulating oxLDL (Kato et al., 2009). 
Therefore, we applied these experimental questions to murine platelets of the 
following genotypes. We compared wild-type C57/Bl6, ApoE -/- and ApoE/GP91 -/- 
mice, where ApoE knockouts are a model of hyperlipidaemia and atherosclerosis 
(Kirii et al., 2003), and GP91 are deficient in the major platelet source of cytoplasmic 
ROS, NOX2 (Magwenzi et al., 2015). Basal mitoSOX in C57/Bl6 mice was consistent 
across all animals tested. However, when compared with ApoE -/- and ApoE/GP91 -/- 
mice, there was a significant increase in superoxide in the mice under 
hyperlipidaemic stress. Furthermore, the inclusion of ApoE/GP91 -/- validated the 
model as independent of NOX2, which has been shown previously to be stimulated 
by oxLDL in platelets to produce ROS (Magwenzi et al., 2015). These differences in 
platelet mitochondrial biology between the transgenic mice requires further 
phenotyping and the inclusion of controls to scavenge superoxide. A further vital 
control to be pursued include a measurement of mitochondrial mass (Zhang et al., 
2019), where this increase in signal from these murine platelets may potentially not 
caused by an increase in superoxide, but rather an increase in mitochondrial mass 
which in turn drives greater dye collection and therefore greater signal. Indeed, such 
a dramatic increase in platelet mitochondrial mass would be equally interesting in this 
context. These novel findings suggest that platelets circulating in murine models with 
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increased lipid stress, and likely circulating oxLDL (Kato et al., 2009), are 
metabolically and functionally different from a healthy donor C57/Bl6.  
To examine our previous observation in transgenic mice further, we applied our 
experimental approach to western diet-fed C57/Bl6 mice at 8 and 16 weeks of 
western diet. This western diet model induces a hyperlipidaemic phenotype which is 
considerably milder than ApoE -/-, particularly in terms of the inflammatory profile 
(Getz and Reardon, 2006). We were able to demonstrate that in the western diet-
induced model of obesity, the C57/Bl6 mice put on weight at an increased rate over 
normal chow. Further analysis suggested that 11-weeks of feeding also showed 
increased resting blood glucose and diminished glucose tolerance but without 
marked insulin resistance. Beyond systemic changes to the mice, we also measured 
for changes in mitochondrial characteristics between the two groups at both 8 and 
16 weeks of feeding using mitoSOX and TMRE to measure mitochondrial superoxide 
and membrane potential respectively. At both time points, 8 and 16-weeks, there 
were no significant differences between the normal chow and western diet-fed 
groups, although, at both stages there was a trend towards an increase in 
mitochondrial superoxide when stimulated with antimycin A and also increased basal 
mitochondrial membrane potential for the WD fed mice compared to the NC mice. 
Reassuringly these trends developed further when comparing them at 8 and 16-
weeks. This pilot study has highlighted the critical difference between western diet 
induced models against transgenic models, suggesting that in less severe 
environments of only dietary pressure, platelets have a capacity to resist dysfunction. 
In interpretation, these results could point towards different phenotypes, for example; 
capacity for mitochondrial superoxide production is increased, mitochondrial 
membrane potential has increased, or tying the two together in a phenotype where 
mitochondrial mass has increased which in turns leads to a greater potential reading 
(due to there being more mitochondria to stain) and a greater superoxide production 
(as there is more mitochondrial surface area). Therefore this study would require 
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additional confirmation of mitochondrial mass changes, measured by either 
transmission electron microscopy (TEM) (Obydennyi et al., 2019) or fluorescent dye 
(Zhang et al., 2019). This study could also be further enhanced by understanding 
how mitochondrial function itself is changing in the presence of oxLDL, notably by 
the bioenergetic measurements of extracellular acidification rate and oxygen 
consumption rate as markers of glycolysis and oxidative phosphorylation respectively 
(Aibibula et al., 2018). The data in terms of increased platelet mitochondrial 
membrane potential in WD may tie in with a study in humans with cardiovascular 
disease, where monocytes bound to platelets were shown to have increased 
mitochondrial membrane potential (Vogel et al., 2015), although this could be from 
the platelets, monocyte or both cells, as the experiments in that study lacked the 
appropriate controls to confirm the source of changes in membrane potential (Vogel 
et al., 2015). Although we were unable to replicate the basal mitochondrial 
superoxide finding of the ApoE -/- models, the differences in systemic phenotype of 
the animals must be considered, where the knockout model is more severe (Getz 
and Reardon, 2006) – however it is likely a viable option to repeat this feeding study 
on animals with an ApoE -/- background to increase the potential for measuring a 
phenotype and repeat mitoSOX, and vitally measured mitochondrial membrane 
potential (TMRE) and add an additional marker of mitochondrial mass. The use of 
TEM (Obydennyi et al., 2019) and fluorescent dye (Zhang et al., 2019) to measure 
mass in conjunction would provide data on; mass, morphology, autophagy, fission 
and fusion simultaneously, all of which have the potential to be affected in a 
hyperlipidaemic environment (Dose et al., 2016). Alternatively, the relatively simple 
approach of continuing to use mitoSOX and TMRE but also measuring these by 
fluorescent microscopy would allow for mitochondrial mass and mitochondrial 
number to be evaluated. 
In summary, we described that oxLDL, but not nLDL, can drive an increase in platelet 
mitochondrial superoxide and membrane potential. Furthermore, in murine models 
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of transgenic hyperlipidaemia, there is a phenotype of increased mitochondrial 
superoxide. However, in diet induced obesity models this is only mildly recapitulated 
and a trend towards increase mitochondrial superoxide and membrane potential. 
This work requires further exploration of mechanisms involved in the transduction of 
oxLDL signal, alongside other changes which may occur in the mitochondria by 
alternative methods and finally investigation into hyperlipidaemic human donors to 
measure if these modifications to platelet mitochondria are present. 
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Chapter 6 
Conclusions and future studies 
6.1 PLATELET REGULATION AND SUBPOPULATIONS 
The application of novel multidimensional analysis to four parameter platelet 
fluorescent flow cytometry is a considerable innovation for platelet biologists. 
Typically, the majority of platelet fluorescent flow cytometry is done using single 
parameter assays, this not only limits the data rich potential of the technique, but it 
prevents true comparisons between markers on single cells and implicates a lack of 
platelet marker controls in each experiment. There are exceptions to this general 
statement, these include the very high parameter application of CyTOF (Blair and 
Frelinger, 2019, Blair et al., 2018) and other multicolour fluorescent flow cytometry 
studies (Reddy et al., 2018, Sodergren and Ramstrom, 2018), however the field is 
still immature compared to cellular immunology where up to 20 parameters are 
routinely applied (Cossarizza et al., 2017). Some groups are however publishing 
guidelines to both advance and standardise best practice in platelet cytometry 
(Spurgeon and Naseem, 2019, Frelinger, 2018, Welch et al., 2018, Ramstrom et al., 
2016, Harrison, 2009, Harrison et al., 2011). The biggest innovation has undoubtedly 
come from the recent analysis of platelets by CyTOF, although the applications of 
CyTOF are powerful (Blair and Frelinger, 2019, Blair et al., 2018), a major caveat is 
the lack of accessibility to mass cytometers, therefore we sought to apply novel 
analytical techniques to fluorescent flow cytometry, an instrument that the majority of 
platelet biologists have access to. Since our initial study validated the potential of 
these analytical innovations paired with four parameter assays and resulted in the 
discovery of rare subpopulations of platelets, we believe this should stimulate the 
field to implement these techniques and continue to investigate and innovate modern 
assay design and analytical approaches. 
Through the measurement of multiple markers simultaneously, we were not only able 
to describe subpopulations and define subsets within large subpopulations, but also 
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able to describe differences in PGI2-cAMP regulation of aspects of platelet activation. 
Reassuringly a recent study, using single colour flow cytometry paired with LTA 
suggested there may well be differences in inhibition of different platelet markers of 
activation (Macwan et al., 2019). We took this further and demonstrated a dichotomy 
in granule secretion and integrin activity or PS exposure through four parameter 
assays with validation by alternative markers. We suggested this plays a role in the 
inhibitory vascular environment in allowing immunomodulatory platelet: monocyte 
interactions but preventing thrombotic platelet: platelet interactions. We further 
applied some mechanistic studies to confirm that PGI2-cAMP protects mitochondria, 
preventing depolarisation upstream of PS exposure and that CD62P is expressed on 
the cell surface independent of robust inhibitory signalling indicated by pVASP-s157. 
 
6.1.1 Future studies 
While several approaches were taken to confirm that cAMP signalling was preserved 
and that CD62P is independent of cAMP-signalling further studies could describe the 
mechanism by which this occurs. 
A primary question is how calcium signalling is regulated in the context of excess 
activation and inhibition. While aspects of calcium signalling are known to be 
independent of cAMP-signalling (Fung et al., 2012), it would be advantageous for this 
study if a calcium dye could be used to understand the flux of calcium and how this 
may compare under conditions where potent inhibition has blunted integrin αIIbβ3 
activity and inhibited PS exposure but where granule secretion has continued. 
Indeed, if residual calcium signal correlated with granule secretion that would suggest 
a mechanism of action and suggest granule secretion is less dependent on calcium 
than other hallmarks of platelet activation.  
As the novel subset we described has previously been suggested to exist in murine 
platelets (Topalov et al., 2012) and was subsequently suggested to be a result of 
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platelet doublets (Choo et al., 2017) forming between PShi and integrin αIIbβ3hi 
platelets, we validated this by a doublet gate based on the increase in pulse width of 
doublets. However, this could further be validated using a model treated with an 
antagonist of integrin αIIbβ3 (tirofiban) which does not perturb calcium levels, though 
this would require that integrin αIIbβ3 activity could still be detected by PAC1 
(Frelinger, 2018) in the presence of inhibitors to distinguish the PShi/αIIbβ3hi subset. 
Future studies should also look to provide a full understanding of the mechanisms by 
which cAMP inhibition may be targeted to discrete aspects of activation. Based on 
previous literature the hypothesis would be that subcellular pools of cAMP are 
targeted to distinct machinery within the platelets (Wehbi and Tasken, 2016, Raslan 
et al., 2015, Raslan and Naseem, 2015). If PKA could be demonstrated to be 
associated with specific aspects of the cellular biology regulating integrin αIIbβ3 and 
PS exposure but not granule secretion, this would demonstrate a definitive 
mechanism for this study. 
Additionally, with modern iterations of in vivo imaging approaches (Imhof et al., 2016), 
it should be feasible to image platelets expressing CD62P in association with 
monocytes, vitally in the context of tonic endothelial inhibition. This would confirm 
that platelet: monocyte interactions can occur independently to active cAMP-
signalling. 
 
6.1.2 Summary of findings 
In this chapter, several novel findings were described by the application of fluorescent 
flow cytometry. Platelet subpopulations using multidimensional FIt-SNE analysis 
were explored, applying this analysis for the first time to platelet fluorescent flow 
cytometry data. This allowed a detailed description of how PGI2 controls the formation 
of platelet subpopulations and this further elucidated a dichotomy in how PGI2-cAMP 
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regulates aspects of platelet function, most notably differences in granule secretion 
when compared with integrin activation and phosphatidylserine exposure. 
• First application of multidimensional analysis to platelet FFC data 
• Description of platelet subsets within PShi established by fibrinogen binding 
• PGI2 inhibition differentially targets fibrinogen binding, PS and granule 
secretion 
• PGI2 resistant CD62P facilitates platelet monocyte interactions 
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6.2 NLRP3 INFLAMMASOME ACTIVATION AND EXPRESSION 
The first report of the NLRP3 inflammasome was published in 2004 (Agostini et al., 
2004), and it was not until 2013 that is was shown to be present and functional in 
human platelets (Hottz et al., 2013). To date there have been a number of papers 
that have described a functional role for NLRP3 in platelet biology (Boone et al., 2019, 
Qiao et al., 2018, Vogel et al., 2018a, Vogel et al., 2018b, Murthy et al., 2017, Vogel 
et al., 2017, Vats et al., 2019). We measured NLRP3 activity in platelets using the 
FLICA assay which fluorescently labels activated caspases. Specifically, we 
measured caspase-1, as caspase-1 cleavage can be used as a marker of NLRP3 
activity. We used this to measure NLRP3 activity downstream of oxLDL, which has 
not been examined in platelets before. Previously, in response to oxLDL, platelets 
have been shown to express markers of activation (Berger et al., 2019b, Wraith et 
al., 2013). Furthermore, oxLDL has been shown to drive NLRP3 activity in other cell 
types (Liu et al., 2014). We were able to describe a novel potentiation of caspase-1 
cleavage by oxLDL treatment that was not seen in the nLDL control, and which was 
dependent on ROS and Ca2+ (Murakami et al., 2012). Additionally, preliminary 
studies here suggested it is not via the well described CD36-signalosome (Berger et 
al., 2019b, Wraith et al., 2013). However, due to a lack of responsiveness to NLRP3 
inhibitors MCC950 (Coll et al., 2015) and glyburide (Lamkanfi et al., 2009) we were 
unable to validate this observation as a definite marker of caspase-1 cleavage. As a 
result, we pursued further questions regarding the validity of the assay and found it 
correlated with markers of apoptosis (Pozarowski et al., 2003). 
Due to concerns over the validity of the FLICA observations we sought to identify the 
components of NLRP3 by immunoblot; NLRP3, ASC, caspase-1, gasdermin D and 
IL-1β (Schroder and Tschopp, 2010). We described a potential NLRP3 band by 
immunoprecipitation, a splice variant of ASC by immunoprecipitation and immunoblot 
(Matsushita et al., 2009), caspase-1 by immunoblot, gasdermin D by immunoblot and 
were unable to identify IL-1β in healthy donors. We cross-referenced this with 
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proteomic (Burkhart et al., 2012, Zeiler et al., 2014) and transcriptomic (Rowley et 
al., 2011) platelet studies, which are generally not supportive of NLRP3 
inflammasome expression and suggest only ASC and gasdermin D are expressed at 
a protein level. 
 
6.2.1 Future studies 
The findings described in this chapter, while novel, are also potentially of great impact 
considering the presence of oxLDL in the vasculature and the literature supporting 
this finding. However, they require further validation, primarily due to assay 
limitations. 
The single series of experiments, which would validate these observations beyond 
doubt, require transgenic murine models. Specifically, repetition of these studies in 
wild type murine models compared with NLRP3 knockout and CD36 knockout murine 
models respectively would confirm; the FLICA assay is correct/incorrect as there is 
no need for biochemical inhibitors of NLRP3, and the potential lack of involvement of 
the CD36-signalosome, again without the need for biochemical inhibitors of the 
receptor and signalling apparatus. 
If transgenic models were available this would further allow for enhanced 
identification of the proteins by immunoprecipitation, as a comparison between wild 
type and transgenic models would immediately demonstrate the loss or otherwise of 
a protein band – thereby identifying that band as the protein in question. If the 
proteins could be confirmed by biochemical means that would allow further studies 
by co-immunoprecipitation (Shi et al., 2016) to understand the conditions under which 
the complex is assembled and potentially co-localisation studies by high-resolution 
microscopy. 
This is also the first description of a spliced variant of ASC in platelets, this should 
also be explored. The size of the variant suggests it may lack a hinge domain and 
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therefore be constitutively active (Matsushita et al., 2009), further studies have also 
suggested that variants of ASC play important roles in the regulation of NLRP3 
activity, both up and down regulation (Bryan et al., 2010). Therefore, additional 
immunoprecipitations of ASC should be performed, and mass spectrometry should 
be performed to confirm that this detected band is indeed a splice variant of ASC. In 
addition to this RT-PCR analysis of the platelet transcriptome would also suggest if 
a splice variant is also expressed at a transcriptional level, further supporting this 
protein observation. To highlight a functional role for a splice variant of ASC, cross-
linked immunoblot assays should be performed to explore whether this splice variant 
of ASC is constitutively oligomerised in platelets, or indeed is even able to 
oligomerise. 
This study also identified the pore forming protein gasdermin D, gasdermin D is 
known to be cleaved by caspase-1 to facilitate pyroptosis (Miao et al., 2011) and 
subsequent release of IL-1β (Liu et al., 2016). However, within platelets, which are 
cells packed with pro-thrombotic proteins, growth factors and chemokines, this may 
represent an additional pathway to the release of platelet contents on activation. In 
context, it has been shown that typical platelet activity does induce NLRP3 activity 
(Murthy et al., 2017, Qiao et al., 2018), which would in turn suggest that gasdermin 
D may be cleaved and pores formed in traditional platelet activation. Therefore, 
further biochemical studies over the capacity of gasdermin D to be cleaved in 
platelets and to form pores on the surface would suggest this is a hypothesis worth 
pursuing. 
While there have been several publications on platelet NLRP3 there has been little 
mechanism described to date. Open questions remain regarding the recruitment and 
particularly the priming of the NLRP3 inflammasome in platelets (Schroder and 
Tschopp, 2010). While the role of transcriptional priming is a challenging avenue 
within platelets, where there is some evidence this may be able to occur (Denis et 
al., 2005), there is clear potential for non-transcriptional priming. Non-transcriptional 
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priming of NLRP3 has been shown in other cells and is driven by pathways common 
to platelets, namely phosphorylation of ASC by Syk (Lin et al., 2015), phosphorylation 
of NLRP3 by JNK1 (Song et al., 2017) or de-ubiquitination of ASC (Rodgers et al., 
2014) or NLRP3 (Song et al., 2016). Additional studies into the mechanism of NLRP3 
activity in platelets should be followed, with emphases on the post-translational 
modifications of NLRP3 components and how this may regulate function in platelets. 
Finally, if the model can be validated, then the propensity for NLRP3 inflammasome 
activity should be measured in clinically relevant murine models such as ApoE 
(hyperlipidaemia) or streptozotocin (diabetes) to understand if activity changes, if so, 
clinical human cohorts are worth pursuing, as current studies suggest the NLRP3 
inflammasome plays an important role in the progression of many human diseases 
(Ridker et al., 2011). 
 
6.2.2 Summary of findings 
Within this chapter the FLICA assay was applied to understand how oxLDL may 
regulate caspase-1 cleavage downstream of postulated NLRP3 activity. A significant 
effect of oxLDL on the potentiation of caspase-1 cleavage was demonstrated, where 
nLDL had no effect and chelation of calcium or scavenging of ROS blocked this 
potentiation effect. The effects of inhibitors against the CD36-signalosome were 
further examined and demonstrated no significant inhibition of potentiation. In 
addition, the expression of components of the NLRP3 inflammasome were measured 
by SDS-PAGE. The relative expression of each constituent was determined, and this 
described that ASC is expressed predominantly as a truncated form and for the first-
time, expression of gasdermin D in human platelets. 
• OxLDL potentiates FLICA signal 
• Potentiation of oxLDL-caspase-1 cleavage is likely not through the CD36-
signalosome 
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• An ASC isoform is expressed in human platelets 
• Caspase-1 and GSDMD are expressed in human platelets 
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6.3 MITOCHONDRIAL DYSFUNCTION UNDER LIPID STRESS 
OxLDL is known to induce mitochondrial dysfunction in other cells (Zmijewski et al., 
2005, Giovannini et al., 2002, Vindis et al., 2005) and mitochondrial dysfunction is 
also known to play a key role in NLRP3 activity (Zhou et al., 2011). Therefore, as 
oxLDL is known to stimulate platelets (Berger et al., 2019b, Wraith et al., 2013) and 
we have made an observation of NLRP3 activity in platelets (chapter IV), we explored 
whether oxLDL may drive mitochondrial dysfunction in platelets. We were able to 
show that oxLDL, but not nLDL, drives both mitochondrial superoxide production and 
membrane potential, and this agrees with results from other cell types that 
demonstrate a similar phenotype in production of mitochondrial superoxide 
(Chowdhury et al., 2010, Zmijewski et al., 2005) and increased mitochondrial 
membrane potential (Giovannini et al., 2002). We further translated this hypothesis 
into western-diet fed (Getz and Reardon, 2006) and transgenic ApoE -/- murine 
models (Kato et al., 2009). We observed that the more severe transgenic model 
drove a significant increase in mitochondrial superoxide and diet-induced drove a 
small increase in superoxide and membrane potential in platelets, this agrees with 
literature demonstrating an increase in endothelial mitochondrial dysfunction in 
hyperlipidaemia (Yu et al., 2012). 
 
6.3.1 Future studies 
While the results within this chapter are preliminary, they highlight some changes to 
platelet mitochondrial metabolism in the context of hyperlipidaemia which should be 
pursued. However, prior to pursuing this, they must be validated. 
The basic observations regarding increases in mitochondrial superoxide or 
mitochondrial membrane potential with oxLDL suggested there may be a phenotype 
in vivo, which was replicated in a severe model of hyperlipidaemia in ApoE animals. 
This observation should be repeated and additional controls to measure 
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mitochondrial mass should be used, as an increase in mass may have given false 
positive increase in signal of superoxide. These can be pursued by fluorescence 
microscopy, TEM or alternative mass dyes by fluorescent flow cytometry (Zhang et 
al., 2019). If mass does change, this must be accounted for, however it may be that 
the change in mass is an important finding. Further to this, the study could be 
expanded to examine other aspects of mitochondrial biology including oxygen 
consumption rate and extracellular acidification rate (Aibibula et al., 2018), to 
understand if oxLDL mitochondrial dysfunction also modulates basal metabolic rate. 
Mechanistically, the pathway by which oxLDL may transduce mitochondrial 
dysfunction should be explored, as it may be via the well described CD36-
signalosome (Chen et al., 2008, Wraith et al., 2013), alone or in heteromeric 
complexes with TLRs (Biswas et al., 2017), or via alternative LOX1 pathways (Holy 
et al., 2016). A combination of biochemical inhibitors targeting these pathways should 
be used before immunoblotting for tyrosine phosphorylation or IRAK phosphorylation 
for CD36 or TLR activity respectively to validate the inhibitors. The effects they have 
on oxLDL induced mitochondrial dysfunction could then be explored. LOX1 as an 
alternative oxLDL receptor should also be explored, as it has been demonstrated to 
transduce signal leading to mitochondrial dysfunction in other cell types (Christ and 
Latz, 2014). 
If the findings can be validated and the mechanism understood, it would be vital that 
this finding was translated to a clinical hyperlipidaemic cohort, as the defects in 
platelet mitochondrial metabolism may drive hyperactivity, dysfunction, or indeed 
NLRP3 activity (Christ and Latz, 2014). 
 
6.3.2 Summary of findings 
In chapter V, how oxLDL may mediate superoxide production within platelet 
mitochondria was explored. This demonstrated that oxLDL, but not nLDL, drove 
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mitochondrial superoxide production and increased mitochondrial membrane 
potential in human platelets. This study was translated into murine models, in 
transgenic ApoE -/- a significant increase in basal superoxide was observed over wild 
type animal. In diet-induced obesity C57/Bl6 models a trend towards increased 
stimulated superoxide production and membrane potential was also measured.  
• oxLDL induces mitochondrial superoxide production 
• oxLDL drives a mitochondrial membrane potential increase 
• Murine models of dyslipidaemia show increased mitochondrial superoxide 
and membrane potential 
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FFC Fluorescent flow cytometry 
FITC Fluorescein 
FIt-SNE Fast Fourier Transform-accelerated Interpolation-based t-SNE 
FLICA Fluorochrome-labelled inhibitors of caspases 
FSC Forward scatter 
GP1b-IX-V Glycoprotein Ib-IX-V 
GPVI Glycoprotein VI 
- 279 - 
HRP Horseradish peroxidase 
IB Immunoblot 
IL-1β Interleukin-1 beta 
IP Immunoprecipitation 
IPR Prostacyclin receptor 
LDL Low-density lipoprotein 
LPS Lipopolysaccharide 
LTA Light transmission aggregometry 
Mg2+ Magnesium ion 
NAC n-acetyl-cysteine 
nLDL Native low-density lipoprotein 
NLRP3 Nacht-leucine rich repeat pyrin domain containing protein 3 
NO Nitric oxide 
oxLDL Oxidised low-density lipoprotein 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PAR Protease-activated receptor 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PE phycoerythrin 
PDE Phosphodiesterase 
PerCP Peridinin-Chlorophyll-protein 
PGI2 Prostaglandin I2 (Prostacyclin) 
PFD Pore forming domain 
PKA Protein kinase A 
PKC Protein kinase C 
PKG Protein kinase G 
PMN Polymorphonuclear leukocyte 
PPP Platelet poor plasma 
PRP Platelet rich plasma 
PYD Pyrin domain 
RD Repressor domain 
ROS Reactive oxygen species 
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SD Standard deviation 
SDS Sodium dodecyl sulphate 
Ser Serine 
sGC Soluble guanylyl cyclase 
SOX Superoxide 
SSC Side scatter 
t-SNE t-Stochastic Neighbourhood Embedding 
TBS(-T) Tris-buffered saline(-Tween 20) 
TLR Toll-like receptor 
TMRE Tetramethyl rhodamine ethyl ester 
VASP Vasodilator-stimulated phosphoprotein 
vWF Von Willebrand factor 
WCL Whole cell lysate 
WP Washed platelets 
 
